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General Introduction
1
Due to the widespread use of modern radiological imaging, focal hepatic tumours 
are detected more often with up to 33% being detected on ultrasound screening, 
CT or MRI (1, 2). Although most of these incidentally detected focal liver lesions are 
benign, a malignancy needs to be ruled out. To discriminate between a benign and 
malignant lesion the imaging findings must be interpreted in the clinical context, 
including the patient’s medical history, previous malignancies, chronic liver disease 
and family history. Discrimination between benign and malignant liver lesions is 
essential as their management greatly differs.
Benign liver tumours do not spread outside the liver and rarely lead to a fatal 
outcome. The most common liver tumours are simple liver cysts, haemangiomas, 
and solid benign liver tumours. The most important solid benign liver tumours in-
clude Focal Nodular Hyperplasia (FNH), Hepatocellular Adenoma (HCA) and Hepatic 
Angiomyolipoma (HAML). In this thesis, we will focus on the two most common solid 
benign liver tumours, FNH and HCA.
FOCAL NODULAR hYPERPLASIA
FNH is a benign liver tumour with an incidence of 0.6-3% in the general population 
(3, 4). The tumour mostly occurs in young women, with a male-female ratio of 1:12 
(5). The potential mechanism explaining this gender difference is unclear. There is 
no data in the literature suggesting an increased risk or growth of FNH on oral con-
traceptives, and cessation of this hormonal treatment is therefore not recommended 
(6). FNH is defined as a hyperplastic reaction resulting from vascular malformation 
or trauma (7, 8).
Macroscopically, FNH is a pale, firm lesion distinct from the surrounding liver 
without a tumour capsule (figure1) (9). It is most often lobulated and in most cases, 
it has a central stellate scar which radiates into nodules of normal hepatocytes (10). 
The central scar contains a malformed vascular structure, the central artery. From 
this anomalous central artery, the arterial blood flows centrifugally (stellate) which 
is in contrast to HCA (11).
FNH tends to be detected as an incidental finding at imaging and although ab-
dominal pain and discomfort are being described, the majority of FNH lesions are 
asymptomatic (3). FNH is a benign lesion with no malignant transformation, a very 
low incidence of bleeding and if symptomatic, complaints resolve during follow-up 
(12, 13). Therefore, if the diagnosis is well established, treatment is rarely indicated 
(10, 13). The biological behaviour of FNH is described in chapter 2.
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hEPATOCELLULAR ADENOMA (hCA)
A hepatocellular adenoma is a benign tumour that occurs most often in women 
in their second or third decade of life (14). The incidence is reported as 1-1.3 per 
100.000 in women who have never used oral contraceptives (OC) and 30-40 per 
100.000 in those on long-term OC-use (15, 16).
Macroscopically, HCA is a well circumscribed lesion, ranging in colour from brown 
to white but mostly yellowish (figure 2). Large plates of hepatic cells, resembling 
normal hepatocytes, are separated by dilated sinusoids. These sinusoids are fed 
only by peripheral subscapular vessels which causes diffuse homogenous arterial 
filling (17). Bile ducts are absent; an important histological feature that helps to 
distinguish it from FNH (18).
HCA and the association with the use of oral contraceptives was first described 
in 1973 by Baum et al. (19). In the subsequent years, many authors supported the 
potential role of sex hormones although the mechanism by which they contribute to 
the development of HCA was, and still is, not understood (16, 20, 21).
Unlike FNH, HCA may require invasive treatment in selective cases as HCA can be 
complicated by rupture, bleeding or malignant transformation (22, 23). The most 
important reason for treatment of HCA is the size of the lesion, as rupture and ma-
lignant transformation are rarely described in lesions smaller than 5cm in diameter 
(24, 25). The first step in the treatment of HCA, independently of the size of the HCA, 
is cessation of OC use. If the HCA still exceeds a diameter of 5cm 6 months after 
cessation of the OC, surgical treatment is recommended. (25-27)
Figure 1. Focal Nodular Hyperplasia (FNH)
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The management of multiple HCAs is more complex and even treatment by total 
hepatectomy and liver transplantation has been described (28). In chapter 3 we will 
describe characteristics of patients with multiple HCA lesions and compare them to 
patients with single lesions. Furthermore, we will investigate whether the presence 
of multiple HCAs should influence management strategies.
Although resection is indicated in HCA lesions larger than 5cm, a conservative 
management might be chosen in case of multiple HCAs as the risk of surgery may 
increase while remnant lesions will remain in situ. In addition, centrally located le-
sions, lesions in patients with comorbidity, or patient’s wishes may influence clinical 
management. A surveillance study on the natural course of HCAs larger than 5 cm is 
described in chapter 4.
As differentiation between HCA and FNH has a major clinical impact imaging tech-
niques should have a high sensitivity and specificity to support reliable diagnostics. 
In chapter 5 we will explore the opportunities of using contrast enhanced ultrasound 
to characterise HCA and FNH. In chapter 6 we will compare the outcome of contrast 
enhanced ultrasound with contrast-enhanced Magnetic Resonance Imaging (MRI); 
the latter considered the gold imaging standard to differentiate between benign 
liver lesions.
In chapters 7 and 8 the impact of MRI in a more detailed diagnostic work-up of 
HCA will be discussed and compared to a pathological classification system, the 
Bordeaux-classification (29, 30). Using this system, 4 subclasses of HCA can be 
identified. We will perform studies to determine whether specific MRI features can 
be used to identify these different subgroups. (26)
In addition to using imaging or pathological characteristics to diagnose liver 
tumours, using serum markers to discriminate between benign and malignant liver 
tumours may have a clinical impact. In chapter 9 a new serum marker is investigated 
Figure 2. Hepatocellular adenoma (HCA)
Chapter 1
14
to differentiate solid benign liver tumours from solid malignant liver tumours as 
HCC.
The biological behaviour of HCA in women during pregnancy is studied in chap-
ters 10 and 11. HCA has the potential to show hormone-induced growth, leading 
to haemorrhage in larger lesions. An investigation into whether surgical resection 
should be recommended before or even during pregnancy will be performed (16, 
31). 12 pregnant women with HCA were monitored closely (32) as described in 
chapter 10. In addition, a multicentre study on the natural course of HCA smaller 
than 5 cm in selected pregnant women will be introduced to confirm the hypothesis 
that pregnancy may be allowed in cases of smaller HCA (chapter 11).
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ABSTRACT
Background/Aims
When a liver lesion diagnosed as Focal Nodular Hyperplasia (FNH) increases in size it 
may cause doubt about the initial diagnosis. In many cases additional investigations 
will follow to exclude hepatocellular adenoma or malignancy. This retrospective 
cohort study addresses the implications of growth of FNH for clinical management.
Methods
We included patients diagnosed with FNH based on ≥2 imaging modalities between 
2002 and 2015. Characteristics of patients with growing FNH with sequential imag-
ing in a 6-month interval were compared to non-growing FNH.
Results
Growth was reported in 19/162 (12%) patients, ranging from 21-200%. Resection 
was performed in 4/19 growing FNHs, histological examination confirmed FNH in 
all patients. In all 15 conservatively treated patients additional imaging confirmed 
FNH diagnosis. No adverse outcomes were reported. No differences were found in 
characteristics and presentation of patients with growing or non-growing FNH.
Conclusion
This study confirms that FNH may grow significantly without causing symptoms. A 
significant increase in size shouldn’t have any implications on clinical management 
if confident diagnosis by imaging has been established by a tertiary benign liver 
multidisciplinary team. Liver biopsy is only indicated in case of doubt after state of 
the art imaging. Resection is deemed unnecessary if the diagnosis is confirmed by 
multiple imaging modalities in a tertiary referral centre.
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INTRODUCTION
Focal Nodular Hyperplasia (FNH) is a benign liver tumour with an incidence in the 
general population of 0.6-3% 1. FNH is especially common in young women, with 
a male-female ratio of 1:12 2. So far, no explanation has been found for the gender 
bias; female hormones or the use of oral contraceptives do not seem to play a role 
in prevalence 3, 4.
An FNH lesion consists of benign hepatocytes surrounding a central fibrous scar 
with a prominent dystrophic artery. The underlying mechanism of FNH formation is 
thought to be due to a vascular malformation and injury 5. Patients do not have an 
underlying liver disease and are mostly asymptomatic 6.
With the current availability of highly sensitive imaging techniques, FNH is diag-
nosed more often as an incidental lesion. Magnetic Resonance Imaging (MRI) with 
liver specific contrast agents has a very high specificity of almost 100% in larger 
lesions (>3cm) but is less accurate with a sensitivity of 70-80% to diagnose smaller 
lesions where the central scar may be missing. In these cases the combination of MRI 
and contrast enhanced ultrasound (CEUS) provides the highest diagnostic accuracy 7.
This year the European Association for the Study of the Liver (EASL) issued the 
first clinical practice guideline for benign liver tumours 8 in which they state that 
treatment of FNH is not recommended because of the benign character of FNH, the 
low incidence of intralesional bleeding 9, 10 and the absence of malignant transfor-
mation 11. In case of doubt about the diagnosis FNH a biopsy may be considered 8. 
The guideline describes treatment is only persued in exceptional cases such as 
expanding FNH.
It has been documented that FNH lesions may show a slow and incidental in-
crease in size during follow-up. However change in size may cause doubt about the 
diagnosis and the benign character of the liver lesion 12. Growth of FNH has been 
suggested to be an indication for resection 13-15, although evidence for this approach 
is weak. The aim of this study was to evaluate how often a FNH grows, what are the 
implications for management and compare the patient characteristics of those with 
and without growing FNH.
Material and Methods
To evaluate the course of disease of FNH lesions increasing in size during follow-
up we performed a retrospective cohort study including all patients who had been 
diagnosed with FNH in the Erasmus University Medical Centre, a tertiary referral 
centre for focal liver lesions. Inclusion started in 2002, from the moment that we had 
the availability of two imaging techniques with high sensitivity and specificity to 
establish the diagnosis FNH and ran until 2015. Diagnosis FNH had to be confirmed 
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on at least two radiologic modalities, including at least one contrast-enhanced MRI 
and one contrast-enhanced CT-scan or CEUS and established in a multidisciplinary 
tumour board committee. Sequential imaging had to be available with at least a six 
month interval.
Baseline characteristics, including gender, age and body mass index (BMI), were 
collected from electronic patient records. Patients were scored as symptomatic if 
abdominal pain or general discomfort was reported in history. Information on the 
number and size of the FNH lesions were collected from radiological and histo-
logical reports. Data on clinical management were obtained from the reports of the 
multidisciplinary tumour board committee and correlated with data obtained from 
surgical, radiological and pathological reports.
The radiological reports of all patients were re-examined and growth was estab-
lished if an increase in size between the diagnostic scan (T1) and follow-up scan at 
least 6 months after the initial scan (T2) was found. The diagnostic and follow-up 
scans were reassessed independently by two experienced radiologists (R.D. and I.P) 
from two tertiary referral centres. Because of the imprecise measurements of size in 
small lesions and potential bias in outcome, patients with lesions <20mm in both 
diagnostic and follow-up scan were excluded. We defined growth as an increase in 
size of at least 20% according to the RECIST criteria for solid liver tumors 16, as no 
other criteria have been validated. To evaluate whether lesion growth was related to 
weight gain additional thickness of the subcutaneous fatty layer in the abdominal 
wall was measured on initial and follow-up imaging. Measurements were performed 
by both radiologists separately in the midline (linea alba) on the level of the origin 
of the celiac artery.
Radiology
In patients with a diagnosis of FNH who were found to have an increase in size, the 
diagnostic and follow-up scan were reviewed. MR imaging was performed with 1.5-T 
MR systems using a standard MRI protocol of T1-weighted, T2-weighted sequences 
and a dynamic contrast enhanced series after intravenous administration of a bolus 
of 30 ml of non-liver-specific gadolinium chelate (gadopentetate dimeglumine, 
Magnevist; Schering, Berlin, Germany). CT scans were performed with 16- and 64- 
detector machines with a multiphase CT protocol consisting of plain, arterial- and 
portal-venous dominant phase scans of the liver after iv administration of 120 cc 
(Visipaque, General Electric Healthcare Medical Systems, Milwaukee, Wisconsin, 
United States). The lesions were scored as typical FNH if they were lobulated, a 
central scar was present, the aspect of the lesion was homogenous on the diag-
nostic MRI conform generally accepted classical imaging features of FNH. If there 
was no consensus on diagnosis or MR imaging showed no typical FNH, pathological 
23
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examination had to have been performed for patients to be included in this study. If 
all imaging had been performed in collaborating hospitals according to our protocol 
the outcome was reviewed in our hospital.
Data analysis
All analyses were performed using the Statistical Package for the Social Sciences 
(SPSS) version 20.0 (SPSS, Chicago, IL, USA). Continuous variables were summarized 
as median and interquartile range and categorical data as n (%) in case of a de-
nominator >50 or a proportion/n in case of denominator <50. Differences between 
groups were assessed using the Mann-Whitney U test for continuous variables and 
χ2-test for binary variables. Correlation between variables was analysed using Pear-
son product-moment correlation coefficient. Statistical significance was considered 
at a p-value < 0.05.
RESULTS & DISCUSSION
Out of 372 patients with a suspected FNH, 162 (44%) were included for growth 
analysis as sequential imaging was available with at least a six month interval (figure 
1). The remaining 210 patients were excluded because follow-up was less than six 
months, they were discharged when diagnosis FNH was established. Three patients 
were excluded from growth analysis because the maximum diameter of the lesion 
was <20 mm on both diagnostic as well as on the follow-up scan. The diagnosis 
FNH was confirmed by the two radiologists in all cases. In 160 patients the diameter 
measurements from the first (T1) and last (T2) radiological reports were examined 
and in 28 patients (18%) an increase in size was found. Confirmation of increase 
with at least 20% was obtained in 19/28 patients as defined by both radiologists 
(figure 2).
Patients with growing and non-growing FNH did not differ regarding gender, age, 
BMI, number of lesions, symptoms or use of oral contraceptives (table 1). The number 
of patients who underwent surgery or embolization of FNH, and underwent follow-up 
for at least six months, was significantly higher in the growing FNH group compared 
to the non-growing FNH group (11% and 5% respectively, p = .009) although these 
patients had no complaints. No adverse events occurred in the patients with an FNH, 
including patients with growing FNH who did not undergo treatment.
Diagnostic biopsy was performed in 18/162 patients (11,1%), 4 histological 
examinations were inconclusive and 14 confirmed the diagnosis FNH. Indications 
for biopsy were growth in 4 and uncertainty about the diagnosis on imaging in 14.
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372 patients with FNH
162 patients with follow-up
≥6 months
210 patients with follow-up
<6 months
159 patients with FNH
diamter ≥20 mm
3 patients with FNH diameter
<20 mm
129 patients with no
suspicion of FNH growth
30 patients with suspicion of
FNH growth
11 patients with no
confirmation of FNH growth
≥20%
19 patient with confirmation
of FNH growth ≥20%
Figure 1. Flowchart inclusion
A B
Figure 2. Example of a growing FNH.
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In total 11/162 (6.7%) patients underwent resection (n=9) or embolization (n=2) 
of FNH. In all resected cases the diagnosis FNH was confi rmed by histological ex-
amination of the specimen. In 4/9 the radiological diagnosis was uncertain, in the 
remaining 5/9 patients the reason for resection was abdominal pain or dyspepsia. 
Abdominal pain only resolved in 1 patient who underwent treatment because of 
symptoms thought to be caused by FNH, in the remaining 4 patients the surgery did 
not provide symptom relief. The indication for embolization was abdominal pain in 
both patients, neither of them experienced symptom relief.
Growing FNhs
Characteristics of growing FNH are summarized in table 2 and 3. In the growing FNH 
group the median follow-up time was 31 months (IQR 25 – 42). Growth percentage 
ranged from 21.1% to 200% (fi gure 3). The majority of lesions (10/19) was located 
in the right hemi liver and 9/12 was left sided. Four patients underwent resection, 
three because growth caused doubt about the diagnosis and one because of a 
symptomatic lesion. Three resected FNH were located in the right lateral liver and 
one in the left lateral liver. Pathology reports of the resected lesions all confi rmed 
benign FNH. None of the patients who underwent resection had a diagnostic biopsy 
of the lesion before surgery.
In all 15 patients treated with a wait and see policy additional imaging was per-
formed (MRI with liver specifi c contrast or CEUS) which confi rmed the lesions to 
Table 1. Patient and lesion characterics
Growing FNH (n=19) Non-growing FNH (n=143) p-value
Female 19/19 137 (96%) .363
Age 33 (24-42) 34 (27-43) .248
BMI 25,5 (24-29) 24,7 (22-30) .351
Lesions     .677
Solitary 12/19 76 (53%)  
Multiple 7/19 67 (47%)  
Symptoms     .962
None 5/19 38 (27%)  
Upper abdominal pain 10/19 73 (51%)  
Atypical complaints 3/19 18 (13%)  
Elevated liver enzymes 1/19 10 (7%)  
Unknown 0/19 3 (2%)  
Treatment     .009
No 15/19 136 (95%)  
Yes 4/19 7 (5%)  
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be FNH. Thirteen out of these 15 were discharged from follow-up or were referred 
back to their initial hospital, two patients were kept in follow-up every 2-3 years 
according to their own wishes.
There was no statistically significant correlation between the growth percentage 
of the FNH and the percentage difference in subcutaneous fat (r =-.214, p =.340).
Table 2. Lesion characteristics of growing FNH
Patient Time between 
imaging 
sessions 
(weeks)
Number of 
lesions
Maximum 
diameter 
first imaging 
session (mm)
Maximum 
diameter 
last imaging 
session (mm)
Percentage 
increase T1 
– T2
Increase 
Subcutis mm 
(%)
1 136148 7 34*26 44*37 29,4% 20,50 (141%)
2 137 3 76*58 92*64 21,1% 2,50 (14%)
3 149 1 35*25 57*47 62,9 % -1,00 (-13%)
4 319 1 61*57 86*74 41,0 % -4,50 (-13%)
5 185 1 8*7 24*23 200,0 % ,50 (2%)
6 118 1 77*71 97*87 26,0 % -,50 (-2%)
7 258 5 66*48 83*53 25,8% 3,00 (9%)
8 235 1 54*46 76*65 40,7% -1,00 (-3%)
9 135 1 28*24 35*31 25,0 % 5,50 (46%)
10 151 2 22*21 58*43 163,6 % -4,50 (-21%)
11 111 1 45*36 61*52 35,6% 4,00 (24%)
12 50 1 53*36 65*49 22,6 % 13,50 (75%)
13 137 1 34*30 48*45 41,2 % 3,00 (15%)
14 115 1 33*24 54*40 63,6 % 7,50 (26%)
15 108 1 46*34 61*50 32,6% 6,50 (25%)
16 53 1 28*33 46*40 64,3 % -5 (- 9%) 
17 164 2 92*60 112*68 21,7 % -1 (- 5%) 
18 435 2 24*21 45*44 87,5 % -1 (-7%) 
19 118 1 52*41 64*46 23,1 % 4 (11%) 
Table 3. Summary of characteristics of growing FNH
Median follow-up time (months) 31 (IQR 25-42)
Location  
Right hemiliver 10
Left hemiliver 9
Conservative treatment 18/19
Resection 4/19
Doubt about diagnosis due to growth 3
Symptomatic lesion 1
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DISCUSSION
This study reports on a large series of patients with FNH and their follow-up. A 
specific focus of attention in our study was to evaluate if growth of FNH should 
have implications on clinical management, as growth may cause doubt about the 
initial diagnosis. In our study population 12% of the lesions showed growth over 
a period of at least six months. It should be noted that this figure most probably 
overestimates the incidence of growing FNH and there may be a bias in observation 
as the patients included in our analysis were referred to a tertiary referral centre 
because of uncertainty about the diagnosis and management.
The diagnosis FNH was confirmed by resection in 4 patients and additional imag-
ing in the form of MRI with liver specific contrast agents or CEUS in the rest of the 
patients. No adverse events were reported in the group of growing FNHs. In line 
with the studies of Weimann et al. 15 who observed 5 patients with growing FNH and 
Perrakis et al. 14 who described 13 patients with growing FNH, we were unable to 
identify risk factors for growth.
In the 18 biopsies that were performed in our cohort, 14 (77.8%) confirmed 
FNH, while in a recent study from Sannier et al. a diagnostic accuracy of 95% in 19 
patients was reported17. This could be explained by the fact that the accuracy for 
histologically diagnosing FNH and especially the distinction from other solid liver 
tumors such as hepatocellular adenoma and hepatocellular carcinoma has improved 
Figure 3. Size growing FNH
This figure shows the size (mm) on T1 (diagnostic scan) and T2 (follow-up scan) of the 19 FNH in 
which growth is confirmed.
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significantly in the study period. In 2009 Bioulac-Sage et al. 18 published a paper in 
which they were the first to describe abundant expression of Glutamine Synthetase 
as a marker to distinguish FNH from other hepatic lesions.
Our results suggest that growth of FNH is quite common and that growth in itself 
should not have any implications for clinical management. Growth may cause doubt 
about the initial diagnosis, but if imaging characteristics are typical for FNH this 
is not necessary. MRI with liver specific contrast agents in combination with CEUS 
has the highest accuracy for FNH diagnosis 19-21. Growth on itself may not be an 
indication for biopsy: in our center the final recommendation on whether or not . 
Growth on itself may not be an indication for biopsy: in our center biopsy is deemed 
necessary is made in a multidisciplinary liver tumour board meeting. In general, our 
recommendation is to only perform a biopsy when a discrepancy in diagnosis exists 
between the two imaging modalities. accurate . This could imply that some of the 
tumors were inadequately diagnosed as FNH before 2008. However by including 
only tumors 22 diagnosed based on two imaging modalities (MRI and CEUS) this 
proportion was kept to a minimum. . This could imply that some of the tumors were 
inadequately diagnosed as FNH before 2008. However by including only tumors 
that were diagnosed based on two imaging modalities (MRI and CEUS) this propor-
tion was kept to a minimum.
Differences in management between FNH and hepatocellular adenomas demand 
an accurate differentiation. Resection is indicated for hepatocellular adenoma if the 
tumour exceeds a diameter of 5cm 6 months after the use of Oral Contraceptive is 
stopped, because of the risk of bleeding 23. In contrast, for FNH no strict indications 
for resection are defined. As liver resections may have a peri-operative complication-
rate up to 20-25%, a diagnostic liver resection is not advisable 24. In the case of FNH, 
the liver-resections are generally performed in young, healthy women. As our study 
showed no complications of the conservative approach we advise to avoid resection 
as described in the EASL Clinical Practice Guideline 8, even if the lesion is growing.
FNH is often an incidental finding discovered by various imaging techniques. In 
our cohort we found that 26.5% of the patients were asymptomatic, while most 
studies have shown a large percentage of asymptomatic patients ranging from 65% 
14 to 90% 25. One possible explanation could be that the Erasmus Medical Hospital 
is a tertiary referral centre, and more patients with symptoms are referred. We as-
sume that most of the symptoms are not caused by the presence of FNH, and that 
FNH indeed could be asymptomatic. If treated, patients need to be comprehensively 
informed and it should be stressed that it may not be guaranteed that the abdominal 
pain will resolve . One possible explanation could be that the Erasmus Medical Hos-
pital is a tertiary referral centre, and more patients with symptoms are referred. We 
assume that most of the symptoms are not caused by the presence of FNH, and that 
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FNH indeed could be asymptomatic. If treated, patients need to be comprehensively 
informed and it should be stressed that it may not be guaranteed that the abdominal 
pain will resolve 26.
The biggest limitation of our retrospective study is the design that is inherent to 
bias. In addition, it may be questioned whether the sample size of the growing FNH 
group is large enough to justify the conclusion; however, with 19 patients we are the 
first to describe such a series of growing FNH and others may be challenged by this 
report to add new data.
In conclusion, our series confirm that FNH is not a static lesion and that growth 
may occur rather frequently. It must be noted that patients with a growing FNH do 
not report more pain or discomfort compared to the patients with non-growing FNH. 
Moreover, growth in itself should not have any implications on clinical management. 
In case of doubt, MRI with liver specific contrast agents in combination with CEUS 
provides the highest diagnostic accuracy. As these imaging techniques are not avail-
able in every hospital, patients could be referred to a centre specialized in focal 
liver lesions. Growth is not an indication for liver biopsy and biopsy should only be 
considered when the two imaging modalities do not provide the same diagnosis. 
No adverse outcomes were observed in patients with growing FNHs, therefore we 
recommend that even growing FNHs should not be resected and follow-up (growing) 
of FNH after a certain diagnosis made in a tertiary referral centre is not indicated.
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ABSTRACT
Aim
To identify patient and lesion characteristics associated with the occurrence of 
single or multiple HCA.
Methods
Using a tertiary centre database, we retrospectively collected information about pa-
tient and lesion characteristics, management and follow-up of all patients with HCA 
included between 2001 and 2016 Patients were classified in three groups; patients 
with a single HCA, 2-9 HCA and ≥10HCA.
Results
458 patients were diagnosed with HCA, including 121(26.4%) with single HCA, 
235(51.3%) with 2-9 HCA and 102(22.3%) with ≥10 HCA. Significant differences 
regarding mean Body Mass Index(BMI) were found with the highest BMI in patients 
with more than 10 HCA; (p<0.05). Mean BMI was significantly higher in patients with 
inflammatory HCA compared to steatotic HCA(31 vs 26 resp., p<0.05). Steatotic HCA 
were more often single lesions(22/55, 40%), while patients with inflammatory HCA 
were often diagnosed with multiple lesions(122/166, 73%).
Conclusions
Our series demonstrate a significantly higher BMI and frequency of inflammatory 
HCA in patients with multiple HCA compared to single HCA.
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INTRODUCTION
A validated molecular and pathological classification of hepatocellular adenoma 
(HCA) was introduced by Bioulac-Sage et al in 2009[1]. This classification identifies 
HCA with a different clinical outcome[1, 2]. One subgroup of steatotic HCA lacks the 
expression of the liver-fatty–acid binding protein and has a very low risk of bleeding 
or malignant proliferation (H-HCA, 35-50%)[3]. A second subgroup includes inflam-
matory HCA (I-HCA, 45-50%), a subtype which is at risk of having a β-catenin muta-
tion associated with an increased risk of malignant transformation and bleeding[4]. 
A third subgroup, is characterized by a β-catenin mutation (B-HCA, 15-18%). Finally, 
a group is being defined as unclassified as it does not show any specific features or 
mutations (U-HCA, 10%)[1, 5, 6].
All these different subtypes may present as a solitary lesion on imaging. A small 
minority of patients with HCA presents with liver adenomatosis (LA), defined by Fle-
jou and colleagues as the presence of more than 10 adenoma lesions in an otherwise 
normal liver parenchyma [7]. Only several case-reports and small case-series with 
patients with more than 10 HCA’s have been described[8]. However, as estimation 
of the exact number of HCA’s appears to be difficult, the term liver adenomatosis 
has been replaced by multiple HCA [9]. Multiple HCA’s have been described to be 
present in approximately 50% of all HCA.
Studies describing risk factors HCA are mainly based on analysis of a solitary HCA 
and include the long-term use of estrogen containing oral contraceptives, female 
gender and obesity[4, 10, 11]. It has yet to be studied whether risk factors for mul-
tiple HCA differ from single HCA.
It may be questioned whether patients with multiple HCA’s must be treated ac-
cording to the same guidelines, as those with solitary lesions. The EASL guideline on 
the management of benign liver tumours suggests to treat these patients based on 
the size of largest nodule as the risk of complications is not related to the number 
of HCA.[3, 12]. However, this might be challenging if there are multiple HCA > 5cm. 
With the availability of advanced imaging techniques and their increased use, liver 
lesions, including multiple adenomas, seem to be diagnosed more often. The man-
agement of these lesions may be a challenge for physicians as the guidelines may 
not always be applicable.
We studied which patients are at risk for multiple HCA and whether patients 
and lesion characteristics between single or multiple HCA differ. Furthermore, we 
investigated whether the presentation of single or multiple adenomas may lead to 
different management strategies.
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MATERIALS AND METhODS
The study protocol was in agreement with the ethical guidelines of the 1975 Decla-
ration of Helsinki and approved by the local Institutional Review Board and Ethical 
Committee from the Erasmus MC University. Informed consent was waived.
All patients who were diagnosed with HCA in our tertiary referral center for focal 
liver lesions (the Erasmus Medical Center, Rotterdam) between 1999 and 2016 were 
included. With the availability of data on the diagnosis of all consecutive patients 
in this period we selected those in whom the diagnosis had been confirmed on at 
least one MRI or, if indicated, by histopathological evaluation. The final diagnosis 
and management strategy had to be confirmed in a multidisciplinary hepatic tumor 
board committee.
From this database, we retrospectively collected baseline characteristics including 
gender, age and body mass index (BMI) from all patients. We derived the number (1 
HCA, 2-9 HCA or >10 HCA), size and presence of bleeding from the radiological and 
pathological reports. Tumour size was defined as the diameter of the largest HCA on 
MRI in mm. Bleeding was defined using MRI criteria: On T1-weighting a hematoma is 
hyperintense in the beginning becoming more and more isointense in the chronic 
phase; On T2-weighting a hematoma starts hyperintense and resolves in the chronic 
phase with zones of signal void (black) due to deposition of hemosiderine, mostly 
in the periphery.
Patients were subdivided in three groups: single HCA, multiple (2-9) HCA (MA) 
and >10 HCA or liver adenomatosis (LA). Noninvasive MRI diagnosis of HCA was 
based typical features including results of using liver specific contrast agents. HCA 
subtypes (H-HCA, I-HCA, β-HCA, β-IHCA and U-HCA) were based on immunohisto-
chemistry as described by the Bordeaux-group[13] or on typical MRI features: H-HCA 
diffuse and homogenous fat signal, IHCA hyperintensity on t2–weighted images and 
T1- hyperintensity on the delayed phase or atoll sign on T2-weighted images. B-HCA 
and U-HCA have no validated specific sign[14, 15].
Data analysis
All analyses were performed using the Statistical Package for the Social Sciences 
(SPSS) (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. 
Armonk, NY: IBM Corp). Differences between groups were assessed using a one-way 
ANOVA for continuous variables or chi-square test for categorical variables. Statisti-
cal significance was considered at a p-value < 0.05.
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RESULTS
Overall, 458 patients were included and 121 were found to have a single HCA 
(26.4%), 235 multiple HCA’s (51.3%) and 102 liver adenomatosis (22.3%). Baseline 
characteristics are presented in table 1. The median age at presentation was 39 (IQR 
15-78). Most patients were female (n=451, 98%) with 12 (2.6%) female patients 
having no history of oral contraceptive use. There were six male patients, all of which 
were diagnosed with a single HCA. One was found to have an H-HCA, 4 an I-HCA and 
1 a U-HCA. The median follow-up period of all patients was 34 months (IQR 17-49). 
No malignant transformation of any HCA into a Hepatocellular Carcinoma (HCC) was 
found in this period.
Comparison between these three groups showed a significant difference in BMI 
(kg/m²) with a median of 27.7 in patients with a single HCA, 30.4 in patients with 
MA, and 31.2 in patients with LA (Figure 1). Pairwise post-hoc analysis showed a 
significant difference on BMI between single HCA and MA, and HCA and LA. No 
difference between MA and LA was observed. Female gender and the use of oral 
contraceptives were significantly different between groups. A pairwise post-hoc 
analysis showed a difference between single HCA and MA and single HCA and LA. 
OC use was significantly higher in MA compared to single HCA and LA. There was no 
difference in age or bleeding of adenomas between groups.
A total of 267 HCA were classified according to the Bordeaux-classification based 
on MRI findings or pathology reports (table 2). The percentage of H-HCA (17%) was 
significantly lower in the group with MA/LA compared to HCA(Figure 2). 8 patients 
were found to have a β-catenin mutation based on pathology. I-HCA was the most 
Table 1. Patient characteristics (N=458)
  HCA
(N=121)
MA
(N=235)
LA
(N=102)
P-value
Age (years)1 38 (20-78) 38(20-66) 39 (15-59) 0.527
Female (n)2 115 (95%) 234 (99.6%) 102 (100%) 0.002
BMI (kg/m²)1 27.7 (17.0-41.0) 30.4 (18.3-62.1) 31.2 (20.3-47.4) 0.001
OC use (n)2 116 (94%) 233 (99%) 97 (94%) 0.005
Tumor size (mm)1 59 (9-177) 58 (9-200) 67 (12-200) 0.097
Tumor bleeding (n) 2 18 (15%) 53 (23%) 24 (24%) 0.172
This table shows patients characteristics of patients with single hepatocellular adenoma (HCA), mul-
tiple hepatocellular adenomas (MA) and liver adenomatosis (LA).
BMI, body mass index; OC, oral contraceptive.
1 Data are presented as median with the range between brackets.
2 Data are presented as numbers with the percentage between brackets.
P-values below 0.05 were considered statistically significant.
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common subgroup in single HCA as well as MA(63%). The median BMI in I-HCA was 
found to be 30.9 compared with a median BMI in H-HCA of 26.0, and 29.7 in U-HCA 
29.7 in B-HCA. Additional analyses were performed in patients in whom the largest 
lesion exceeded 50 mm as this specific group should be considered for resection 
Figure 1. This figure shows BMI of patients with a single hepatocellular adenoma, multiple liver 
adenomas and liver adenomatosis. HCA, hepatocellular cellular adenoma; MA, multiple adenoma’s; 
LA, liver adenomatosis; CI, confidence interval; BMI, body mass index.
Table 2. Bordeaux Classification
  Single HCA
(N=75)
MA/LA
(N=192)
P-value
H-HCA 22 (29%) 33 (17%) 0.023
I-HCA 44 (59%) 122 (64%) 0.485
B-HCA 1 (2%) 7 (4%) 0.449
U-HCA 7 (9%) 28(15%) 0.315
I-HCA +B-HCA 1 (1%) 2 (1%) 1.000
This table shows the Bordeaux classification the adenoma of patients with a liver adenomatosis, 
multiple liver adenomas and a single hepatocellular adenoma. HCA hepatocellular cellular adeno-
ma; MA multiple adenomas; LA liver adenomatosis; H-HCA steatotic HCA;, I-HCA Inflammatory HCA; 
B-HCA HCA with mutations of the β-Catenin Gene; U-HCA Unclassified HCA without markers.
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Figure 2. Multiple and subtype distribution of HCA depending on BMI
A,C,E; blue H-HCA; Green I-HCA, Grey B-HCA; Purple U-HCA, Yellow IB-HCA (Inflammatory and B-cat 
positive HCA)B,D,F; blue; single HCA, green: multiple HCA
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or other curative treatment as described in the EASL Clinical Practice Guidelines on 
the management of benign liver tumours[3]. Larger lesions were found in 56 (46%) 
single HCA’s, 109 (46%) MA’s and 54 (52%) LA’s. There were significant differences 
in intervention between the three groups (table 3). More patients with a single HCA 
underwent resection if the lesion exceeded 50 mm compared to patients with larger 
lesions in MA or LA.
DISCUSSION
In this study, we describe the largest series of patients with HCA, MA and LA with a 
follow-up of more than a decade. A review by Veteläinen et al. described 94 patients 
from case-reports and case-series with LA[8]. They reported abdominal ultrasound 
to be the initial imaging in all 94 patients but confirmation of the diagnosis using 
highly advanced imaging modalities like MRI, with or without contrast, or a contrast 
enhanced ultrasonography (CEUS) was often missing. Currently, in our hospital all 
patients with suspected benign hepatic tumour will receive an MRI, in at least four 
phases (precontrast, arterial, portal and delayed) after administration of an intrave-
nous bolus non-liver-specific gadolinium chelate or a liver specific contrast agent 
(Gadoxetate disodium, Primovist, Bayer Healthcare, Berlin, Germany or Gadobenate 
dimeglumine, Multihance, Bracco Imaging, Milan, Italy). Furthermore, patients are 
assessed with CEUS, using a second generation contrast agent Sonovue (2.4-4.8 
mL i.v. Bracco). Both imaging methods provide additional information that improves 
differentiation of liver lesions [16, 17].
In our series, we did not find MA in male patients. All 6 male patients had a single 
HCA. No patients had a history of using anabolic steroids.
The aetiology and pathogenesis of HCA is unknown although an association with 
the use of estrogens was described in 1973[18]. In the following years, many authors 
confirmed the hypothesis of an association between estrogen containing contracep-
tives and HCA[19-23]. Withdrawal of oral contraceptive in these patients will usu-
ally show regression of HCA[5]. However, we have yet to discover the physiological 
explanation for the association between estrogen and HCA. The data on sex steroid 
receptors are rare, inconsistent and some of them used outdated techniques[24]. 
The largest study which used immunohistochemical analysis, found an estrogen 
and progesterone receptor in 26% of the HCA[25]. However, they did not draw any 
conclusions about the correlation between the number of HCA and the presence of 
the sex steroid receptors. New steroid hormone receptors have been identified in 
recent years but have not yet been tested on HCA tissue[26-28].
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Estrogens are mostly known to be produced by the ovary. However adipose tis-
sue can contribute significantly to the pool of estrogens[26, 29]. Previous studies 
demonstrated that obese patients have higher estrogen levels compared to healthy 
individuals[29, 30]. This could explain the relation between BMI and number of HCA 
in this group of patients. In 2012 Rui et al. conducted a study in which they found 
that high BMI had a significant positive association with the risk of liver tumours[30]. 
Bioulac-Sage et al. first suggested a connection between overweight and HCA[31]. 
Bunchorntavakul et al. found 23 cases of MA in obese patients and suggested a 
correlation between MA and obesity[32]. We describe a significant difference in BMI 
between single HCA, MA and LA. Median BMI is highest in the group of patients 
with LA. We confirmed the suggested association between the number of HCA and 
BMI in a large group of patients. It has been suggested that HCA could decrease or 
disappear if patients lose weight[10]. The decrease could be attributed to a lower 
concentration of hormones due to weight loss[33]. Another explanation could be 
less inflammation due weight loss as enhanced inflammation in the metabolic syn-
drome allows cell growth to develop HCA[31, 32]. Currently all patients with HCA 
are advised to stop the use of OC as well as losing weight. Therefore it is not always 
clear if the regression is caused by the withdrawal of OC or by the weight loss.
The Bordeaux subtype classification was introduced and included in our data. Sub-
classification of the largest HCA was conducted in 267 patients. The incidence of the 
subgroup H-HCA has previously been reported as 30-40% of all HCA [34]. Patients 
with H-HCA and thereby germline mutations of HNF1A are predisposed to develop 
LA[34]. However in our cohort, only 8 patients with LA were classified as H-HCA. 
In patients with I-HCA obesity is a known risk factor. Furthermore the presence of 
I-HCA is associated with MA as well[8, 31, 32, 35, 36]. I-HCA and a high BMI seemed 
to cause LA in our cohort as well. The BMI in the patients with I-HCA was significantly 
higher compared to the patients with H-HCA and LA.
In our cohort the incidence of I-HCA is much higher compared to the distribution 
between the different subgroups described by the Bordeaux-group[34]. This could 
be explained by the rapidly rising incidence of obesity in women worldwide[37]. The 
rising incidence of obesity could lead to a shift towards I-HCA, which will be more 
frequently observed. Furthermore the prevalence of obesity in women is higher in 
the Netherlands (46.1%) compared to France (36.9%)[37].
We acknowledge that our study has a limitation. The final diagnoses were not all 
histologically proven. In those cases, combined imaging was used as the reference 
method for the final diagnosis, which was made after consensus in our multidisci-
plinary tumor board committee. In the early years diagnoses of HCA has been dif-
ferentiated from FNH with at least a conventional MRI. According to signal intensity 
and dynamic vascular patterns after intravenous aspecific gadolinium injection the 
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different benign liver tumors are differentiated[14]. However during the inclusion 
period of this study specific hepatobiliary contrast agents are introduced and the 
differentiation is now more specific in challenging cases[38].
Biopsy is only approved in our hospital only if there is doubt about the diagnosis 
or radiological examinations are not in agreement. However MRI approves a highly 
accurate diagnosis with a sensitivity of 91-100% and a specificity 87-100% for 
differentiating HCA from FNH[39]. The Bordeaux subtype classification was in most 
patients performed on MRI, it should be noticed the MRI features of B-HCA are 
not completly defined[40], therefor there could have been false negatives on MRI 
resulting in possibly an underestimation of B-HCA.
Further research regarding the role of obesity in HCA and the effect of weight loss 
needs to be done. Because of the higher risk of surgery and the co-morbidities of 
fatty liver we suggest to start with weight reduction in all obese patients[3]. If follow 
up demonstrates no decrease of the HCA treatment should be decided depending 
on the anatomic location and the steatosis of remaining liver tissue. The manage-
ment should be discussed by a multidisciplinary committee and strategies may be 
individualized.
Conclusion
Our series demonstrates a significantly higher BMI and frequency of inflammatory 
HCA in patients with multiple HCA compared to single HCA. As weight reduction 
could decrease the size of these HCA, this finding may help to personalize treat-
ment, focusing on tailor-made lifestyle monitoring with OC cessation and body 
weight reduction in this specific subgroup.
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ABSTRACT
Background
Hepatocellular adenoma(HCA) is a benign liver tumor that may be complicated by 
bleeding or malignant transformation. Present guidelines advise cessation of oral 
contraceptives and surgical resection if the lesion is still >5cm at six months after 
diagnosis. The aim of this study was to evaluate whether this six month interval is 
sufficient to expect regression to ≤5cm in large HCA.
Method
This retrospective cohort study included all patients with HCA >5cm diagnosed 
between 1999-2015 with a follow-up time of at least six months. Medical records 
were reviewed for patient characteristics, clinical presentation, lesion characteris-
tics, management and complications. Differences in characteristics were addressed 
between patients kept under surveillance and patients who underwent treatment 
for HCA>5cm.
Results
Some 194 patients were include, of which 192 were female. Patients in the surveil-
lance group(n=86) had a significantly higher BMI(p=.029), smaller baseline HCA-
diameter(p<.001), more centrally located(p<.001) and more frequently multiple 
lesions(p<.001) compared to the treatment group(n=108). No significant differences 
were found for sex, baseline-age, symptoms, complication-rates and HCA-subtype 
distribution. Time-to-event analysis in conservatively treated and patients undergo-
ing treatment >six months after diagnosis showed 69/118 HCA(58.5%) regressing 
to ≤5cm after a median of 104 weeks(95%-CI 80-128). Larger HCA took longer to 
regress(p<.001). No complications were documented during follow-up.
Conclusion
This study suggests that a six-month cut-off point for assessment of regression 
of HCA >5cm to ≤5cm is too early. As no complications were documented during 
follow-up, the cut-off point in females with typical, non-β-catenin mutated HCA 
could be prolonged to twelve months irrespective of baseline-diameter.
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INTRODUCTION
Hepatocellular adenoma (HCA) is a benign liver tumor occurring mostly in women in 
their reproductive phase. It has an incidence of approximately one per million per 
year in the general population compared to 30-40 per million per year in long-term 
estrogen-containing oral contraceptive (OC) users [1, 2]. Regression of HCA may oc-
cur with cessation of OC [3]. Other conditions that have been associated with HCA 
are obesity, the metabolic syndrome and the intake of androgens [4-7].
Four HCA subgroups have been described based on genetic and phenotype 
characteristics. These include steatotic (H-HCA), inflammatory (I-HCA), β-catenin ac-
tivated (β-HCA) and unclassified (U-HCA) adenomas. Another combined group that is 
both inflammatory and β-catenin activated (β-IHCA) has also been suggested to exist 
[8, 9]. Distinction between the subtypes can be made immunohistochemically and 
radiologically. HCA can be complicated by growth and rupture causing potentially 
life-threatening hemorrhage. The latter is thought to occur mostly in I-HCA [10]. An-
other possible complication is malignant degeneration to Hepatocellular Carcinoma 
(HCC) which has been reported particularly in β-HCA [11, 12]. Both hemorrhage and 
malignant degeneration occur mostly in HCA >5cm [13].
The diagnosis HCA can be made based on contrast-enhanced MRI (CE-MRI), 
contrast-enhanced CT (CE-CT) or contrast-enhanced ultrasound (CEUS) [14, 15]. In 
case of inconclusive imaging, a liver biopsy may be considered if the result would 
have an impact on treatment decisions.
In 2016 the European Association for the Study of the Liver (EASL) issued a guide-
line regarding the management of benign liver tumors [16]. In females a conserva-
tive approach was deemed justified which consists of cessation of OC and weight 
reduction. Significant growth (>20% according to the RECIST criteria [17]) or a HCA 
diameter >5cm after six months was stated as an indication for resection. In case 
of contraindications for resection, trans arterial embolization (TAE) was suggested 
for consideration as a treatment of larger HCA and radio frequent ablation (RFA) for 
smaller HCA [16].
As many HCAs regress after cessation of OC, waiting for the lesion to shrink to 
<5cm might be sensible. Evidence regarding the optimal timing of surgery for HCA 
is lacking in the world literature and the six month interval as suggested in the EASL 
guideline is based on expert opinions. In large HCA lesions located centrally in the 
liver or in multiple bilobal HCA, resection may be challenging. As liver resections 
may have a perioperative complication rate up to 20% and mortality rate up to 
3.1%, which increases with the presence of steatosis, resection should only be 
considered if necessary[18-21].
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The aim of this study was to determine if a 6-month follow-up period is sufficient 
in large HCA (>5cm) to expect regression to ≤5cm, as is suggested in the EASL 
guideline. In addition, the differences in clinical and lesion characteristics between 
patients who were kept under surveillance and patients who underwent treatment 
for HCA >5cm and the indications for treatment were assessed.
METhODS
This was a retrospective cohort study performed in a tertiary hepatobiliary referral 
center in the Netherlands. All patients, both male as female, diagnosed with a base-
line HCA diameter >5cm between January 1999 and December 2015 were included. 
The diagnosis of HCA had to be based on imaging (CE-MRI) or histological examina-
tion (biopsy or resection specimen). Patients with less than 6 months follow-up time 
at the authors institute were excluded.
Medical records were reviewed for patient characteristics (sex, age at diagnosis, 
BMI), clinical presentation (symptoms), OC use, lesion characteristics (size of the 
lesion, location of the HCA in the liver, number of lesions, HCA-subtype), manage-
ment (treatment, follow-up) and the occurrence of complications (hemorrhage or 
malignant degeneration).
Symptoms were scored as no symptoms, upper abdominal pain or atypical com-
plaints at the time of diagnosis. The location of HCA in the liver was described as 
centrally located in the liver (segment I-IV-V-VIII) or in the left (segment VI-VII) or 
right (segment II-III) hemiliver. The number of HCAs were documented as solitary 
or multiple (>1). HCA subtypes were based on immunohistochemistry as described 
by the Bordeaux-group [22] or on typical MRI features [15, 23, 24] and subdivided 
in H-HCA (steatotic HCA), I-HCA (inflammatory HCA), β-HCA (β-catenin activated 
HCA),β-IHCA (combined inflammatory and β-catenin activated HCA) and U-HCA (un-
classified HCA). If the HCA subtype had not yet been established by MRI or biopsy in 
patients, previous available MRI imaging was reassessed by a specialized abdominal 
radiologist. Hemorrhage of HCA was divided into grade I (intratumoral), grade II 
(intrahepatic) and grade III (extrahepatic) [10]. Malignant degeneration was based 
on histological examination of biopsies or resection specimens.
All imaging performed during follow-up was reviewed to assess whether lesions 
regressed to ≤5cm and how many weeks after diagnosis and cessation of OC this 
reduction occurred. Size of the HCA was documented at four moments in time: 
baseline imaging at the moment of diagnosis (T0), at ± 26 weeks (T1), ± 52 weeks 
(T2) and at last imaging available (T3). Patients were subdivided into two groups: 
one group of patients who were kept under surveillance with regular imaging and 
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did not undergo any intervention and a second group of patients who underwent 
surgery or other interventional techniques as a treatment for HCA. All patients in 
the surveillance group were advised to stop OC or other systemic hormonal con-
traceptives (hormonal intrauterine devices were allowed) and in case of obesity to 
lose weight. In the intervention group the intervention performed was documented, 
as were the indication for intervention and time from diagnosis to intervention. A 
sub division was made between patients who underwent an intervention without 
follow-up imaging beyond T0 (early interventions) and patients who underwent an 
intervention after imaging at T1, T2 or T3 (late interventions). Time-to-event analysis 
for the event “regression to <5cm” was performed in patients in the surveillance 
group and patients in the late intervention group. Patients in the early intervention 
group were excluded from time-to-event analysis.
Statistical analysis was performed with IBM SPSS software version 21.0 (Chicago, 
Illinois). Continuous variables were summarized as mean (µ) and standard deviation 
(SD) in case of normal distribution and as median and interquartile range (IQR) in 
case of non-normal distribution. Binary variables were summarized as frequency 
(n) and percentages (%). Differences between groups were analyzed using student 
T-test or Mann-Whitney U test for continuous variables and χ2 test for categorical 
variables. Time-to-event analysis was performed using the Kaplan-Meier method 
and log-rank test. A p-value of <.05 was considered as the level of significance. This 
study was approved by the accredited local institutional review board.
RESULTS
A total of 241 patients with an HCA >5cm at baseline were identified. Forty-seven 
patients were excluded because follow-up time at the institute was <6 months: these 
patients were either referred back to the initial hospital or lost to follow-up due 
to patient non-compliance. Of the remaining 194 patients (of which 192 female), 
86 were kept under surveillance and 108 were treated with resection or another 
intervention. In the surveillance group, 70/86 had MRI proven HCA and 16/86 had 
biopsy proven HCA.
Comparison of clinical and lesion characteristics
The comparison of clinical and lesion characteristics between the surveillance group 
and intervention group is summarized in table 1. There were no statistically signifi-
cant differences for sex, median age at diagnosis, OC use, symptoms, hemorrhage or 
malignant degeneration.
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Table 1. Comparison of clinical and lesion characteristics: surveillance vs intervention
  Surveillance (n = 86) Intervention (n = 108) p-value
Sex     ns.
  Male 0 2 (1.9%)  
  Female 86 (100%) 106 (98.1%)  
Median age at diagnosis (yr) 38 (31-46) 36 (30-44) ns.
Median BMI (kg/m2) 31,6 (25,8-35,1) 28,5 (24,5-33,0) .029
Symptoms     ns.
  None 30 (34.9%) 34 (31.5%)  
  Upper abdominal pain 45 (52.3%) 58 (53.7%)  
  Atypical 11 (12.9%) 16 (14.8%)  
Oral contraceptive use   ns.
  Never 2 (2.3%) 5 (4.6%)  
  At diagnosis 57 (66.3%) 51 (47.2%)  
  Before diagnosis 27 (31.4%) 47 (43.5%)  
  Unknown 0 3 (2.8%)  
Median diameter of HCA at diagnosis (mm) 71 (60-90) 88 (72-110) <.001
Location of HCA      
  Right hemiliver 25 (29.1%) 52 (48.1%) .007
  Left hemiliver 9 (10.5%) 29 (26.9%) .004
  Central 52 (60.5%) 27 (25.0%) <.001
No. of lesions     .001
  Solitary 13 (15.1%) 39 (36.1%)  
  Multiple 73 (84.9%) 69 (63.9%)  
HCA subtype      
  H-HCA 11 (12.8%) 16 (14.8%) ns.
  I-HCA 40 (46.5%) 60 (55.6%) ns.
  β-HCA 0 1 (0.9%) ns.
  β-IHCA 0 3 (2.8%) ns.
  U-HCA 5 (5.8%) 11 (10.2%) ns.
  Unknown 30 (34.9%) 17 (15.7%) 0.002
Hemorrhage     ns.
  Grade I 18 (20.9%) 25 (23.1%)  
  Grade II 5 (5.8%) 4 (3.7%)  
  Grade III 2 (2.3%) 0  
  No 61 (70.9%) 79 (73.1%)  
Malignant degeneration     ns.
  Yes 0 3 (2.8%)  
  No 86 (100%) 105 (97.2%)  
This table shows baseline characteristics of patients in the surveillance group and intervention 
group and whether the characteristics between the groups differ significantly. Values are in median 
(IQR) or n (%). The HCA-subtypes are explained in the methods section.
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Patients who were kept under surveillance had a higher median BMI than patients 
in the intervention group (p=.029). The median diameter of HCA at diagnosis was 
higher in the intervention group (p<.001). In the surveillance group, HCAs were 
more often located centrally in the liver (p<.001) while in the intervention group 
HCAs were more often located in the right or left hemiliver (p=.008 and p=.003, 
respectively). In the intervention group more patients had solitary lesions compared 
to the surveillance group (p<.001).
The distribution of HCA-subtypes in the surveillance and intervention group was 
not statistically different, although the proportion of unknown subtypes was higher 
in the surveillance group (p=.002).
Intervention group
Out of 108 patients who underwent an intervention, 94 (87.0%) had a resection, 9 
(8.3%) underwent TAE and 5 (4.6%) underwent RFA (table 2). The median time from 
diagnosis to resection was 5 months (IQR 3,5-17). Seventy-three resections were 
early interventions, of which the majority I-HCA (56.2%). The most common indica-
tions were atypical characteristics on imaging and size >5cm. Twenty-one resections 
were late interventions of which also the majority were I-HCA and size as the most 
common indication.
The median time from diagnosis to TAE was 7 months (IQR 2,5-19,5). Out of the 
nine patients who underwent TAE, three were early interventions, 2 because of hem-
orrhage and 1 because of size >5cm. The remaining 6 TAE were late interventions 
and indications were size in 3, previous hemorrhage in 2 and pregnancy wish in 1.
All 5 RFAs were late interventions with a median time from diagnosis to RFA of 
34 months (IQR 18,5-46). In all patients the lesion regressed to ≤5cm. In four the 
indication for RFA was a pregnancy wish and one patient had a residual adenoma 
after hemorrhage for which RFA was performed.
Time-to-event analysis
The median diameter and IQR of HCA at the four time points is depicted in figure 1A. 
Out of the 86 patients who were kept under surveillance, four patients did not have 
follow-up imaging at T1, one due to patient non-compliance and in three patients a 
one-year interval was decided instead of a six-month interval. Fifteen patients did 
not have imaging at T2 because a one-year interval was decided after T1. Another 
fifteen patients did not have imaging at T3: seven were referred back to their initial 
hospital, six are still in follow-up and two patients were lost to follow-up. 32 patients 
from the intervention group had imaging beyond T0.
A total of 118 patients were included in the time-to-event analysis. At 26 ± 4 
weeks 10-18 out of 118 HCAs (8.5 - 15.3%) showed regression to ≤5cm and at 52 
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± 4 weeks this was 28-32 out of 118 (23.7 – 27.1%). At the end of follow-up a total 
of 69 HCA (58.5%) showed regression to ≤5cm after a median time of 104 weeks 
(95%-CI 80-128 weeks) (figure 1B).
A sub-analysis based on baseline HCA diameter showed that 38/44 HCA <7cm 
regressed to ≤5cm after a median time of 63 weeks, 25/51 HCA 7-10cm after a 
median of 109 weeks and 6/23 HCA >10cm after a median of 208 weeks (p<.001)
(figure 1C). No statistically significant differences were found between HCA-subtype 
and median time for the event “regression ≤5cm” to occur (p=.476, figure 1D). An 
example of a regressing HCA is shown in figure 2.
Out of the 69 patients in whom the HCA regressed to ≤5cm, 45 (65.2%) stopped 
OAC at the moment of diagnosis, 23 (33.3%) prior to diagnosis and 1 never used 
Table 2. Interventions for HCA.
Intervention n Mo. from diagnosis 
tointervention
Resection 94 (87.0%) 5 (3,5-17)
TAE 9 (8.3%) 7 (2,5-19,5)
RFA 5 (4.6%) 34 (18,5-46)
 
 
Early interventions Late interventions
Resection 
(n=73)
TAE 
(n=3)
RFA 
(n=0)
Resection 
(n=21)
TAE 
(n=6)
RFA 
(n=5)
HCA-subtype            
  H-HCA 12 (16.4%) - - 1 3 -
  I-HCA 41 (56.2%) - - 18 1 -
  β-HCA 1 (1.4%) - - - - -
  β-IHCA 3 (4.1%) - - - - -
  U-HCA 9 (12.3%) 1 - 1 - -
  Unknown 7 (9.6%) 2 - 1 2 5
Indication            
  Size 24 (32.9%) 1 - 11 3 -
  Atypical imaging characteristics 22 (30.1%) - - 2 - -
  Pregnancy wish 8 (11.0%) - - 1 1 4
  Hemorrhage 5 (6.8%) 2 - 1 2 1
  Growth 7 (9.6%) - - 1 - -
  No regression after cessation of OAC 4 (5.6%) - - 4 - -
  Symptoms 1 (1.4%) - - 1 - -
  Need for hormonal substitution 1 (1.4%) - - - - -
This table shows the median (IQR) time from diagnosis to intervention in months. Interventions were 
subdivided in early interventions (without follow-up imaging beyond T0) and late interventions (af-
ter imaging at T1, T2 or T3). The HCA-subtypes are explained in the methods section.
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OAC. Out of the 49 patients in whom the HCA did not regress to ≤5cm, 28 stopped 
OAC at the moment of diagnosis, 19 prior to diagnosis and 2 never used OAC.
There were 22 patients in whom the HCA remained the exact same size at T1 com-
pared to T0 (with a 5mm measurement error). Twelve out of these 22 HCA eventually 
did regress to ≤5cm . No complications occurred during the surveillance period. In 
all of the patients who had a bleed from an HCA, that was the initial presentation.
DISCUSSION
This retrospective cohort study including 194 patients with an HCA greater than 5cm 
at baseline evaluated if a 6-month follow-up period after stopping OC is sufficient 
Figure 1. Diameter of HCA and regression to ≤ 5cm.
A: Median diameter and IQR of HCA at four moments in time: baseline imaging at the moment of 
diagnosis (T0, 75mm), at 6 months (T1, 61.5mm), 12 months (T2, 56mm) and at last imaging avail-
able (T3, 44mm).
B: Kaplan-Meier curve for the event regression to ≤ 5cm, all HCAs combined.
C: Kaplan-Meier curve for the event regression to ≤ 5cm, subdivided per baseline HCA diameter.
D: Kaplan-Meier curve for the event regression to ≤ 5cm, subdivided per HCA-subtype.
H-HCA: steatotic HCA. I-HCA: inflammatory HCA. U-HCA: unclassified HCA.
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to expect regression of the HCA to less than 5cm. This time period is suggested in 
the EASL guideline on the management of benign liver tumors [16]. As evidence 
regarding the optimal timing of surgery for HCA is lacking in the world literature, the 
suggested six-month interval is based on expert opinion [25]. The present results 
suggest that this interval is too short and that surgery for large HCAs should prob-
ably be performed with more restraint.
In this study less than 15% of the HCAs showed regression to less than 5cm after 
interval half year and only about 25%after a year. At the end of follow-up about 60% 
decreased in size to ≤5cm after about two years by extending the follow-up time, 
many unnecessary resections could be avoided. As patients with HCA frequently 
have obesity and hepatic steatosis 26 and the risk of complications due to surgery 
is higher in these patients [20, 21], this could provide a considerable health benefit.
Figure 2. Example of a patient with HCA regression over time.
T1-weighted MRI in the arterial phase after injection of contrast. Twenty-three year old patient who 
used oral contraceptives, incidental finding on ultrasound.
A: Baseline imaging, 93mm I-HCA in segment 6/7/8.
B: Imaging 7 months after cessation of oral contraceptives, regression of the HCA to 55mm.
C: Imaging 16 months after baseline, regression to 45mm.
D: Imaging 29 months after baseline shows regression to 14mm seen as a small perfusion defect.
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Additional analysis showed that HCAs with a larger diameter at baseline take 
considerably longer to regress to ≤5cm. Hemorrhage was only seen at initial presen-
tation and no rupture or bleeding of HCAs was reported during the follow-up period. 
There were no differences between HCA-subtypes in median time to regression to 
≤5cm. However, this lack of differences in the sub analysis might be a result of the 
small sample size.
Of the patients in whom regression to ≤5cm was reported, two thirds stopped OAC 
at the moment of diagnosis and one third prior to diagnosis. Similar numbers were 
seen in patients in whom the HCA did not regress to ≤5cm.
A comparison between patients kept under surveillance and patients who had 
intervention for HCA >5cm showed that BMI was higher for patients in the surveil-
lance group. The mean diameter of HCA at diagnosis was higher in the intervention 
group. Additionally, more patients with centrally located HCA and multiple lesions 
were kept under surveillance. This could be explained by the fact that in patients 
who are less suitable for surgery due to a higher BMI, multiple lesions or tumor 
location, clinicians are more likely to propose a conservative approach due to a 
higher chance of perioperative complications. Additionally, in patients with larger 
HCA at the time of diagnosis, clinicians might assume the tumor will not reach the 
point of regression to ≤5cm and therefore resection is thought to be inevitable. No 
differences between the surveillance and intervention group were found for sex, 
mean age at diagnosis, symptoms, HCA-subtype and the occurrence of hemorrhage 
or malignant degeneration.
Most patients in the intervention group underwent resection of the HCA. A subdi-
vision into early and late interventions showed atypical imaging characteristics and 
size to be indications for the majority of early resections and size >5cm to be the 
indication for the majority of late resections. Indications for early TAE were hemor-
rhage and for late TAE size >5cm, hemorrhage or pregnancy wish. All RFAs were late 
interventions performed in patients with HCA that had already regressed to ≤5cm. 
Indications were pregnancy wish or residual adenoma after hemorrhage.
Based on this study, a more conservative approach of HCA seems justified. How-
ever, as β-HCA and β-IHCA have a higher risk of malignant degeneration [11, 12], the 
determination of HCA-subtype becomes increasingly important. In this cohort, all 
four patients with β-HCA and β-IHCA had early resections. A conservative approach 
may not be justified if the HCA-subtype is not established. There are still some cases 
that require early resection and should not be kept under surveillance, for instance 
in biopsy proven β-HCA and β-IHCA, atypical imaging characteristics and HCA in 
men. In this cohort, 12 patients with H-HCA also underwent early resection. Given 
the most recent literature concerning low risk of complications in H-HCA and the 
results of the present study, a more conservative approach in these patients seems 
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justified. Unfortunately, the reliability of biopsy for HCA is not well studied and the 
number of misclassifications is unsure. Therefore, future studies should focus on the 
diagnostic value of biopsy for subtype classification and the distinction between 
HCA and well differentiated HCC.
As the risk of complications is higher in large HCAs, it would be advisable to keep 
patients under strict follow-up. Follow-up every six months when the lesion is >5cm 
and annually or biennially when the lesion has regressed to ≤5cm, until the occur-
rence of menopause, seems justified (figure 3) [26].
The strength of the present study is that all results were based on a large, repre-
sentative cohort with long follow-up. In 2015 Chun et al. performed a retrospective 
cohort study of 79 patients in which they aimed to validate a surveillance algorithm 
for women with small (<5cm) HCA [27]. They concluded that patients with HCA <5cm 
Figure 3. Flowchart for the management of benign liver tumors.
Adapted from EASL Clinical Practice Guidelines on the management of benign liver tumors16.
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can be kept under surveillance at 6, 12 and 24 months after diagnosis and that 
cessation of follow-up may be considered if lesions remain stable or decrease in 
size. The present study also assessed the surveillance interval of large HCAs. Future 
research should focus on the identification of factors that influence the natural 
course of HCA with the aim of predicting which HCA will regress to ≤5cm and which 
will require invasive treatment.
The present study might be subject to a few limitations. The retrospective design is 
inherent to bias. Another limitation might lie in the fact that patients were included 
between January 1999 and December 2015. In this time frame the quality of the im-
aging techniques has improved considerably, especially regarding the classification 
of HCA subtypes. A final limitation of the present study is the interval censoring, as 
the follow-up scan provided the measurements at a set moment in time. Therefore 
the exact moment at which the HCA became ≤5cm remains unknown. To overcome 
this limitation, the number of HCA that became ≤5cm after a half year and a year is 
reported with a 4-week interval. The present results suggest that a cut-off point of 
six months for the consideration of resection in HCA >5cm is insufficient to expect 
regression and that surgery for large HCA should be delayed and exercised with 
more restraint.
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ABSTRACT
Contrast-enhanced ultrasound (CEUS) is an emerging imaging technique that is 
increasingly used to diagnose liver lesions. It is of the utmost importance to differ-
entiate between the two most common solid focal liver lesions (i.e. hepatocellular 
adenoma (HCA) and focal nodular hyperplasia (FNH)), because their management 
and follow-up differ greatly.
The main objective of our study was to determine how frequently the specific 
CEUS features of HCA and FNH are visible on CEUS and to define their predictive 
value for discrimination between HCA and FNH.
In total, 324 CEUS examinations performed on patients with FNH (n=181) or HCA 
(n=143) were included. Patients with HCA and FNH significantly differed with respect 
to age and CEUS features of steatosis, echogenicity, homogeneity, the presence of a 
central scar, central artery, arterial enhancement pattern, necrosis or thrombus, and 
enhancement in the late venous phase.
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INTRODUCTION
Abdominal ultrasound examination is readily available and frequently used in virtu-
ally every hospital. Consequently, during examination of complaints that are not 
directly related to the liver, a lot of patients are misdiagnosed with a focal lesion in 
the liver on ultrasound. Most of these lesions are of benign origin, such as heman-
giomas, simple cysts, focal nodular hyperplasia (FNH) or hepatocellular adenoma 
(HCA). Some lesions, such as simple cysts, can be diagnosed on ultrasound. However, 
solid liver lesions, such as FNH and HCA, need further characterization. Accurate 
diagnosis is of the utmost importance because treatments for the conditions differ 
greatly. FNH is a benign lesion with no malignant transformation, symptoms that 
may resolve during follow-up and a very low incidence of bleeding (Behrend and 
Flemming 2001, Belghiti and Cauchy 2014). Therefore, if the diagnosis is firmly 
established, treatment is rarely indicated (Belghiti and Cauchy 2014, Terkivatan 
and Hussain 2006). HCA, on the other hand, has a risk of hemorrhage, rupture and 
malignant transformation, and treatment might be indicated (European Association 
for the Study of the Liver . Electronic address 2016).
Macroscopically, FNH tends to be lobulated and in most cases it has a central 
stellate scar (central element) which radiates into nodules of normal hepatocytes 
(Terkivatan and Hussain 2006). The central scar contains a fibrous stroma and mal-
formed vascular structure, the central artery. From this anomalous central artery, the 
arterial blood often flows centrifugally (stellate-type contrast agent distribution), 
which is in contrast to HCA (Hussain and Terkivatan 2004). HCA tends to have pe-
ripheral subscapular vessels, which cause diffuse homogenous arterial filling. These 
characteristics can be used to discriminate the two conditions.
Until recently, magnetic resonance imaging (MRI) or needle biopsy were needed for 
characterization (Thomeer and ME 2014, van Aalten and Thomeer 2011). However, 
recent FDA approval of the contrast agent Lumason (Sonovue, Bracco) will increase 
interest in, and use of CEUS in clinical medicine.
CEUS is an emerging imaging technique that is increasingly used to diagnose 
solid focal liver lesions. The use of microbubble ultrasound contrast agents allows 
detailed assessment of vasculature patterns. The detection and characterization 
of solid liver tumors has improved considerably using CEUS (Claudon and Dietrich 
2013).
The extensively described washout phase, defined as negative enhancement in 
the tumor 75 seconds after injection of the microbubble contrast agent, is used to 
differentiate between benign and malignant liver lesions (Bhayana and Kim 2010). 
Furthermore, a centrifugal hypervascular enhancement pattern (FNH), diffuse 
arterial enhancement in the arterial phase (HCA), a central scar (FNH), contrast-
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enhancement in the late phase (FNH) and the presence of thrombus or necrosis 
(adenoma) are CEUS characteristics that help to differentiate between FNH and HCA. 
Moreover, a centrifugal hypervascular enhancement pattern in the arterial phase 
may be an essential feature for the diagnosis of non-typical FNH (Alberti and Frulio 
2014). However, the frequency of the presence of features for HCA and FNH on CEUS 
and its capacity to differentiate between HCA and FNH have only been described 
in a few small series (Friedrich-Rust and Klopffleisch 2013, Kong and Wang 2015, 
Roche and Pigneur 2015). A meta-analysis concluded that a detailed evaluation of 
HCA by CEUS was not possible because of the low numbers of patients with HCA 
(Friedrich-Rust and Klopffleisch 2013). Thereafter, 28 patients with FNH and 10 
patients with HCA have been described and showed 66% of the lesions using CEUS 
were correctly diagnosed compared to 40% of the lesions using color Doppler ul-
trasound (Kong and Wang 2015). Roche (2015) described 40 patients (31 with only 
FNH, seven with only HCA and two patients with both FNH and HCA) and suggest 
that it is a useful adjunct tool, especially in assessing smaller lesions, with an almost 
perfect inter-observer agreement (Roche and Pigneur 2015).
Guidelines outline steps for diagnosing benign solid liver tumors with CEUS and 
indicate that the specific feature in FNH is a centrifugal hypervascular enhancement 
pattern in the arterial phase. This specific feature can be used to differentiate FNH 
from HCA and could even be an essential step for the diagnosis of non-typical FNH 
(Alberti and Frulio 2014).
HCA, on the other hand, should have a diffuse arterial enhancement in the arterial 
phase. Other known patterns include central scar (in B-mode as a CEUS late phase), 
contrast enhancement in the late phase (both patterns described in FNH), or the 
presence of thrombus or necrosis (adenoma).
According to the literature, describing the characteristics of FNH and HCA in MRI, 
some findings are more typical than others (Thomeer and ME 2014). For example, the 
central scar, which is more commonly described in FNH, was also found in 21% of 
confirmed HCA cases (Hussain and Terkivatan 2004, van Aalten and Thomeer 2011).
How often the specific features described for HCA and FNH are present and visible 
on CEUS has not been satisfactorily described. Therefore, the main objective of our 
study was to determine how frequently the specific features of HCA and FNH are 
displayed on CEUS. We also sought to define the predictive value of features for the 
discrimination between HCA and FNH on CEUS.
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MATERIALS AND METhODS
The study was performed in accordance with the ethical guidelines of the 1975 
Declaration of Helsinki and approved by the local Institutional Review Board and 
Ethical Committee from the Erasmus MC University Medical Center. The need for 
written informed consent was waived.
Patients
In total, 324 CEUS examinations performed between 2007 and 2014 in patients with 
confirmed FNH or HCA were available for review in this study. CEUS findings were 
only included if the diagnosis of the lesion had been confirmed using at least two 
radiologic modalities, including at least one magnetic resonance imaging (MRI) ex-
amination with the use of a liver-specific contrast agent. Consensus on the diagnosis 
was reached after discussion within our multidisciplinary tumor board committee or 
if the lesion was histologically confirmed (by biopsy or surgical resection). Patient 
characteristics were collected from the electronic hospital records.
Contrast-enhanced ultrasound (CEUS)
CEUS was introduced in our hospital as an additional radiologic modality. CEUS was 
performed by various sonographers, but all exams were reviewed by a specialist 
with more than 20 years of experience in liver ultrasound and more than nine years 
of experience in CEUS. The sonographers were blinded to the patients’ pre-existing 
imaging (computed tomography (CT), MRI) information. CEUS was performed using 
the Hitachi 900 and Hitachi Preirus ultrasound platforms (Hitachi Medical Systems, 
Japan) with real-time grayscale, contrast-tuned imaging and a 2.5–5.0 MHz probe. 
The contrast agent used was SonoVue (Bracco, Italy; dose range 1.0–2.4 ml; repeated 
if needed and flushed by isotonic saline).
Ultrasound examination was performed in a standardized fashion. First, all 
patients underwent unenhanced abdominal and hepatic sonography using the 
fundamental color/power Doppler technique. The location, number, size, and so-
nographic features of the focal liver lesions were recorded. In case of significant 
hepatic steatosis, identifying a specific liver mass with Ultrasound (US) might be 
more difficult. However, when switched to the CEUS mode, specific features appear, 
which can be used to differentiate the different liver masses. Three phases can be 
observed with CEUS because of the unique network of the hepatic artery and the 
portal vein, (Claudon and Cosgrove 2008, Jang and Kim 2006, Piscaglia and Len-
cioni 2010, Piscaglia and Venturi 2010). CEUS was performed during the hepatic 
arterial (10–40 s post-injection), portal venous (40–120 s post-injection), and late 
parenchymal phases (> 120 s, bubble disappearance), according to the standardized 
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EFSUMB protocol (Piscaglia and Nolsoe 2012). The vascularity and enhancement 
pattern of the lesions were compared with the adjacent liver parenchyma. Accord-
ingly, CEUS was performed five minutes after application of the contrast agent. The 
flash-replenishment technique was applied when needed. Still images and digital 
cineloops were saved and later reviewed. Central arteries were defined by the pres-
ence of enhancing central arteries with a spoke-wheel appearance. A central scar 
was defined as a central stellate hypoechogenic area without contrast enhancement 
in the portal venous phase. Necrosis or a thrombus caused by previous bleeding 
was defined as an irregular area without contrast filling. Late contrast-enhancement 
(contrast agent retention) was defined as the presence of hyperechogenic filling 
(mostly fine) compared to adjacent liver parenchyma in the late portal phase.
Statistical analyses
All statistical analyses were performed using SPSS (version 16.0, SPSS Inc., Chicago, 
IL, USA). Normality of continuous data was checked by inspecting the distribution. 
Parametric tests were used for continuous data, as these were all normally distrib-
uted. Continuous variables are presented as means with standard deviations and 
categorical variables as numbers and percentages.
First, a univariate analysis was performed by comparing characteristics between HCA 
and FNH. All p-values < 0.05 (two-sided) were considered as statistically significant.
Next, a multivariable logistic regression analysis was performed to investigate the 
association between the different covariates and the definitive diagnosis of HCA. A 
stepwise regression model with backward elimination was used. All items included 
in the univariate analysis were initially included as a covariate in the initial model. 
After each step, the covariate with the worst predictive value was removed until 
the best-fit model remained. The classification cut-off for elimination was set as p = 
0.05. The coefficients of the final multivariate model were used to create a formula 
for the prediction of the probability that the lesion was HCA.
RESULTS
A total of 324 CEUS examinations were performed in patients diagnosed with FNH or 
HCA. Patients and lesion characteristics of the CEUS examinations of FNH and HCA 
are summarized in Table 1. Of the 324 patients, 311 patients (96%) were female 
and 143 (44%) patients had a HCA. The median age at diagnosis for all patients with 
HCA was 41 years (range 4–63 years). The median age of the 181 (56%) patients 
with FNH was 37 years (range 17–61). The lesions had a mean diameter of 56 mm, 
ranging from 10 to 180 mm.
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Steatosis in a non-tumorous parenchyma was observed in 47% of the patients 
with HCA compared with 23% in patients with FNH. Necrosis or thrombus formation 
was observed in 18% of the patients with HCA compared to 3% necrosis or throm-
bus formation in the patients with FNH. There was no acute bleeding or thrombus 
formation observed.
Results from the univariate analysis of possible patient-related predictors com-
bined with features on CEUS between the group of patients with HCA and FNH are 
shown in Table 1. HCA and FNH patients differed significantly with respect to age 
and the CEUS features of steatosis, echogenicity, homogeneity, central scar, central 
artery, arterial enhancement pattern, necrosis or thrombus, and enhancement in the 
late portal phase (contrast agent retention).
In a multivariable analysis, the subsequent items were eliminated in the following 
order: homogeneity (p = 0.888), enhancement in the late venous phase (contrast re-
tention) (p = 0.797), necrosis or thrombus caused by previous bleeding (p = 0.527), 
Table 1. Univariate analysis of possible predictors for HCA and FNH
HCA (n = 143)
n (%)
FNH (n = 181)
n (%)
p value
Patient Age, years (range) 40.6 (18–77) 36.8 (17–61) 0.001
  Size lesion (mm) 54 (10-180) 59 (15-175) 0.04
Liver Steatosis 67 (47) 41 (23) < 0.001
Ultrasound before 
contrast
Echogenicity (M = 1) < 0.001
  Hypo 48 (34) 31 (17)  
  Iso 59 (42) 137 (76)  
  Hyper 35 (25) 13 (7)  
Homogenicity (homo) 107 (75) 156 (86) 0.009
Central scar 34 (24) 145 (80) < 0.001
Central artery (M = 1) 46 (32) 150 (83) < 0.001
CEUS arterial phase Enhancement pattern (M = 16) < 0.001
  Fugal 14 (11) 98 (56) 
  Mixed 19 (14) 40 (23) 
  Petal 99 (75) 38 (22) 
Necrosis or bleeding (M = 1) 26 (18) 6 (3) < 0.001
CEUS portal venous 
phase (M = 3)
 Sustained/retention 20 (14) 73 (40) < 0.001
  Iso 92 (66) 95 (53) 
  Hypo 21 (15) 8 (4) 
  Hetero 7 (5) 5 (3) 
Univariate analysis results for various comparisons for HCA and FNH. p < 0.05 was considered statis-
tically significant. Data were analyzed using a t-test or Pearson’s chi-squared test where appropriate. 
Values in parentheses are percentages unless otherwise noted. HCA, hepatocellular adenoma; FNH, 
focal nodular hyperplasia; CEUS, contrast-enhanced ultrasound.
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echogenicity (p = 0.108) and steatosis (p = 0.193). The regression coefficients of the 
final regression model are given in Table 2. Using these coefficients, the predicted 
probability of HCA was calculated using the following formula:
Predicted Probability (P) =1/(1+e(0.778+(0.36 *Age) + (-1.251*central scar) 
+(-1.198*central artery) +(0.541*enhancement mixed) +(1.157*enhancement 
petal)))
A receiver operating characteristic (ROC) curve was plotted and showed an area 
under the curve (AUC) of 0.854 (Figure 1). Figure 2 shows the predicted probability 
that the definitive diagnosis is HCA for increasing age and visualization of a central 
scar and central artery for different enhancement patterns.
DISCUSSION
Liver Steatosis
Currently, fatty liver disease is the most common chronic liver disease with an es-
timated incidence of 30% in Western countries (Browning and Szczepaniak 2004). 
Liver steatosis is often accompanied by obesity. HCA seems to also be associated 
with obesity, explaining why significantly more people with HCA have liver steatosis 
(47%) compared to patients with FNH (23%). Identifying a specific liver mass with 
US might be more difficult in obese patients. However, specific features can be 
depicted using CEUS, which can aid in differentiating the various liver masses.
HCA can be hyperechogenic in an otherwise normal liver during ultrasound with-
out the use of contrast (“fat-containing HCA”); however, we also found that 7% of 
FNHs were hyperechogenic. This rare hyperechogenicity of FNH could be explained 
by the occasional presence of fat in FNH, which has been previously described and 
Table 2. Multivariable logistic regression analysis for the prediction of HCA based on patient char-
acteristics and features of contrast-enhanced ultrasound examinations
  p value Regression 
coefficient
95% confidence 
interval
Age 0.015 1.037 1.007–1.067
Central scar 0.020 0.286 0.129–0.634
Central artery 0.010 0.302 0.148–0.615
Enhancement pattern    
Fugal 0.056     
Mixed 0.221 1.718 0.722–4.090 
Petal 0.017 3.182 1.229–8.239 
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Figure 1. Receiver Operating Charac-
teristic (ROC) Curve
The receiver operating characteristic 
curve for the prediction of HCA us-
ing the formula 1/(1+e(0.778+(0.36 
*Age) + (central scar) (central artery) 
(enhancement mixed) (enhancement 
petal), showing an area under the 
curve value of 0.854.
(years)
Figure 2. HCA diagnosis
The figure shows the predicted probability that the definitive diagnosis is HCA.
The visualization of a central scar and a central artery on CEUS indicates which quadrant of the 
figure should be used. The different colored lines in each quadrant stand for the different enhance-
ment patterns (blue, fugal; green, mixed; yellow, petal). By using the age of the patient at the mo-
ment of diagnosis on the corresponding colored line in the figure, the predicted probability that the 
definitive diagnosis is HCA can be determined.
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should be considered in ultrasound and imaging diagnostics (Burt AD 2012). When 
other classical FNH findings are seen, the presence of fat in the lesion can occasion-
ally make the diagnosis less robust.
Central Scar
A classic FNH is composed of nodules surrounded by radiating fibrous septa origi-
nating from a central scar (Fukukura and Nakashima 1998, Hussain and Terkivatan 
2004). The central scar in FNH is a collection of blood vessels, bile ducts, and fibrosis 
stroma (Elsayes and Peterson 2007). With CT and MRI, the central scar has been 
reported in 22 to 85% of FNH cases (Bartolotta and Taibbi 2014, Mortele and Praet 
2000). On CEUS, in which the central scar appears as a hypoechogenic area in the 
delayed phase (Piscaglia and Lencioni 2010), or on B-scan ultrasound, where it ap-
pears as a white fibrotic stripe, we identified a central scar in 80% of the FNH cases. 
However, fibrotic stripes similar to a central scar have been observed in 24% of 
HCA cases as well. Recently, fibrotic scars have also been described in 21% of HCAs 
on MRI (Thomeer and ME 2014, van Aalten and Thomeer 2011). The central scar is 
characterized on MRI by a T2-weighted late enhancement in the delayed phase. As 
a central scar could also be visible in HCA, differentiation between HCA and FNH 
should not be based on the appearance of the central scar alone, fibrotic stripes 
could have the same appearance.
Necrosis or thrombus
A thrombus caused by previous bleeding was present in 18% of the HCA and 3% of 
the FNH in this study. Thrombus caused by bleeding in HCA is fairly common, with 
an average overall frequency of 27.2% and a maximum reported frequency of 64% 
(Bieze and Phoa 2014, van Aalten and de Man 2012). It should be noted that if an 
irregular area without contrast enhancement is observed on CEUS, no differentia-
tion among necrosis, thrombus from an old bleeding, or a large central scar can be 
made (Behrend and Flemming 2001, Nguyen and Flejou 1999). The presence of an 
avascular area (necrosis/thrombus) in FNH is very rare, but can be present and is not 
exclusively diagnostic for HCA on ultrasound.
Central artery and enhancement pattern
As expected, a central artery with centrifugal (stellate) filling was more common in 
FNH, and a petal filling was most common in HCA (Kim and Jang 2008).
Arteries in FNH can be abnormally large for the region of the liver they perfuse, and 
in some nodules, color Doppler examination can be diagnostic. It may sometimes be 
difficult to localize the central part of the arterial tree with single-plane ultrasound 
because it can be located eccentrically and not centrally. A subset of patients have 
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not one, but two or more centers with stellate arterial projections. In these cases, 
the centers probably tend to be faint and not robust. Further technological develop-
ment, such as the regular use of 3D CEUS, could be of benefit here.
Contrast agent retention in the late portal phase
This ultrasound sign was confirmed to be predominant in FNH but was found only 
in 40% of FNH patients. This level was statistically significant but not exclusive; up 
to 14% of adenomas were hyperechogenic in the late phase. Contrast retention 
can be confusing because 25% of adenomas are already hyperechogenic on B-scan 
ultrasound. The sonographer should carefully differentiate between an already hy-
perechogenic tumor background and an influence of the presence of contrast agent.
Some atypical FNHs may show a washout-like image in late phase – in our series 
4%, which is usually seen in Hepatocelullar Carcinoma (HCC) and also in some HCAs 
(15% in our study).
Limitations
Our study has limitations. First, the final diagnoses were not all histologically 
validated. In those cases, combined imaging was used as the reference method 
for the final diagnosis, which was made after consensus was reached within our 
multidisciplinary tumor board committee. If we had only selected patients with a 
histologically-proven diagnosis, a bias would have been introduced because a biopsy 
is only approved in our hospital if there is doubt about the diagnosis or radiological 
examinations are not in agreement. Second, because the lesions were not biopsied, 
it was not possible to link the specific features to the Bordeaux classification of HCA 
subtypes and their ultrasonographic appearance.
The aim of this study was to differentiate FNH and HCA, two solid benign liver 
tumors. In clinical practice it is also of the utmost importance to exclude hepatocel-
lular carcinoma. The most important feature to differentiate benign and malignant 
liver lesions on CEUS is the presence of washout (Bernatik and Seitz 2010, Bhayana 
and Kim 2010). However, this feature showed no additional value in differentiating 
between FNH and HCA. It is essential to first rule out a malignancy, before using this 
model, which gives insight into the predicted probability of HCA.
CONCLUSIONS
In conclusion, increased age and CEUS features of liver steatosis, tumor echogenicity, 
homogeneity, thrombus presence, filling pattern and central scar, central artery, arte-
rial enhancement pattern, and absence of enhancement in the portal venous phase 
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were found to be predictive in distinguishing between HCA and FNH. A reliable 
model using age and the presence of a central scar, central artery, and enhance-
ment pattern can predict the probability that the definitive diagnosis is HCA. If the 
diagnosis of HCA or FNH is equivocal on MRI, CEUS can be used to differentiate the 
two lesions, as a combination of the two methods provides the highest diagnostic 
accuracy (Soussan and Aube 2010). This study gives insight about the reliability 
of the features on CEUS and helps clinicians to decide whether further liver mass 
biopsy is needed.
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ABSTRACT
Purpose
To compare the diagnostic performance of contrast-enhanced ultrasonography 
(CEUS) with MRI using gadobenate dimeglumine (CEMRI) for diagnosis of hepatocel-
lular adenoma (HCA) and focal nodular hyperplasia (FNH) of the liver.
Materials and methods
Patients referred to a tertiary center for hepatobiliairy diseases with suspicion of 
HCA or FNH were included. All patients had undergone a prospective work-up of 
CEUS and CEMRI. Final diagnosis was considered firm when outcome of CEUS and 
CEMRI were concordant. Histopathologic assessment (PA) followed in case of dis-
crepancy between CEUS and CEMRI. CEMRI was considered as the reference method 
for final diagnosis when patient refused biopsy. Sensitivity, specificity, area under 
the ROC curve and predictive values were calculated for CEUS.
Results
One hundred eighty-two patients (155 female, 27 male, mean age 38 years, range 
17-76 years) were included. CEUS and CEMRI were concordant in the majority of 
patients (n=131, 72%). Discrepancy between CEUS and CEMRI in 51 patients (28%). 
PA followed in 28 cases (55%), in two cases biopsy could not distinguish between 
HCA and FNH. In the remaining PA- proven cases (n=26) , CEMRI was correct in 20 
cases (77 %) and CEUS in 6 cases (23 %) . In the remaining cases (n=23, 45%), 
CEMRI was considered as reference for final diagnosis. Sensitivity and specificity 
were respectively 82,5% and 71,7% for CEUS for diagnosis of HCA and FNH with an 
area under the ROC of 0.766.
Table 1. CEUS outcome and Final diagnosis
CEUS outcome Final HCA Final FNH Total
HCA 49 29 78
FNH 9 81 90
CEUS Other Diagnosis 2 1 3 
CEUS Inconclusive 4 7 11
Total 64 118 182
FNH; focal nodular hyperplasia, HCA; hepatocellular adenoma.
CEUS outcome versus final diagnosis.
Sensitivity 82,5% (49/(49+9)), specificity 71,7% (81/(81+29+3)) , Area under the ROC: 0.766
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Conclusion
Concordance between CEUS and CEMRI is fair for diagnosis of HCA and FNH. In 
discordant cases CEMRI is highly accurate and superior to CEUS in histopathology 
confirmed diagnoses.
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INTRODUCTION
Hepatocellular adenoma (HCA) and focal nodular hyperplasia (FNH) are benign 
solid liver lesions that are mostly found in young women. Although both entities 
are benign and often asymptomatic, the pathogenesis and clinical management is 
different. Accurate diagnosis is therefore important (1-3). Contrast enhanced ultra-
sonography (CEUS) and MRI with liver- specific contrast agent (CEMRI) are imaging 
modalities with reported specific imaging features for both HCA and FNH that may 
lead to confident diagnosis (3-7). At present, both CEUS and CEMRI are regarded as 
best complementary techniques for diagnosing HCA or FNH and final diagnosis is 
considered correct in case of concordance between outcomes of CEUS and CEMRI 
(3). In uncertain or atypical cases, final diagnosis with histopathology (PA) is impera-
tive (3, 8). Recent studies have reported CEMRI to be highly accurate for diagnosis 
of HCA and FNH (1, 6, 9-11). However, CEMRI is costly and time consuming. CEUS on 
the other hand has the potential to provide confident diagnosis at lower costs than 
CEMRI (12-14).
The purpose of this study was to compare the diagnostic performance of CEUS 
with CEMRI for the diagnosis of HCA and FNH.
MATERIALS AND METhODS
Study population
Our institutional ethics committee approved this retrospective study and informed 
consent was waived.
Patients were selected from prospective collected databases from the depart-
ments of radiology and gastroenterology. Inclusion criteria were patients with final 
diagnosis of HCA or FNH who had undergone both CEUS and CEMRI of the liver 
between May 2008 and December 2016. Exclusion criteria: final diagnoses other 
than HCA or FNH, patients with history of cancer or known chronic liver disease, 
multiple lesions with both FNH and HCA.
Standard work-up procedure
Patients referred to our center with suspicion of HCA or FNH received a standard 
work-up with CEUS and CEMRI of the liver. CEUS was performed or supervised by a 
gastroenterologist with 21 years of experience in ultrasound of the liver, including 
5 years of experience in CEUS. Subsequently, MRI examinations were evaluated and 
reported by one of three experienced abdominal radiologists with expertise in liver 
imaging (respectively 8, 10 and 11 years), without regard to the CEUS outcome. . In 
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case of uncertainty, cases were discussed between two or three radiologists and 
consensus was reached on final diagnosis.
CEUS
CEUS was performed using the Hitachi 900 and Hitachi Preirus ultrasound platforms 
(Hitachi Medical Systems, Japan) with real-time grayscale, contrast-tuned imaging 
and a 2.5–5.0 MHz probe. Contrast agent used was SonoVue (Bracco, Italy; dose 
range 1.0–2.4 ml; repeated if needed and flushed by isotonic saline). Examination 
were executed in a standardized fashion: first, all patients underwent unenhanced 
abdominal and hepatic sonography using conventional color/power Doppler 
techniques, with location, number, size, and sonographic features of the focal liver 
lesions recorded. Because of the unique network by the hepatic artery and the 
portal vein, three phases can be observed with CEUS (4-7). Acquisition included 
hepatic arterial (10–40 s post-injection), portal venous (40–120 s post-injection), 
and late parenchymal phases (>120 s, bubble disappearance) conform the European 
federation of societies for ultrasound in medicine and biology (EFSUMB) protocol 
(8). Vascularity and enhancement pattern of the lesion was evaluated for up to 5 
minutes post-injection of contrast. Still images and digital cine loops were saved 
and later reviewed for final assessment and report. Central arteries were defined by 
the presence of enhancing central arteries with a spoke-wheel appearance. A central 
scar was defined as a central stellate hypoechoic area without contrast enhance-
ment in the portal venous phase. Necrosis or previous intralesional hemorrhage was 
defined as an irregular heterogeneous area without contrast filling. Late contrast 
enhancement (contrast agent retention) was defined as the presence of hyperechoic 
contrast filling compared to adjacent liver parenchyma in the portal phase.
MRI
MRI was performed on a 1.5 Tesla (T) unit (General Electrics, Signa, Milwaukee, WI) 
with a four-channel, phased-array body coil. The MRI protocol was identical for all 
patients: single- shot fast spin echo (SSFSE, slice thickness = 7 mm; repetition time/
echo time (TR/TE) (ms) = 832/80–120; flip angle = 90°), fat-suppressed T2W fast 
spin echo (FSE) (5–8 mm, 6315/90– 93, flip angle = 90°), and T1-weighted in- and 
opposed-phase gradient-echo (GRE) sequences (7 mm, shortest/4.6 and 2.3, respec-
tively; flip angle = 80°). Fat-suppressed, dynamic contrast- enhanced T1-weighted 
GRE imaging (4–5 mm, 2.7–3.5/1.2; flip angle = 12°) was performed in at least four 
phases (precontrast, arterial, portal, and delayed), following administration of an 
intravenous bolus (2–2.5 mL/s) of gadobenate dimeglumine (Multihance, Bracco 
Imaging, Milan, Italy) at a dose of 0.05 mmol per kilogram body weight. The optimal 
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arterial phase was based on bolus tracking. Finally, the same scan was repeated 
during a late hepatobiliary excretory phase at 1 to 1.5 hour after injection.
Reference standard
Final diagnosis was established within a Multidisciplinary Hepatobiliary Tumor 
Working Group. This group consists of one or more specialized radiologists, sur-
geons, gastroenterologists and oncologists. Diagnosis was considered firm in case 
of concordance between CEUS and CEMRI. In case of discordance between CEUS 
and CEMRI, histopathology analysis (PA) of the lesion followed after percutaneous 
image-guided biopsy. When biopsy was undesirable or contra-indicated, CEMRI was 
considered as the reference method for final diagnosis in case of confident findings 
on MRI.
Case evaluation procedure
Patients’ age and sex, previous imaging reports, CEUS reports, CEMRI reports, Mul-
tidisciplinary Hepatobiliary Tumor Working Group decisions, pathological reports 
and final clinical diagnoses were registered using a standardized and anonymized 
clinical reporting form in the online clinical software program ‘openclinica’. From the 
reports the confidence level of diagnosis with CEUS and CEMRI were graded using a 
five-point scale (5=definite/confident diagnosis, 4=preferable/probable diagnosis, 
3=relative uncertain diagnosis, 2=very uncertain diagnosis, 1= no diagnosis). For 
final analysis, grade 5 or 4 were regarded as conclusive outcomes, and grade 3, 2 or 
1 as inconclusive outcomes.
Data analysis and statistical methods
Descriptive statistics were used to describe the study population and outcomes of 
both imaging modalities. The association of categorical variables were presented 
by numbers and percentages, and tested by Fishers’ exact test. The primary analysis 
was patient based. Inconclusive outcomes of CEUS and CEMRI (with confidence 
level scores less than 4) were considered as false positives or false negatives for the 
statistical analysis. Sensitivity, specificity, area under the receiver operating charac-
teristic/ROC-curve (AUC) were calculated with SPSS (version 21, IBM, Chicago). All 
tests were regarded statistically significant if the p-value was less than 0.05.
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RESULTS
Study population and fi nal diagnosis
A total of 182 patients (155 female and 27 male) were included. Mean age was 38 
years; range 17 to 76 years. Final diagnosis was FNH in 117 (65 %) patients and HCA 
in 63 patients (35%).
Women were signifi cantly overrepresented compared to men (p <0.001) with no 
signifi cant diff erence found in sex (p=0.528) or age (p=0.721) between FNH and 
HCA.
CEUS - CEMRI agreement, PA-proven cases
CEUS and CEMRI were concordant in 131 out of 182 patients (72%) (fi gure1) , and 
discordant in the remaining patients (n=51, 28%). PA was obtained in 28 out of 51 
(55%) discordant cases, and in the remaining 23 cases (45%), CEMRI was consid-
ered as reference for fi nal diagnosis.
From the 28 cases in which the diagnosis diff ered and biopsies were performed, 
2 biopsies were not conclusive. In the remaining 26 PA-confi rmed cases CEMRI was 
correct in 20 cases (77%) and CEUS in six cases (23%). This diff erence is statistically 
signifi cant (p=0.03).
182 patients with 
HCA or FNH 
underwent both 
CEUS and CEMRI
51 (28%) CEUS and 
CEMRI discordant
131 (72%) CEUS and 
CEMRI concordant
25 (55%) PA 
followed*
23 (45%) CEMRI 
chosen as the gold 
standard
6 (23%) Agreement 
CEUS
20 (77%) Agreement 
CEMRI
Figure 1. Flow diagram summarizes patient sampling.
*2 biopsies not conclusive
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Confidence level of CEUS and CEMRI
For CEUS, the result was conclusive in 171 out of 182 cases (93%), with 148 out of 
182 cases (81%) a confident diagnosis (grade 5) and 23 out of 182 cases (13%) a 
preferable or probable diagnosis (grade 4). Inconclusive diagnoses with CEUS were 
found in 11 out of 182 cases (6%).
The result of CEMRI was conclusive in 181 out of 182 cases (99.5%). Inconclusive 
diagnoses with CEMRI were found in 1 out of 182 cases (0.5%).
Diagnostic performance CEUS
When only cases with a conclusive outcome by CEUS are considered sensitivity and 
specificity are respectively 83% (49/(49+9)) and 72% (81/(81+29+3)) for diagnosis 
of HCA and FNH, with an area under the ROC of 0.77.
DISCUSSION
We found that agreement between CEUS and CEMRI was fair for diagnosis of FNH 
and HCA. Furthermore, in twenty-six PA proven cases, CEMRI was correct in all twenty 
cases, whereas CEUS was correct in six cases. Another important finding is that CEUS 
has a confident diagnosis in 81% and conclusive result in 93 % and inconclusive 
result in 7%, whereas CEMRI was conclusive in almost all cases. Based on these 
results we believe that CEUS is less suitable as a stand-alone imaging modality for 
final diagnosis of FNH and HCA. CEUS seems more suitable as an adjunct tool for 
diagnosis in typical cases that were suggested on multiphase CT scan and follow up 
of lesions that were otherwise confirmed as HCA by CEMRI or PA. The advantage of 
CEMRI over CEUS can be explained by the lack of hepatobiliary excretory proper-
ties of ultrasound contrast medium. While the morphologic characteristics can be 
assessed by both imaging modalities, including contrast enhancement patterns, the 
decisive feature for diagnosis on CEMRI is the hepatobilairy excretory phase for 
differentiating HCA from FNH. Previous studies have shown that 20% of FNH lack 
typical morphologic features on imaging, including a central scar (15). In addition, 
a subgroup of HCA (beta- cathenine positive subgroup) may demonstrate scar-like 
features on MRI with Gadolinium- chelates (16). Furthermore, CEMRI has the advan-
tage of presenting a comprehensive evaluation of lesions, not only in differentiating 
between HCA and FNH, but also in demonstrating features which may be indicative 
of transformation to HCC in case of HCA. Our study has limitations. First, because of 
the retrospective analysis and the relative limited number of PA proven diagnoses. 
Currently, dedicated CEMRI with confident diagnosis is considered confirmative for 
diagnosis of FNH and HCA in expertise centers (6, 7, 9-11). Therefore it would be 
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unpractical and maybe unethical to biopsy all lesions, even though the diagnosis is 
confident on CEMRI.
Another potential limitation might be selection bias. As the analysis were done 
retrospectively, patients were selected based on final diagnoses of FNH or HCA. 
False-positive outcomes in case of other diagnoses, like liver hemangioma, are left 
out which may culminate in an overestimated specificity for FNH or HCA. However, 
the purpose of the study was to assess the value of CEUS for diagnosis when com-
pared with CEMRI. We believe that our study design serves this purpose well.
In conclusion, CEUS has fair agreement with CEMRI for the diagnosis of HCA and 
FNH with a diagnostic performance being inferior to CEMRI in discordant cases.
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ABSTRACT
Hepatocellular adenoma (HCA) is a rare, benign liver tumor. Discovery of this tumor 
is usually as an incidental finding, correlated with the use of oral contraceptives, or 
pregnancy. Treatment options have focused on conservative management for the 
straightforward, smaller lesions (<5cm), with resection preferred for larger lesions 
(>5cm) that pose a greater risk of hemorrhage or malignant progression. In recent 
years, a new molecular subclassification of HCA has been proposed, associated with 
characteristic morphological features and loss or increased expression of immuno-
histochemical markers. This subclassification could possibly provide considerable 
benefits in terms of patient stratification, and the selection of treatment options. 
In this review we now discuss the decision-making processes, and associated risk 
analyses, that should be made based on lesion size, and subtype. The usefulness 
of this subclassification system in terms of the procedures instigated as part of the 
diagnostic work-up of a suspected HCA will be outlined, and suitable treatment 
schemes proposed.
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INTRODUCTION
Hepatocellular adenoma (HCA) is an uncommon, solid, benign tumor of the liver, 
with an estimated incidence of 3-4 per 100,000 women [Bioulac-Sage et al., 2010]; 
this frequency is based on population research including women using oral contra-
ceptives (OC) [Baum et al., 1973]. A causal role for hormone activity in HCA growth 
is suggested by data linking adenoma regression to the cessation of OC use, and 
growth associated with pregnancy [Cobey et al., 2004].
Typically, HCA is treated conservatively, with patients advised to avoid oral contra-
ception. The risks of growth and rupture of HCA during pregnancy has to be under-
lined, especially in larger HCAs. Tumor progression, suggested by internal bleeding 
and malignant transformation, necessitates a more aggressive therapeutic approach, 
with lesions larger than 5 cm considered as the primary risk factor [Marrero et al., 
2014]. The introduction of a new subclassification system for HCA has been sug-
gested to help clinicians to stratify patients according to imaging criteria, expression 
of associated immunohistochemical markers and/or molecular findings. These data 
may influence the treatment selected [Marrero et al., 2014] since certain subtypes of 
HCA pose a greater risk of progression to hepatocellular carcinoma (HCC) than oth-
ers. For example, a subtype of HCA defined by the reduced expression of liver-fatty 
acid binding protein (LFABP) ordinarily indicates a subtype with a less aggressive 
course and a tendency towards a benign phenotype.
Based on the recent literature, we will describe the impact of this newly instigated 
HCA subclassification, and discuss whether this knowledge, combined with imaging 
data, improves our risk analyses for patients with HCA. Furthermore, we will outline 
the different therapeutic options indicated by each HCA subtype.
The Bordeaux classification of hCA
In recent years, four distinct subtypes of HCA have been recognized: inflammatory HCA 
(40-50%, IHCA), HNF1A-mutated HCA (30-40%, H-HCA), b-catenin activated HCA (10-
15% b-HCA), and unclassified HCA (10-25%, U-HCA) [Nault et al., 2013]. In these differ-
ent subtypes, several genetic mutations are identified, causing (benign) proliferation of 
hepatocytes and in some HCA, malignant transformation [Pilati et al., 2014].
Patients presenting with IHCA demonstrate both serum, and lesional indicators of 
an active inflammatory response. In these lesions, increased expression is seen of 
the markers serum amyloid A and C-reactive protein, both classic indicators of the 
acute phase response [Bioulac-Sage et al., 2007]. Patients within this HCA category 
frequently demonstrate increased body weight, and a high alcohol intake [Bioulac-
Sage et al., 2007, Paradis et al., 2007, Bioulac-Sage et al., 2009]. In approximately 
10-20% of these lesions, a b-catenin mutation is found. [Van Aalten et al., 2011].
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A second subtype of HCA, H-HCA, is characterized by a downregulation of the liver 
fatty acid binding protein (LFABP); this phenotype, which is not apparent in the other 
HCA subtypes, rarely leads to malignant progression [Zucman-Rossi et al., 2006].
Subtype b-HCA is typified by activating mutations of b-catenin that resist 
phosphorylation-mediated down-regulation by the GSKB/APC/AXIN complex [Nault 
et al., 2013]. Particularly the exon 3 mutation of b-catenin plays a significant role 
in malignant progression in contrast to exon 7/8 mutations [Pilati et al., 2014]. The 
result is an accumulation of nuclear b-catenin which, combined with deletion of 
APC, favors progression to HCC [Nault et al., 2013]. The comparatively small num-
ber of b-catenin positive nuclei can lead to this phenotype being overlooked in 
small biopsies [Van Aalten et al., 2011]. The b-HCA subtype also demonstrates an 
overexpression of GLUL (encoding glutamine synthase, GS), which can be used as a 
sensitive diagnostic biomarker for this subtype [Van Aalten et al., 2011].
The final subtype, UHCA, is not yet defined by any specific genetic mutation, but 
is instead characterized by various histologic criteria that are unusual in the other 
subtypes; the under-lying pathogenesis of this subtype remains unclear [Blanc et 
al., 2015].
Magnetic resonance imaging (MRI) of the different subtypes of hCA
The primary differential diagnosis for HCA is focal nodular hyperplasia (FNH). If in 
doubt, a biopsy should be taken, especially for larger lesions, as the clinical manage-
ment will differ for either pathology. In most cases these diagnoses can be differen-
tiated according to signal intensity and dynamic vascular patterns after intravenous 
aspecific gadolinium injection (conventional MRI)[Van Aalten et al., 2011]. Different 
patterns can be used for confident diagnosis as proposed by Thomeer et al[Thomeer 
et al., 2014].
In more challenging cases specific hepatobiliary contrast agents can be used. 
Two agents are currently available, gadobenate dimeglumine, and gadoxetate 
disodium.[Grazioli et al., 2013, Thomeer et al., 2014, Mcinnes et al., 2015] If the 
lesion turns hypointense to the surrounding liver in the hepatobiliary phase FNH 
can be excluded in most cases. If the lesion becomes iso- to hyperintense the dif-
ferential diagnosis is FNH or in exceptional cases HCC. However, it should be noted 
that IHCA can also be isointense in the hepatobiliary phase[Agarwal et al., 2014, 
Thomeer et al., 2014]. This might be explained by the presence of internal bile duct 
proliferation, previously thought to be only visible in FNH. This diagnostic pitfall 
can be visualized when using gadobenate dimeglumine[Thomeer et al., 2014], or 
gadoxetate disodium[Agarwal et al., 2014]. A recent systematic review about the 
value of gadoxetate disodium has shown that apart from this pitfall, adequate dif-
ferentiation is possible in most cases[Mcinnes et al., 2015]. It was reported that the 
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hepatobiliary phase has a sensitivity of 91-100 % and a specificity of 87-100 % for 
differentiating HCA from FNH. In the largest study this was only seen in 13 % of the 
cases[Bieze et al., 2012].
In conclusion, in the vast majority lesions can easily be differentiated based on a 
combination of typical findings on conventional MRI and features on hepatobiliary 
phase MRI.
Some typical MRI features allow us to discriminate different subtypes of HCA (table 
1): IHCA can be hyperintense on T2-weighted images, with persistent enhancement 
on delayed imaging in the venous phase [Laumonier et al., 2008]. Ronot et al. vali-
dated this feature as being highly specific for IHCA, with a sensitivity of 82% (28/34, 
CI 65-93%), and an optimal specificity of 100% (12/12, CI 75-100%) [Ronot et 
al., 2011]. Another diagnostic indicator for IHCA is the atoll-sign [Van Aalten et al., 
2011], a hyperintense rim on T2-weighted images at the periphery of the lesion 
(resembling an atoll) that is enhanced late in the venous phase. This feature is pres-
ent in 27% of IHCAs in this study [Van Aalten et al., 2011].
Whilst H-HCAs are typically characterized by a large amount of aberrant fat 
which can be readily appreciated by out-of phase imaging, or on a fat-saturated 
T1-weighted image [Laumonier et al., 2008, Van Aalten et al., 2011], Van Aalten et 
al failed to detect fat by MRI for as many as 22% of cases (2/9)[Van Aalten et al., 
2011]. Ronot et al. validated the diagnostic feature of diffuse and homogeneous 
signal dropout on out-of-phase T1 weighted imaging, with a reported sensitivity of 
90% (10/11, CI 58-99), and specificity of 88% (32/36, CI 73-96)[Ronot et al., 2011]. 
The main drawback of this marker is that diffuse intralesional steatosis may also 
be present in up to 11% (4/34) of IHCAs [Ronot et al., 2011], although, according 
to the authors, this does not represent a major pitfall as fat is usually distributed 
heterogeneously within IHCAs (figure 1).
The MRI features of b-HCA are not well defined, principally because these lesions 
are comparatively rare. Van Aalten et al. reported poorly delimited, high-signal 
intensity areas, to be typical of this subtype (5/7, 71%), but additional investiga-
Table 1. Typical MRI findings according to suybtypes of HCA. HCA: hepatocellular adenoma, H-HCA: 
HNF1A-mutated HCA, IHCA: inflammatory HCA, b-HCA: b-catenin activated HCA, UHCA: unclassified 
HCA.
Subtype Most typical MRI signs
IHCA -  Hyperintense on T2-weighted images, with persistent enhancement in the venous phase
- Atoll-sign
H-HCA Diffuse and homogenous fat deposition (figure 1)
b-HCA (Vaguely demarcated scar)
UHCA No typical sign
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tions are warranted [Van Aalten et al., 2011]. Table 2 shows the various MRI features 
reported in the literature for b-HCA, although, where reported, these features are 
inconsistent. Despite significant numbers of false negatives, the specificity of these 
MRI features is very high, leading us to conclude that if any one of these signs are 
present, a diagnosis of the corresponding MRI subtype can be made with some 
certainty. Larger datasets will be needed to determine the true value of MRI in 
HCA imaging for all subtypes; currently, this technique is of most use in evaluating 
prognosis.
Reviewing the known complications
Intralesional bleeding
On reviewing the recent literature, van Aalten et al. detected evidence of hemor-
rhage in 27.2% of all patients (315/1160) with one or more HCAs, giving a 15.8% 
chance of hemorrhage for every HCA (118/748) [Van Aalten et al., 2012]. Acute rup-
ture and intraperitoneal bleeding were reported in 17.5% of patients. A size for the 
smallest HCAs showing hemorrhage was reported for 13 of the 28 articles reviewed; 
hemorrhage generally arose in the larger lesions (greater than 5 cm), although 
Figure 1a/b. In- and out-of-phase MRI of a 
typical case of histochemistry proved H-HCA 
which was resected. Note the diffuse and ho-
mogenous signal drop-off on the out-of-phase 
image (a) versus the in-phase image (b). This 
correlates with diffuse intralesional fat identi-
fied by histology. MRI differentiation between 
H-HCA and IHCA would not be possible when 
the signal drop is more heterogeneous.
HCA, hepatocellular adenoma; H-HCA, HN-
F1A-mutated HCA; IHCA, inflammatory HCA; 
MRI, magnetic resonance imaging.
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smaller lesions could also bleed (table 3), albeit at much lower rates. These data 
should be interpreted with caution, as only the resected cases were included. The 
actual chance of bleeding in the different subtypes is likely to be significantly lower. 
The risk of bleeding was inconsistent across the subtypes of HCA: IHCA showed a 
higher propensity for macroscopic hemorrhage (30%), than H-HCA (8%) [Dokmak 
et al., 2009] which can presumably be attributed to the larger number of venous 
structures, or telangiectatic changes in this subtype.
Table 2. Recently published b-HCAs with their typical characteristics defined by MRI. Note the low 
prevalence in the literature of MRI data, with inconsistent findings. HCA: Hepatocellular adenoma, 
b-HCA: b-catenin positive HCA, T2W:T2-weighted
Authors Year of 
publication
Number of 
b-catenin HCA
MRI findings
Van Aalten et al. [[Van 
Aalten et al., 2011]]
2012 7 -  Vaguely defined scar on T2W sequences (3 
cases)
Laumonier et al. 
[[Laumonier et al., 
2008]]
2008 5 -  Marked hyperintensity on T2W sequences 
and persistent delayed enhancement (3 
cases)
-  Isointensity on T2W sequences, with strong 
arterial enhancement and delayed wash-out 
(2 cases)
Yoneda et al. [[Yoneda 
et al., 2012]]
2012 1 -  Vaguely defined scar on T2W sequences
Table 3. Summary of the findings of an earlier review of 12 articles in which the percentage of 
hemorrhaged HCAs, and minimal lesion sizes, were reported. Hemorrhage occurred mostly in larger 
HCAs (>5 cm; minimally 42.2%), but smaller lesions also showed some bleeding (range 8.3–11.5%).
Series
Patients with 
hemorrhaged hCA
Size of smallest 
hCA (cm)
Percentage <5 cm of 
total (%)
[Reddy et al. 2001] 3 of 25 4 –
[Hung et al. 2001] 4 of 25 4.2 –
[Toso et al. 2005] 10 of 25 1.7 –
[Cho et al. 2008] 12 of 41 1 8.3 (1/12)
[Bioulac-Sage et al. 2009] 23 of 128 <5 –
[Edmondson et al. 1976; 
Dokmak et al. 2009]
26 of 122 <5 11.5 (3/26)
[Edmondson et al. 1976] 10 of 42 >5 0
[Leese et al. 1988] 2 of 24 5 0
[Ault et al. 1996] 4 of 12 6 0
[Closset et al. 2000] 7 of 16 7 0
[Deneve et al. 2009] 31 of 124 >5 0
[Chung et al. 1995] – 5 0
HCA, hepatocellular adenoma.
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Although there may be a difference in prevalence of internal bleeding, all subtypes 
bear this intrinsic risk [Laumonier et al., 2008, Dokmak et al., 2009, Ronot et al., 
2011, Van Aalten et al., 2011], which diminishes the utility of subtype classification 
in terms of the clinical management of this risk. Furthermore, more data are needed 
to prove any correlate between reduced bleeding and the H-HCA subtype.
Bieze et al. described a series of 45 patients with 195 lesions. In this cohort, there 
was a tendency to an enhanced risk of bleeding when the lesion was located in 
the left lateral liver (11/32 versus 31/163 in other regions), and showed exophytic 
growth (16/24 versus 9/82) [Bieze et al., 2014] (Fig. 1). The latter phenomenon is 
probably due to the subcapsular location, with no intrinsic capsule, and minimal sur-
rounding liver with which to prevent rupture of the hematoma into the abdominal 
cavity. However, no other data are available to support this theory, and preventive 
treatment in these cases does not appear to be warranted.
As for the clinical application of these findings, there is no evidence that supports 
the use of subtype classification in the stratification and management of individual 
patients. Moreover, size still remains the most important marker to predict those at 
risk for larger bleeding in follow up.
Malignant transformation
Malignant transformation of HCA to HCC is rarely reported, but is an accepted risk, 
particularly when the diameter of the adenoma exceeds 5 cm (figure 2) [Stoot et al., 
2010, Grazioli et al., 2013]. In a systematic review, Stoot et al. reported an overall 
frequency of malignant transformation of 4.2% for HCAs [Stoot et al., 2010] (67 of 
1635 HCAs, interval: 0 -100 %). Only three cases showed malignant transformation 
for tumors smaller than 5 cm in diameter, which represented 4.4% of the total num-
ber of HCCs arising from HCAs (3 out of 67). As suggested for the internal bleeding 
data, these reports should be interpreted with caution.
Of the four HCA subtypes, (exon 3) b-HCAs are known to trigger a potent mito-
genic signaling pathway that is prominent in HCC [Zucman-Rossi et al., 2007, Chu et 
al., 2013, Pilati et al., 2014], which suggests a positive correlate between the two. 
Zucman-Rossi et al. reported an incidence of HCCs, or borderline malignant tumors 
in b-HCAs, of up to 46%; this malignant progression was seldom seen in other 
subtypes [Zucman-Rossi et al., 2007], and was over-represented for male patents (5 
cases, 38%; P =.02)[Hussain et al., 2006]. Since the β-catenin pathway can also be 
activated in IHCA [Van Aalten et al., 2011], both the b-HCA and IHCA subtypes may 
necessitate more aggressive treatment than either the H-HCA or U-HCA, although 
the clinical relevance of this determination has yet to be broadly accepted. In 
follow-up, malignant progression of HCA to HCC has only rarely been demonstrated, 
with questionable quality of the imaging data for those rare, reported cases. There-
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fore it is presently difficult to prove that HCC is a transition from HCA, although the 
presence of β-catenin has been suggested as a criterion for the selection of HCA, 
or well-defined HCC, for resection [Bioulac-Sage et al., 2013]. Interestingly, figure 2 
shows a lesion with a typical nodule-in-nodule appearance which suggests a form of 
Figure 2. A 32-year-old female using oral contraceptives with a 11 cm lesion in the liver. Based on 
MRI this lesion was compatible with a HCA. However, both on T2-weighting (Figure 1(a)) as on the 
images after contrast injection the lesion appeared heterogeneous with a focus of diffusion restric-
tion (typically a low ADC value, (b)). Diffusion restriction is thought to be a typical sign of malignancy 
in liver lesions. Based on the findings above and because the lesion was larger than 5 cm, the le-
sion was resected 3 months later. On gross pathology there was a focal nidus (Figure 1(c), arrow, 
concordant with the nidus on MRI) which appeared to be an HCC in a HCA (‘nodule-into-nodule’). 
On histology (H–E × 25, (d)) at the interface HCA/HCC, the upper part of the tumor showed prolifera-
tion of hepatocytes without obvious cytological anomalies, intermingled with thin/isolated vessels 
(down side of dotted line), favoring an HCA. ‘Nodule-into-nodule’ consists of clearer cells with mild 
atypia (above dotted-line, (d)), disorganized or decreased reticulin fibers (e) and obvious positivity 
for Glypican-3 (f), favoring an HCC (well differentiated). (g) GS-staining pattern at the periphery of 
the HCA. Glypican-3, Serum Amyloid A and CRP were negative in the HCA. β-catenin staining showed 
only membranous expression. Based on the above we interpreted this HCA as a b-HCA.
CRP, C-reactive protein; HCA, hepatocellular adenoma; HCC, hepatocellular carcinoma; GS staining, 
glutamine synthetase immunostaining indicative of b-HCA; MRI, magnetic resonance imaging.
Chapter 7
100
transition from HCA to HCC. Another problem is that corroboration of the pathology 
is seldom available, due to the fact that biopsies of HCA are rarely performed, with 
diagnoses generally made with MRI [Hussain et al., 2006]. A final diagnosis of b-HCA 
based solely on MRI findings would be helpful, but the MRI findings published to 
date for this subtype are sparse (Table 2). Finally, it should be mentioned that HCA 
shows a higher risk of malignant transformation in men [Farges et al., 2011]. In these 
cases, the possibility of hepatitis, an underlying glycogen storage disease (figure 3), 
or sex steroid hormone abuse, should all be considered as all predispose to HCC 
[Yoneda et al., 2012]. A more aggressive treatment is advised in such cases, even for 
lesions smaller than 5 cm.’
Finally, according to the recent literature, H-HCA almost never degenerate into 
HCC, although some very rare cases have been reported (Stueck et al 2015). The low 
risk of H-HCA degeneration may help to simplify the management of liver adenomas 
as will be discussed later.
As for clinical application, mainly b-HCA and IHCA are prone to malignant de-
generation, and mostly if larger than 5 cm. In these instances invasive treatment is 
recommended.
Figure 3. A 50-year-old male with multiple hypervascular lesions. These lesions were diagnosed 
as HCA or HCC based on imaging and clinical (glycogen storage disease) findings. (a) An axial MR 
image, with T1 weighting, after contrast injection in the arterial phase. In segment 5, a small lesion 
with a cystic central portion (large arrow) was biopsied, and subsequently diagnosed as HCC follow-
ing positive GS staining with negative β-catenin staining. Posteriorly, a second, smaller lesion was 
visualized (<1 cm, small arrow). Histologic sample of a lesion with diffuse GS-positivity (b). Axial MR 
image with T1-weighing after contrast injection in the arterial phase (c). In this image, taken 3 years 
later, the second lesion has grown (now 3 cm, small arrow). The large arrow shows the resection/ab-
lated part of the liver (from lesion 1). A new hypervascular lesion (curved arrow) was also detected 
outside the liver, which proved to be a trajectory metastasis. These lesions (large arrow, curved ar-
row) were successfully ablated. This patient is currently being followed at regular, short intervals, 
and is on the waiting list for a liver transplantation.
GS staining, glutamine synthetase immunostaining indicative of b-HCA, even with a negative 
β-catenin staining; HCA, hepatocellular adenoma; HCC, hepatocellular carcinoma; MR, magnetic 
resonance.
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Pregnancy
Women with HCA who are pregnant, or wish to become pregnant (figure 4), should 
be closely monitored for HCA size (with ultrasound or MRI) during their pregnancy, 
due to the tendency of the lesion to grow, especially during the 3rd trimester when 
high levels of estrogens are present [Cobey et al., 2004]. Hormone-induced growth, 
and possible rupture, may result in potentially lethal complications for the mother 
and unborn child. Treatment of HCA during pregnancy may be indicated when the 
lesion shows signs of growth or bleeding, however specific figures for the risk of 
HCA complication during pregnancy are not yet available.
Whether some subtypes are more prone to complications during pregnancy is not 
known, mainly because the majority is diagnosed non-invasively.
The choice of follow-up, surgery, radiofrequency ablation (RFA) or transcatheter 
arterial embolization (TAE) for the treatment of HCAs in pregnancy is often a matter 
of debate. Surgery of lesions located at the periphery of the liver can be performed 
safely within the first or second trimester, and will usually be indicated by the size of 
the lesion, and its change in size. Radiation exposure and/or exposure to iodinated 
contrast media during RFA or TAE may be contraindicated during the early phase 
of pregnancy, with the treatment of smaller lesions not being indicated. Given the 
increased risk of hemorrhage in larger HCAs (> 5 cm), or when a previous preg-
nancy was complicated by either minor or major bleeding, we currently advocate a 
Figure 4. A 25-year-old female with a MRI diagnosis of single HCA, probably inflammatory subtype. 
As the patient wished to become pregnant, despite growth of her HCA, a decision to treat with TAE 
was taken. Coronal MR image with T1-weighting of the upper abdomen (a). A hypervascular HCA 
is indicated (small arrow), adjacent to the gallbladder (long arrow). Ablation was contraindicated 
due to the close proximity of the gallbladder. Angiogram (b) before TAE showing an arterial tumor 
‘blush’ in the HCA (short arrow), with the gallbladder perfused by the same local hepatic artery 
division (long arrow). This finding contraindicated TAE due to the possibility of gallbladder necrosis 
following infarction. Instead, a decision to operate was made, with resection of the gallbladder, and 
subsequent intraoperative RFA of the HCA. Axial postoperative CT image after contrast injection in 
the venous phase (c). The gallbladder was resected, in combination with intraoperative RFA (arrow).
CT, computerized tomography; HCA, hepatocellular adenoma; RFA, radiofrequency ablation; TAE, 
transcatheter arterial embolization.
Chapter 7
102
preemptive treatment strategy before pregnancy, as proposed by van Aalten et al. 
[Broker et al., 2012]. Whenever a HCA is discovered during pregnancy, the second 
trimester is the optimal moment for invasive treatment, if indicated, as anesthesia is 
well tolerated at this stage, and the fetus is not yet so large as to interfere with liver 
surgery [Parangi et al., 2007].
Liver adenomatosis
Hepatic adenomatosis (HCAs more than ten) is regarded by some authors as a differ-
ent entity[Barthelmes et al., 2005, Frulio et al., 2014]. There seems not to be a strong 
association with oestrogen or anabolic steroid use[Chiche et al., 2000, Grazioli et al., 
2000]. However, there is a strong association with glycogen storage disease[Chiche 
et al., 2000, Frulio et al., 2014]. Mostly , these adenomas are of the H-HCA and IHCA 
subtypes[Frulio et al., 2014]. The nodules in hepatocellular adenomatosis are often 
of the same subtypes. Although one might assume that multiple HCAs increase the 
propensity for lesional bleeding, previous data have shown no significant difference 
in macroscopic bleeding between single and multiple HCAs (p<0.155) [Dokmak et 
al., 2009].According to literature there seems no indication to suggest that the risk 
of malignant transformation is increased in hepatic adenomatosis compared with 
solitary HCAs[Barthelmes et al., 2005]. However, hepatic adenomatosis are more 
often found in glycogen storage disease and in man[Chiche et al., 2000],and as such 
at risk for increased malignant potential. Presently, there is no systematic review 
available which evaluates the malignant potential of hepatic adenomatosis.As for 
clinical management, and there is no data suggesting that hepatic adenomatis 
should be treated differently from solitary HCAs.
Biopsy in the management of HCA
Since the introduction of the HCA subclassification system, several authors have 
attempted to further refine the diagnostic work-up using additional techniques, in-
cluding immunohistochemistry [Zucman-Rossi et al., 2006]. The primary motivation 
for the introduction of additional biopsies was the prospect of identifying HCAs with 
greater malignant potential (such as exon-3 b-catenin mutated HCAs). There seem to 
be no unique MRI features with which to assign a b-HCA subtype risk, which offers 
one argument for the expansion of the use of diagnostic biopsy in order to arrive at 
a correct diagnosis.
However, at present there is no consensus regarding the diagnostic work-up of 
HCA [Nault et al., 2013, Marrero et al., 2014]. Nault et al. regard histologic analysis 
as the backbone of HCA diagnosis, with the detection or exclusion of b-HCA as the 
main input [Nault et al., 2013]. They argue that biopsy should be offered in all cases 
of HCA smaller than 5 cm with no typical MRI sign of H-HCA. Lesions larger than 5 
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cm do not require biopsy since they are all preferably resected. In our opinion, and 
in accordance with recent American College of Gastroenterology guidelines for liver 
lesions, the diagnostic work-up of suspected HCA should be based primarily on MRI 
findings, with biopsy in cases where the lesion cannot be clearly differentiated from 
FNH [Marrero et al., 2014]. Other indications for biopsy are an atypical presentation 
of the HCA on imaging, with the main differential diagnosis being HCC in a non-
cirrhotic liver [Marrero et al., 2014].
The biopsy of all HCAs (with the exclusion of typical H-HCAs based on MRI) found 
by imaging would be impractical. Most patients with HCA are young, with minor 
symptoms on malignant progression; invasive procedures should preferably be 
avoided. While the risk of bleeding complications is very low when using an 18G 
core needle biopsy (0.6%) [Haage et al., 1999, Kadri Aribas et al., 2010, Aribas et 
al., 2012], the risks are not negligible, and deaths due to bleeding complications 
have been reported [Stattaus et al., 2007]. In our practice a biopsy has not been 
performed to date, except where the diagnosis of a specific adenoma subtype was 
expected to alter clinical management.
Unquestionably, a biopsy for further characterization may add important informa-
tion in well-defined cases. For example, a biopsy with the additional help of im-
munostaining could facilitate better discrimination between HCA and FNH, as shown 
in a large retrospective study in France where the investigators compared biopsies 
against a final diagnosis based on surgical resection [Bioulac-Sage et al., 2012]. 
A total of 239 needle biopsies were compared with the final diagnosis made on 
resection. A difference in sensitivity of 74.3% with immunostaining versus 58.6% 
achieved with routine analyses without GS or other molecular features was reported 
[Bioulac-Sage et al., 2012]. These data suggest that immunostaining should be made 
available in centers that routinely treat HCAs.
What is the best approach in cases where differentiation between HCA and HCC is 
not evident based on MRI? In cases where there is a major suspicion of malignancy 
(e.g. HCC in non-cirrhotic liver) based on a combination of clinical findings, size of 
the lesion, increased serum alpha-fetoprotein, and MRI findings (such as heteroge-
neous presentation with heterogeneous enhancement, wash-out, and true capsula) 
(figure 2), resection without prior biopsy can be recommended. Although biopsy of 
each suspect lesion would undoubtedly help in detecting HCC, this approach may 
be impractical due to the significant level of false-negative findings, the chances of 
seeding (figure 3), and the enhanced risk of bleeding, which is particularly relevant 
when multiple biopsies are taken. Furthermore, in cases with a typical presentation, 
a biopsy will not influence the decision to remove the lesion. Therefore, we sug-
gest to biopsy in selected cases only. Interestingly, the HCC literature documents a 
similar debate on whether it is acceptable to diagnose HCC in a cirrhotic liver based 
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solely on MRI findings, or whether the use of routine biopsies should be advocated 
for all suspected lesions in patients with liver cirrhosis [Sherman et al., 2015, Tor-
benson et al., 2015]. Even in high grade dysplastic nodes, follow-up by imaging is 
still preferred above biopsies.
As for daily practice, we recommend biopsy only in very selected cases where 
HCA cannot be differentiated from FNH with any imaging modality. The clinical 
repercussion of a wrong diagnosis of either HCA or FNH can have a large influence 
on a patient’s future in terms of treatment and prognosis. When there are signs of 
malignancy patients should preferentially be forwarded to an experienced referral 
center for further evaluation. One should be aware that in some cases MRI or biopsy 
will be unable to differentiate between HCA and well differentiated HCC.
Treatment options for hCA
Historically, HCAs were treated with a wait-and-see policy, with surgical intervention 
preferred for larger (>5cm) growing tumors. Current management options for HCAs 
may also include RFA, and TAE, mainly due to the advantages of these minimally 
invasive techniques. In the following section we will discuss routine, as well as less 
commonly used HCA treatment options, with a focus on minimally invasive, image-
guided, treatment options.
Conservative treatment
When HCAs are smaller than 5 cm, or regress (to < 5 cm) following cessation of OCs, 
with no further growth detected, a wait-and-see policy is warranted. Although no 
widely accepted approach has yet been published, we prefer to schedule a patient 
for follow-up, including MRI, or ultrasound in a yearly follow up until menopause.
Surgery
Surgery has long been considered the treatment of choice because complete surgi-
cal removal of the lesion can be achieved in a controlled and relatively safe manner. 
Elective surgical resection is considered for all lesions greater than 5 cm in diameter. 
With a mortality of 1.1% (review by Lin et al., n = 170), surgery is a relatively safe 
procedure. In one review, 93% of patients with ruptured, or non-ruptured HCAs, 
were primarily treated with surgery, with complications that included two deaths, 
one biloma, one bile leakage, one infection, and one case of sepsis [Lin et al., 2011]. 
In another, single-center retrospective analysis of 41 cases, no perioperative mortal-
ity was found, and only minor complications arose. These included pleural effusion 
requiring drainage (n=2), pneumonia (n=1), and wound infection (n=1) [Cho et al., 
2008].
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In the latter study nine cases were operated on laparoscopically, a technique 
that is increasingly popular, where appropriate. deÁngelo et al. described 62 HCA 
patients who underwent either an open procedure or laparoscopy [De’angelis et al., 
2014]. They found no difference in postoperative morbidity and zero mortality, with 
no long-term complications or recurrence of HCA. However, patients with smaller 
lesions were preferentially treated with laparoscopy (68 versus 9). These authors 
concluded that laparoscopic liver resections may be limited by lesion size and loca-
tion, and that the technique requires advanced surgical skills. Given the precision 
required, robotic surgery may prove to be useful in the future, and could reduce 
complications; we await further evaluation of its efficacy [Jackson et al., 2015].
In rare circumstances, the treatment of HCA may also involve liver transplanta-
tion, a procedure described in a case report by Venarecci et al. [Vennarecci et al., 
2013]. Obesity, steatosis, and diabetes, are frequent co-morbidities in patients with 
HCAs, particularly the inflammatory subtype. These factors, and especially obesity, 
make surgery less attractive. For those patients who are poor candidates for surgery 
(centrally located lesions, multiple adenomas, or morbid obesity), RFA and TAE may 
instead be offered.
Radiofrequency Ablation (RFA)
RFA is a minimally invasive technique used in the treatment of hepatocellular 
carcinoma (HCC), other liver lesions such as colorectal metastases [Solbiati et al., 
2001, Cabibbo et al., 2013], and HCAs [Van Aalten et al., 2010, Van Vledder et al., 
2011]. Laparoscopic RFA, or perioperative RFA, may also be considered when the 
anatomical location (i.e. close proximity to the bowel or gallbladder (Fig. 3)) leads to 
an increased risk using a percutaneous approach. The use of RFA in the treatment of 
HCAs has only been described in small case series.
Vledder et al. described one case series including 45 HCAs, in 18 patients, that 
were ablated in 32 RFA sessions (open, n=4; percutaneous, n=28) [Van Vledder et 
al., 2011]. Twenty-six of 45 HCAs were successfully treated in one RFA session, with 
no visible residual disease. A further 9 HCAs were totally ablated following a second 
RFA session. Three HCAs required 3 or more RFA sessions, with all but 7 of the 45 
HCAs totally ablated after three or more sessions. The treated HCAs had a median 
size of 3.0 cm (ranging from 0.8 cm-7.3 cm). Only minor complications were attribut-
able to the RFA procedure; none of which required additional intervention (class A 
according to the Society of Interventional Radiology scoring system for complica-
tions). A single class D major complication was reported; a cerebrovascular accident 
during open surgery combined with RFA. Though severe, this complication was 
linked to anesthesiological and hemodynamic changes during laparotomy, rather 
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than the RFA procedure. In conclusion, RFA can be effectively and safely used in the 
treatment of HCA, although multiple sessions may be required for larger lesions.
In a review of HCA cases reported between 1998-2008, Haoming Lin et al. identi-
fied 356 HCA patients in reports from China, Europe, North-America, and South-East 
Asia [Lin et al., 2011]. Only 14 (3.9%) of these cases were treated with RFA, and no 
severe complications were reported. However, no results in terms of efficacy were 
provided. In 2008, Rhim et al. assessed the therapeutic efficacy and safety of RFA 
for HCAs [Rhim et al., 2008], and reported their initial experience in 10 patients with 
12 HCAs. Tumor sizes ranged from 1.5-4.5 cm. As no complications were reported 
after RFA, and no progression or recurrence was noted, RFA was considered a safe 
and effective treatment option. A minimal ablative margin of 5 mm is recommended 
during the radical treatment of lesions when using thermal ablation of HCCs. It is 
presently unclear if a similar margin should be applied to HCAs, as these lesions are 
assumed to be benign. No data are yet available regarding the ideal ablative margin 
during thermal ablation of HCAs. In our opinion, volume reduction is more important 
than an ablation margin, as the former correlates strongly with a risk of bleeding, and 
malignant transformation. Follow-up imaging after both RFA, and TAE, is routinely 
performed in our institution by MRI, six months after treatment.
As HCAs requiring treatment are generally large (>5 cm), a promising alternative 
for RFA may be microwave ablation (MWA). Based on preliminary data, MWA was 
shown to produce larger ablation zones, in less time, in patients treated for HCC 
and colorectal metastases. MWA delivers high frequency microwaves (0.9-2.4 GHz) 
into tumor tissue, which causes fast spinning of molecules and thus destroys tis-
sue. No data are available concerning efficacy and complications after MWA. MWA 
has specific advantages over RFA, such as larger ablation zones, higher treatment 
temperatures, and less susceptibility to local cooling by adjacent large blood ves-
sels (heatsink). Although larger zones of ablation can probably be achieved by using 
single-electrode needles and MWA to treat HCAs, to the best of our knowledge, no 
data currently exists to substantiate this idea.
Transcatheter Arterial Embolization (TAE)
As HCAs are hypervascular arterial lesions, bleeding may be treated by selective 
TAE in cases where patients present with hemodynamic instability. Embolization of 
HCAs is a safe but relatively challenging procedure due to multiple small feeding 
vessels [Van Aalten et al., 2010]. Nonetheless, in cases of spontaneous rupture and 
bleeding, TAE should be considered as a first line treatment as it is highly successful 
and minimally invasive in an acute setting. Although high success rates have been 
described for TAE, there is only a sparse literature comparing TAE with either surgery, 
or conservative management. In one study Karkar et al. described 52 patients with 
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100 HCAs, of which 37% were treated with TAE [Karkar et al., 2013]. In most of these 
cases TAE was performed in a (semi) elective setting, with rupture and hemorrhage 
as indications in 20%, and suspected malignancy in 56%. Success rates of up to 
92% were claimed for TAE (32), and of the 37 HCAs embolized, only three required 
secondary interventions (8.1%). All other embolized lesions were treated success-
fully; some disappeared (5/34), most decreased in size (22/34), or remained stable 
(7/34). Recurrence rates were also low. It is worth noting that the HCAs embolized 
were relatively small, with a median diameter of 2.6 cm. However, we feel that resec-
tion is indicated if malignancy is suspected and no contra-indications for surgery 
exist. In a report by Erdogan et al. six HCAs were primarily embolized [Erdogan et 
al., 2007], four because of bleeding, and two electively, one year after bleeding. 
No complications were reported, and all HCAs ceased bleeding. Two of the lesions 
were resected after embolization, two regressed visibly on follow-up imaging, and 
two HCAs were only seen after resorption of hematoma on follow-up imaging. These 
last two patients were managed with a wait-and-see policy. In a retrospective study 
by Dheodar et al., seventeen embolizations where successfully performed in eight 
patients [Deodhar et al., 2011], with five patients undergoing more than one embo-
lization. The mean size of the treated HCAs was 3.6 cm, and regression was noted 
in all embolized HCAs after embolization. As noted by Karkar et al., TAE may also 
be used in an elective setting where no acute intervention is needed [Karkar et al., 
2013]. This approach is of clinical interest and deserves further consideration.
Proposed management strategy
One of the major discussions on the management strategy of hepatocellular adeno-
mas involves the clinical application of these recent findings in the dynamic field of 
adenoma subtyping. How should we take into account these new insights into daily 
practice? In our view, more data are needed to implement this subclassification in 
the diagnosis and treatment of adenomas, balancing the risk of an invasive liver 
biopsy with the additional benefits in terms of individualized therapy and prognos-
tic stratification. A major effort should be made by expert centers involved in the 
diagnosis and treatment of hepatocellular adenomas to work on this collaboratively, 
preferably in research setting, to gather more data on the potential benefits for an 
individual patient.
Based on our review of the current literature, we propose a management strat-
egy applicable to most cases in which there is a suspicion of HCA (figure 5). This 
decision tree may not be appropriate for all patients; for some, a more custom-
ized approach may be required. In standard situations, mainly when a lesion is 
larger than 5 cm, oral contraceptives should be stopped and MRI performed after 
6 months. If the lesion has contracted to less than 5 cm, clear signs of an H-HCA 
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should be ruled in or out (figure 1). In scenarios where H-HCAs are subsequently 
identified, therapy can be less aggressive as inherent malignant progression is very 
low. Follow-up is then advised, initially every 6 months, and if the lesion shows 
no further alteration, follow-up can be stopped or simply repeated yearly until 
menopause [Marrero et al., 2014]. Since typical H-HCAs are easily identified using 
out-of-phase MRI sequences, intravenous contrast can be obviated at follow-up. A 
second option is to apply sonography during follow-up which is cheaper and less 
inconvenient for patients. For small lesions (<5 cm) that are categorized as IHCA, 
therapy should ordinarily not be altered (in standard cases). However, some may 
Figure 5. The management decision tree used in our tertiary academic medical center. This decision 
tree may not be appropriate for all patients; for some, a customized approach should be considered.
*One option is to biopsy those lesions where a subtyping diagnosis by imaging is impossible to 
achieve, or those lesions with typical signs of IHCA. Currently, this option is considered impractical 
given the large number of biopsies involved.
**Follow up is advised initially, at 6-monthly intervals. Thereafter, if the lesion shows no further 
alteration, follow up can be stopped, or repeated yearly until menopause. If the lesion is a typical 
H-HCA, follow up can be less stringent, possibly involving sonography, or MRI without contrast.
***Referral to an expert center is advised for the evaluation of any indication requiring intervention. 
This decision should be taken with consideration of contraindications (obesity, diabetes, centrally 
located tumor, ASA classification). Treatment can be primarily surgical, and in selected cases, RFA or 
local embolization.
b-HCA,β-catenin activated HCA; GSD, glycogen storage disease; HCA, hepatocellular adenoma; H-
HCA, HNF1A-mutated HCA; IHCA, inflammatory HCA; M, months; RFA, radiofrequency ablation.
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opt for a biopsy in order to exclude b-catenin mutation. This could also be the 
case if a subclassification cannot be made with MRI. For larger lesions (>5cm) with 
a b-catenin mutation or if the patient has an aggravating status such as male sex, 
steroid use, glycogen storage disease, or underlying viral hepatitis, intervention 
may be the first alternative. Treatment can be primarily surgical, and, in selected 
cases, RFA or TAE may be used. Depending on the underlying risks (obesity, diabe-
tes, centrally located tumor), the best option would be to evaluate these patients 
in an expert referral center.
CONCLUSIONS
MRI is the preferred tool in the management of HCA, its current principle use being 
size evaluation (cut-off 5 cm), identification of signs of malignancy, and exclusion of 
H-HCAs, recognized for their benign course and permitting a conservative approach. 
Until now, there is no reliable MRI characteristic to diagnose non-invasively b-HCA, 
being the most important lesion to diagnose as it may have the highest malignant 
potential .
Conservative management remains the strategy of choice for uncomplicated small 
HCAs, and surgery may be indicated if imaging shows heterogeneous signal and 
growing smaller lesions suspected of being highly differentiated HCC. Further pro-
spective cohort studies are warranted to support the choices made between these 
treatment strategies and to determine the role of biopsy in the subclassification of 
HCAs. In cases where a HCA requires treatment, and surgical resection of smaller 
lesions (<3cm) carries an unacceptable risk, RFA or TAE may be considered.
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ABSTRACT
Hepatocellular adenoma (HCA) is a generally benign liver tumor with the potential 
for malignancy and bleeding. HCAs are categorized into four subtypes on the basis 
of genetic and pathological features: hepatocyte nuclear factor 1α-mutated HCA, 
β-catenin-mutated HCA, inflammatory HCA, and unclassified HCA. Magnetic reso-
nance imaging (MRI) plays an important role in the diagnosis, subtype characteriza-
tion, and detection of HCA complications; it is also used to differentiate HCA from 
focal nodular hyperplasia. In this review, we present an overview of the genetic ab-
normalities, oncogenesis, and typical and atypical MRI findings of specific subtypes 
of HCA using contrast-enhanced MRI with or without hepatobiliary contrast agents 
(gadobenate dimeglumine and gadoxetate disodium). We also discuss their different 
management implications after diagnosis.
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Hepatocellular adenoma (HCA) is a rare, benign tumor of the liver that occurs pre-
dominantly in young and middle-aged women (1). In contrast to focal nodular hy-
perplasia (FNH), HCA may involve complications, such as a life-threatening bleeding 
and malignant degeneration (1–3). The strong association between the occurrence 
of HCA and the use of oral contraceptives was first acknowledged in 1970s (4), and 
the incidence of HCA is now thought to be 30 times greater in oral contraceptive 
users compared to nonusers (5, 6). A dose-dependent association and spontaneous 
regression following the withdrawal of estrogens have also been described (4, 7). 
However, the exact role of estrogen in HCA is still poorly understood.
In this review, we present an overview of the typical and atypical magnetic 
resonance imaging (MRI) findings of different HCAs compared to FNH, and discuss 
various pitfalls that may be encountered with MRI.
ThE NEw CLASSIFICATION OF hEPATOCELLULAR ADENOMA
A molecular and immunohistochemical classification of HCA has been introduced by 
the Bordeaux group (Table 1) (8, 9); in this classification, HCAs are divided into four 
subgroups based on clear genetic differences.
The first group accounts for 30% to 40% of cases and is defined by the pres-
ence of hepatocyte nuclear factor 1α (HNF1A) mutations (10). The HNF1A gene 
controls lipid metabolism and mediates the downregulation of liver fatty acid 
Table 1. Immunohistochemical and MRI signs used for differentiating the HCA subtypes
  HNF1A-mutated 
HCA
β-catenin- 
mutated HCA
Inflammatory HCAa Unclassified 
HCA
Immunohistochemical staining
 Glutamine synthetaseb − +/− +/− −
 β-catenin − + +/− −
 C-reactive protein − − + −
 Serum amyloid A − − + −
 LFABP − + + +
Typical MRI findingsc Diffuse 
homogenous 
lesional steatosis
Faint scar 
strong, diffuse,
Atoll sign and 
hyperintense signal 
on T2-weighting
 
aInflammatory HCAs may show β-catenin positivity, in these cases most lesions may also show ho-
mogenous glutamine synthetase staining.
bIn exceptional cases, glutamine synthetase can be normal in β-catenin-mutated HCAs.
cThe MRI signs are preliminary and based on three recent papers (13, 21, 23).
HCA, hepatocellular adenoma; HNF1A, hepatocyte nuclear factor 1α; MRI, magnetic resonance imag-
ing; LFABP, liver fatty acid binding protein.
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binding protein (LFABP). LFABP downregulation is typically observed using LFABP 
staining, which is 100% accurate (8, 11). The most typical presentation of group 1 
(i.e., HNF1A-mutated) HCA lesions is the aberrant presence of internal steatosis. It 
should be noted, however, that internal steatosis is not sufficient for diagnosing this 
HCA subtype, as other subtypes may also exhibit internal steatosis (12). We prefer 
to avoid the term steatotic HCA, which is used in some literature on this particular 
subtype (13). Some patients with HNF1A-mutated HCA have an associated mutation 
that is thought to be responsible for maturity-onset noninsulin-dependent diabetes 
(14). Therefore, once this HCA subtype has been diagnosed, the clinician should be 
warned of the possibility of underlying diabetes.
A second group containing 10% to 15% of cases is identified by the presence 
of activating mutations of β-catenin (15). While β-catenin is phosphorylated and 
degraded by proteasomes under physiological conditions, tumors fail to down-
regulate β-catenin and instead show nuclear accumulation of the protein (16). This 
accumulation is known to trigger an important signaling pathway in several cancers 
but is typified by hepatocellular carcinoma (17). Although β-catenin activation is not 
sensitive enough for immunohistochemical classification due to its visibility in only 
a few sporadic nuclei (12), another product of the same β-catenin. Therefore, it has 
been stated that these cases could be at increased risk of malignant degeneration 
(12).
The final group accounts for 10% to 25% of HCA cases and shows no specific ge-
netic alterations; this group is therefore currently referred to as “unclassified” (16).
IMPLICATIONS FOR DIAGNOSIS
While immunohistochemical staining of LFABP, β-catenin, glutamine synthetase, se-
rum amyloid A, and C-reactive protein has proven to be very effective in differentiat-
ing between the four subtypes of HCA, it is also useful in the differentiation between 
HCA and FNH (9, 20). In a retrospective, multicenter study in France, Bioulac-Sage 
et al. (20) found that the certainty of biopsy diagnosis of FNH increased from 53% 
to 87% when additional immunohistochemistry markers and glutamine synthetase 
immunostaining were used. The certainty of biopsy diagnosis of HCA also increased 
from 59% to 74% when immunohistochemistry analyses were used. Prior to the in-
troduction of these markers, HCA was often misdiagnosed as FNH during histological 
examination, especially when inflammatory HCA (formerly known as telangiectatic 
FNH) was involved (19). The latter lesions include the bile duct proliferation seen 
in FNH but demonstrate the behavior of a HCA (including the previously described 
risk of malignant degeneration and bleeding). This confusion should be taken into 
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account when evaluating older radiologic descriptions of HCA and FNH, as the refer-
ence standard has only become significantly more accurate since the introduction 
of these markers.
While immunohistochemical staining of LFABP, β-catenin, glutamine synthetase, 
serum amyloid A, and C-reactive protein has proven to be very effective in differentiat-
ing between the four subtypes of HCA, it is also useful in the differentiation between 
HCA and FNH (9, 20). In a retrospective, multicenter study in France, Bioulac-Sage 
et al. (20) found that the certainty of biopsy diagnosis of FNH increased from 53% 
to 87% when additional immunohistochemistry markers and glutamine synthetase 
immunostaining were used. The certainty of biopsy diagnosis of HCA also increased 
from 59% to 74% when immunohistochemistry analyses were used. Prior to the in-
troduction of these markers, HCA was often misdiagnosed as FNH during histological 
examination, especially when inflammatory HCA (formerly known as telangiectatic 
FNH) was involved (19). The latter lesions include the bile duct proliferation seen 
in FNH but demonstrate the behavior of a HCA (including the previously described 
risk of malignant degeneration and bleeding). This confusion should be taken into 
account when evaluating older radiologic descriptions of HCA and FNH, as the refer-
ence standard has only become significantly more accurate since the introduction of 
these markers While immunohistochemical staining of LFABP, β-catenin, glutamine 
synthetase, serum amyloid A, and C-reactive protein has proven to be very effective 
in differentiating between the four subtypes of HCA, it is also useful in the differen-
tiation between HCA and FNH (9, 20). In a retrospective, multicenter study in France, 
Bioulac-Sage et al. (20) found that the certainty of biopsy diagnosis of FNH increased 
from 53% to 87% when additional immunohistochemistry markers and glutamine 
synthetase immunostaining were used. The certainty of biopsy diagnosis of HCA 
also increased from 59% to 74% when immunohistochemistry analyses were used. 
Prior to the introduction of these markers, HCA was often misdiagnosed as FNH dur-
ing histological examination, especially when inflammatory HCA (formerly known 
as telangiectatic FNH) was involved (19). The latter lesions include the bile duct 
proliferation seen in FNH but demonstrate the behavior of a HCA (including the 
previously described risk of malignant degeneration and bleeding). This confusion 
should be taken into account when evaluating older radiologic descriptions of HCA 
and FNH, as the reference standard has only become significantly more accurate 
since the introduction of these markers
Conventional MRI findings for hepatocellular adenoma
HCA is primarily diagnosed by noninvasive imaging techniques (1), and typical 
MRI characteristics can be used for differentiating between HCA and FNH. Accord-
ing to recent literature, some MRI findings are more typical than others (Table 2). 
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T1-weighted hyperintensity seems to be prevalent only in HCAs and is most likely 
caused by blood degeneration products or glycogen storage (21–23).
Other signs of non-neoplastic degeneration can be appreciated in some HCAs 
through the visualization of internal bleeding cysts, necrosis or fluid. To the best 
of our knowledge, these finding have not been described for FNH (2). A strong T2-
weighted hyperintense band in peripheral areas of the lesion is a typical sign of HCA 
and was only (possibly) visible in one FNH case in our series to date (see below) (21).
The finding of a central scar is a more commonly described imaging character-
istic of FNH (2). However, we also found linear central scars in 21% of confirmed 
HCAs (21). This sign, which is characterized by a T2-weighted central scar with late 
enhancement on delayed phase, does not seem to be sufficiently robust to allow 
differentiation between these two lesions. Additionally, β-catenin-mutated HCAs 
appear to have a faint central scar in up to 75% of cases (Fig. 1) (21). On the other 
hand, in our experience a typical ‘spoke wheel’ appearance of a central scar is only 
visible in FNH (Fig. 2) (2).
The surrounding liver steatosis, intralesional fat accumulation, faint arterial en-
hancement pattern and presence of multiple lesions are more or less typical for HCA 
but can also occur in FNH (21–23). A lobular border is often described as a typical 
sign for the diagnosis of FNH, but our research group and others have found that the 
occurrence of a lobular border is not uncommon in HCAs (21, 22).
Table 2. Classical MRI signs that can be used for differentiating HCAs from FNHs
HCA FNH
Strong signs Strong signs
 Strong hyperintensity on T2-weighting  Spoke wheel appearance of scar
 Hyperintensity on T1-weighting  
 Cystic parts  
 Hemorrhagic parts  
 Diffuse intralesional steatosis  
 Atoll sign  
Weak signs Weak signs
 Faint arterial enhancement  Scar
 Liver steatosis  Lobular contours
 Multiple lesions  Strong arterial enhancement
We distinguish strong signs from weak signs. Strong signs are defined to be characteristic for that 
lesion. Weak signs are more common in either HCA of FNH, but can occur in both.
FNH, focal nodular hyperplasia; HCA, hepatocellular adenoma; MRI, magnetic resonance imaging.
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MRI FINDINGS BASED ON ThE NEw SUBCLASSIFICATION
Laumonier et al. (23) were the first to publish the typical MRI features of HCA ac-
cording to the subgroup classification. A homogeneous dropout of signal on the 
T1-weighted out-ofphase sequence had a sensitivity of 86.7% and a specificity of 
100% for HNF1A-mutated HCA (Fig. 3), whereas this dropout was absent or only 
focal (heterogeneous) in inflammatory HCA. Moreover, marked hyperinten sity on 
T2-weighted sequences was found to be typical for inflammatory HCA, with a sensi-
tivity of 85.2% and a specificity of 87.5%.
We found similar presentations for HNF1A-mutated HCA and inflammatory HCA 
(21). Additionally, we showed that a hyperintense rim on the T2-weighted sequences 
was diagnostic for inflammatory HCA. This hyperintense rim sign corresponds to si-
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Figure 1 a/b 
 
Axial T2-weighted (a) and T1-weighted (b) MR images of the liver after contrast injection. 
Histologically, β-catenin staining is positive in this patient. The faint scar-like region is T2 
hyperintense (a, arrow) with late enhancement after contrast injection of a nonspecific gadolinium-
based contrast agent (b, arrow), a finding that is similar to that expected in focal nodular hyperplasia 
(FNH). In our opinion, a lesion with a scar but lacking a “spoke wheel” aspect is not only typical of 
FNH, but may also occur in hepatocellular adenoma (HCA) and more typically in β-catenin-mutated 
HCA. 
 
Figure 2a/b/c 
 
Axial T2-weighted (a), venous phase T1-weighted (b), and 20-min T1-weighted (c) MR images of a 
patient with the “spoke wheel” aspect that is typical for FNH. A central scar with divergences to the 
periphery is visible on T2-weighting and is reminiscent of a “spoke wheel” (a). These so-called spokes 
are normally enhanced in the venous phase using a nonspecific contrast agent or gadobenate 
dimeglumine. However, when using gadoxetate disodium, the central scar and the spokes are 
hypointense due to pseudo washout (b). After 20 min, the majority of the lesion (except the scar) 
becomes hyperintense due to internal bile duct proliferation (c). 
Figure 1a/b. Axial T2-weighted (a) and T1-weighted (b) MR images of the liver after contrast injec-
tion. Histologically,β-catenin staining is positive in this patient. The faint scar-like region is T2 hyper-
intense (a, arro ) with late nhancement after contrast injection of a nonspecific gadolinium-based 
contrast agent (b, arrow), a finding that is similar to that expected in focal nodular hyperplasia (FNH). 
In our opinion, a lesion with a scar but lacking a “spoke wheel” aspect is not only typical of FNH, 
but may also occur in hepatocellular adenoma (HCA) and more typically in β-catenin-mutated HCA.
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periphery is visible on T2-weighting and is reminiscent of a “spoke wheel” (a). These so-called spokes 
are normally enhanced in the venous phase using a nonspecific contrast agent or gadobenate 
dimeglumine. However, when using gadoxetate disodium, the central scar and the spokes are 
hypointense due to pseudo washout (b). After 20 min, the majority of the lesion (except the scar) 
becomes hyperintense due to internal bile duct proliferation (c). 
Figure 2a/b/c. Axial T2-weighted (a), venous phase T1-weighted (b), and 20-min T1-weighted (c) MR 
images of a patient with the “spoke wheel” aspect that is typical for FNH. A central scar with diver-
gences to the periphery is visible on T2-weighting and is reminiscent of a “spoke wheel” (a). These 
so-called spokes are normally enhanced in the venous phase using a nonspecific contrast agent 
or gadobenate dimeglumine. However, whe  using gadoxetate disodium, the central scar and the 
spokes are hypointense due to pseudo washout (b). After 20 min, the majority of the lesion (except 
th  scar) becomes hyperintense due to intern l bile duct proliferation (c).
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nusoidal dilatation (Fig. 4) and is also referred to as an “atoll sign”. This characteristic 
includes a hyperintense rim in the periphery of the lesion on T2-weighted imaging 
with an isointensity in the center of the lesion reminiscent of the sea within an atoll 
(24). Small intralesional T2-hyperintense nodules can be found in the center of the 
lesion (small islands) (21).
Several authors have reported that a faint scar may be a possible sign of β-catenin-
mutated HCA (21, 23, 25), but the number of published β-catenin-mutated HCA 
cases to date is too low to draw any firm conclusions.
 
Figure 3 a/b 
 
Axial T1-weighted in-phase (a) and opposed-phase (b) MR images of a hepatocyte nuclear factor 1α 
(HNF1A)-mutated HCA. This lesion shows the typical diffuse and homogeneous suppression of signal 
in the lesion due to fat accumulation. Also note the blood residue centrally located in the lesion as a 
T1-weighted hyperintense zone. In addition to steatosis, this lesion showed no liver fatty acid binding 
protein staining upon histology, which is a very sensitive marker for HNF1A mutation. 
 
Figure 4a/b/c
 
Axial T2-weighted (a), arterial (b), and venous (c) T1-weighted MR images of the liver with a typical 
presentation of an inflammatory HCA. The lesion presents with an “atoll sign” (a), which appears as a 
T2-weighted hyperintense rim (peripheral island with central sea) with or without central 
hyperintense islands as can be found inside an atoll. The lesion is hypervascular in the arterial phase 
(b), with late enhancement of the peripheral rim and central islands (c). Upon histology, these lesions 
Figure 3a/b. Axial T1-weighted in-phase (a) and opposed-phase (b) MR images of a hepatocyte 
nuclear factor 1α (HNF1A)-mut ted HCA. Thi  lesion hows the typical diffuse and homogeneous 
suppression of signal in the lesion due to fat accumulation. Also note the blood residue central-
ly located in the lesion as a T1-weighted hyperin ense zone. In addition to st atosis, this lesion 
showed no liver fatty acid binding protein staining upon histology, which is a very sensitive marker 
for HNF1A mutation.
 
Figure 3 a/b 
 
Axial T1-weighted in-phase (a) and opposed-phase (b) MR images of a hepatocyte nuclear factor 1α 
(HNF1A)-mutated HCA. This lesion shows the typical diffuse and homogeneous suppression of signal 
in the lesion due to fat accumulation. Also note the blood residue centrally located in the lesion as a 
T1-weighted hyperintense zone. In addition to steatosis, this lesion showed no liver fatty acid binding 
protein stai ing upo  histology, which is a very sensitive arker for HNF1A mutation. 
 
Figure 4a/b/c
 
Axial T2-weighted (a), arterial (b), and venous (c) T1-weighted MR images of the liver with a typical 
presentation of an inflammatory HCA. The lesion presents with an “atoll sign” (a), which appears as a 
T2-weighted hyperintense rim (peripheral island with central sea) with or without central 
hyperintense islands as can be found inside an atoll. The lesion is hypervascular in the arterial phase 
(b), with late enhancement of the peripheral rim and central islands (c). Upon histology, these lesions 
Figure 4a/b/c. Axial T2-weighted (a), arterial (b), and venous (c) T1-weighted MR images of the 
liver with a typical presentation of an inflammatory HCA. The lesion presents with an “atoll sign” 
(a), which appears as a T2-weighted hyperintense rim (peripheral island with central sea) with or 
without central hyperintense islands as can be found inside an atoll. The lesion is hypervascular 
in th  ar rial hase (b), with late enhancement of the p ripheral im and c islands (c). Upon 
histology, these lesions demonstrate positive immunostaining of inflammatory proteins including 
C-reactive protein and serum amyloid A. The T2-weighted hyperintense rim is thought to be caused 
by local peliosis.
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MRI FINDINGS AFTER USING LIVER-SPECIFIC CONTRAST AGENTS
With the introduction of hepatobiliary contrast agents, an important tool became 
available for differentiating HCA from FNH (26).
Two gadolinium-based contrast agents are currently available, gadobenate 
dimeglumine (Multihance, Milan, Italy) and gadoxetate disodium (Primovist, Berlin, 
Germany; brand name in the USA, Eovist).
Both agents show hepatocyte uptake and biliary excretion, with a hyperintense 
liver in the hepatocyte phase on T1-weighted imaging as a conse quence. Lesions 
that involve bile ducts also appear to enhance. This observation is typically the case 
in FNHs and in some hepatocellular carcinomas (26). The most important finding is 
that HCAs do not normally show hepatocyte uptake and biliary excretion and are 
therefore observed as hypointense compared to the liver in the hepatocyte phase.
There are strong arguments for the uptake of gadoxetate disodium in FNHs and 
some hepatocellular carcinomas by organic anion transporter polypeptide channels 
(25, 27, 28). However, one study suggested another mechanism of uptake of both 
gadobenate dimeglumine and gadoxetate disodium in the liver (29).
Yoneda et al. (27) found that organic anion transporter polypeptide-8 is present in 
the periphery and not in the center of FNH, explaining the peculiar aspect of some 
FNH cases in the hepatocyte phase (ring-enhancement-type).
Gadobenate dimeglumine is excret ed by the liver at a significantly lower percent-
age (5%) than gadoxetate disodium (50%) (26). As a result, gadoxetate disodium 
produces a significantly greater signal intensity change in the hepatocyte phase than 
gadobenate dimeglumine. This greater change can be helpful in cases where liver ac-
tivity and thus changes in enhancement are low, as is observed in cirrhosis. One cause 
of this lower liver enhancement is the competitive uptake between these contrast 
agents and bilirubin, with uptake of the latter increased in patients with liver cirrhosis. 
Additionally, lesions that have an intrinsic T1-weighted hyperintensity, as frequently 
observed in HCAs, may often show insufficient liver enhancement when using gado-
benate dimeglumine. This insufficient enhancement results in the hyperintense HCA 
becoming isointense instead of hypointense compared to the surrounding liver (30).
Whether there is a difference in uptake of hepatobiliary contrast agents between 
the different HCA subtypes is still largely unknown. Our recently reported initial 
results noted that inflammatory HCAs range from isointense to hyperintense in rela-
tion to the liver in the hepatocyte phase (Fig. 5) (30). However, the underlying cause 
of this finding was not obvious. Of particular interest is the fact that, in contrast to 
other HCAs, inflammatory HCA often harbors internal bile ducts, which could possibly 
explain the late isointensity in the hepatocyte phase. However, this phenomenon is 
difficult to discern from isointensity due to intrinsic hyperintensity prior to contrast.
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Implications for patient care
Though the use of either gadobenate dimeglumine or gadoxetate disodium may 
often be indicated, it can be difficult for a radiologist to choose between these two 
contrast agents. The major differences are listed in Table 3.
As previously noted by others, gadoxetate disodium may be preferred over 
gadobenate dimeglumine when considering the rapid hepatobiliary phase at 20 
minutes or earlier, whereas in patients scanned with gadobenate dimeglumine, the 
hepatobiliary phase is obtained with a second MRI performed a minimum of one 
hour after the initial MRI and injection of contrast agent (24). However, it is important 
to note that the early hepatobiliary excretion of gadoxetate disodium prevents the 
dynamic phase from being separated from the hepatobiliary phase, which results in 
the disturbing interpretation of the dynamic phase in cases of suspected hemangio-
mas. Additionally, when using gadoxetate disodium, a large number of liver lesions 
become hypointense in the late dynamic phase due to pseudo washout rather than 
actual washout (due to enhancement of the surrounding liver). Finally, radiologists 
demonstrate positive immunostaining of inflammatory proteins including C-reactive protein and 
serum amyloid A. The T2-weighted hyperintense rim is thought to be caused by local peliosis. 
 
Figure 5a/b/c
 
Enhancement curve (a) of a known inflammatory HCA that was scanned every 2.5 min over a period 
of one hour following the injection of gadobenate dimeglumine. This approach allows an 
enhancement curve that shows no late enhancement to be reproduced. Comparison of axial fat-
saturated T1-weighted sequences prior to contrast injection (b) and one hour after contrast injection 
(c) reveals that the lesion remains isointense (arrows) due to intrinsic hyperintensity 
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Table 3. Comparison of the hepatobiliary contrast agents gadobenate dimeglumine and gadoxetate 
disodium for liver imaging
  Gadobenate 
dimeglumine
Gadoxetate 
disodium
T1 effect +++ +
Cost + ++
Shortness of investigation + ++(+)
Differentiation of HCA from FNH + +
Differentiation of benign liver lesions (hemangiomas) ++ − (+)
Hepatobiliary excretion + +++
FNH, focal nodular hyperplasia; HCA, hepatocellular adenoma.
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should be aware that because of this pseudo washout, the central scar in FNH may 
become hypointense instead of hyperintense in the late venous phase when using 
gadoxetate disodium.
Another argument in favor of gadobenate dimeglumine over gadoxetate disodium 
is the considerably lower cost of the former. This difference is most likely due to the 
wider range of possible indications for the use of gadobenate dimeglumine, which 
appears to be a useful, nonspecific gadolinium-based contrast agent. With the less 
pronounced T1-effect of gadoxetate disodium, this agent is indicated for specific 
liver imaging only.
In the case of an atypical liver lesion where the differential diagnosis is broad 
and includes hemangioma and malignant tumors, a nonspecific contrast agent or 
gadobenate dimeglumine is generally preferred over gadoxetate disodium. In cases 
where MRI is prescribed solely for the differentiation between FNH and HCA, ga-
doxetate disodium should be sufficient, which is often the case when preliminary 
external computed tomography or MRI data are present.
Although contrast-enhanced ultrasonography is beyond the scope of this review, 
it may be speculated that in the near future differentiation between the different 
HCA subtypes may also be possible with the use of contrast sonography (31).
Additionally, other markers may come to play a more prominent role in the dif-
ferentiation of HCA from FNH or hepatocellular carcinomas (32, 33).
MALIGNANT DEGENERATION OF hEPATOCELLULAR ADENOMA
Malignant degeneration of HCA has been reported but seems to occur very rarely. 
In a recent meta-analysis, a total of 1635 HCA cases were examined and yielded an 
overall malignant transformation frequency of 4.2%. Most of those lesions were 
larger than 5 cm in diameter. However, the described overall frequency is most likely 
an overestimation due to the limited sample sizes of the studies and the fact that 
most studies only described resected HCA (29).
Furthermore, it is interesting that these so-called malignant degenerated HCAs 
show a pattern of a nodule within a nodule or two tumors lying adjacent to each 
other (28, 30). In this situation, it might be questioned whether these nodules have 
undergone the same cellular changes.
The malignant potential of HCA seems stronger in β-catenin-mutated HCA, which 
is also more prevalent in men (15). Bioulac-Sage et al. (15) reported the occurrence 
of six hepatocellular carcinomas in 128 proven cases of HCA, all of which were 
β-catenin-mutated HCAs, whether they were inflammatory or not. Management of 
these β-catenin-mutated HCAs can vary between hospitals from conservative to 
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aggressive (surgical). Additional experiences from more hospitals are needed to 
correlate the classification system with clinical management (28).
INTERNAL BLEEDING IN hEPATOCELLULAR ADENOMA
Rupture and bleeding have both been described in HCA; the hypervascular nature 
of these lesions may make them more prone to bleeding. In contrast, FNHs do not 
demonstrate rupture or bleeding despite their hypervascularity. In a meta-analysis, 
we determined a HCA rupture prevalence of 16% (3). However, the papers studied 
did show some evidence of selection bias, as patients with silent HCAs were under-
reported due to the lack of any indication for imaging in most of these patients. The 
meta-analysis showed that larger lesions (larger than 5 cm) are more often involved. 
There also seems to be no difference in the occurrence of internal bleeding depend-
ing on HCA subtype. After analyzing their own database, Bioulac-Sage et al. (15) 
also found no difference in the chance of macroscopic bleeding between HNF1A-
mutated HCA and inflammatory HCA, the two most prevalent subtypes (Fig. 4).
As the actual risk of bleeding is reported to be higher in lesions larger than 5 cm, 
resection of these lesions may be warranted. Decisions related to the treatment 
of smaller HCAs are still complex and other characteristics, such as male gender, 
β-catenin positivity, and the wish to become pregnant, can also play an important 
role. Larger studies will need to be performed to evaluate whether there is a cor-
relation between the subtype and bleeding and rupture. Pregnant patients with HCA 
deserve special attention, as maternal and fetal mortality rates are not negligible 
(34–36). We advocate that patients with a HCA larger than 5 cm be treated before 
becoming pregnant. In cases where a HCA larger than 5 cm is found during preg-
nancy, the data are currently too sparse to draw firm conclusions, and we believe 
that the management in these patients should be individualized (36, 37).
Hepatocellular adenoma in males
HCA mainly occurs in women in their second and third decades of life (5), and the 
incidence in men is very low. Most described cases of HCA in men occurred after the 
chronic intake of exogenous hormones (38) or in men with glycogen storage disease 
(39). Because of its low incidence, its diagnosis should be questioned, and we advise 
that a biopsy be performed more often when these tumors are found in men to 
exclude the presence of a premalignant or malignant liver tumor.
123
Genotype-phenotype correlations in hepatocellular adenoma: an update of MRI findings
8
CONCLUSION
In summary, advances in recent years have greatly improved our understanding of 
HCA, leading to subtype recognition and better differentiation from FNH. Reports 
and conclusions drawn from MRI data in older studies, particularly prior to the 
introduction of glutamine synthetase staining, should therefore be evaluated with 
caution.
HCA diagnosis has been improved by additional experiences with atypical find-
ings and potential pitfalls that may be encountered with MRI. The introduction of 
hepatobiliary contrast agents has helped even more, particularly in differentiating 
between HCA and FNA, and these agents have now become valuable tools in daily 
clinical practice. However, the radiologist must always be aware of possible errors 
in diagnosis due to differences between hepatobiliary and nonspecific gadolinium-
based contrast agents. With respect to the treatment of HCA, a number of recom-
mendations can be made; however, other questions require further studies.
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ABSTRACT
Introduction
In the work up of primary solid liver lesions it is essential to differentiate correctly 
between benign and malignant tumors, such as hepatocellular adenoma (HCA) and 
hepatocellular carcinoma (HCC) respectively. A promising new marker to detect HCC 
is Golgi Protein 73 (GP73). Studies comparing patients with HCC and cirrhosis with 
normal controls suggested that GP73 is specific for patients with HCC; however, pa-
tients with other liver tumors were not included. We therefore studied the predictive 
value of GP73 in differentiating between solid benign and malignant liver tumors.
Materials and methods
This study included 264 patients: 88 patients with HCC, 88 with hepatocellular 
adenoma (HCA), and 88 with focal nodal hyperplasia (FNH). A blood sample was 
collected from each patient to measure GP73 levels using a quantitative ELISA assay 
and differences in outcome between subgroups were compared. The receiver oper-
ating characteristic (ROC) curve, sensitivity and specificity of GP73 were calculated 
and compared to alpha-fetoprotein (AFP) levels.
Results
When comparing malignant and benign liver tumors the area under ROC was 0.701 
and 0.912 for GP73 and AFP respectively. Test characteristics revealed a sensitivity 
of 60% for GP73 and 65% for AFP; in addition the specificity was 77% for GP73 
and 96% for AFP.
Conclusion: Although the literature suggests that GP73 is a valuable serum marker 
in patients with HCC, the serum concentration may also be increased in patients with 
solid benign liver tumors. Therefore, a GP73 assay is less suitable for discriminating 
between primary malignant and benign tumors of the liver.
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INTRODUCTION
Over the past 15 years ultrasound examination of the liver has increased in fre-
quency [1,2]. Ultrasonography can be used to detect solid liver lesions in asymptom-
atic patients [3]. Unfortunately, such a finding may cause distress when additional 
characterization is unable to differentiate between a benign liver tumor, such as 
hepatocellular adenoma (HCA) and focal nodular hyperplasia (FNH), and a malignant 
tumor such as hepatocellular carcinoma (HCC). Even when more refined imaging 
technologies are used, such as contrast-MRI or contrast-enhanced ultrasound, a 
definitive diagnosis may be difficult to establish in such solid ‘incidentaloma’ in the 
liver [4], eventually leading to a liver biopsy.
Although in some cases it may be possible to differentiate between malignant 
and benign tumors using molecular markers, the low sensitivity of tests to detect 
HCC via serum alpha-fetoprotein (AFP) limits clinical decision making [5]. Therefore 
more accurate markers are needed. Golgi Protein 73 (GP73), also named Golgi 
phosphoprotein 2 (GOLPH2), was recently introduced as a potential new candidate 
to identify HCC. GP73 is a resident Golgi-specific membrane expressed by biliary 
epithelial cells and is enhanced in HCC cells [6].
Several studies have described GP73 as a HCC-specific marker. However, these 
studies mainly included patients with liver cirrhosis and/or healthy people as con-
trols [7,8], and thus lack information on patients with other liver tumors such as HCA 
and FNH. We therefore determined whether GP73 can differentiate between solid 
benign and malignant liver tumors and whether GP73 has a predictive value if an 
unknown solid liver ‘incidentaloma’ is present.
MATERIALS AND METhODS
Study protocol was in conformity with the ethical guidelines of the 1975 Declaration 
of Helsinki and approved by the local Institutional Review Board and Ethical Com-
mittee from the Erasmus MC University. Oral informed consent was obtained from all 
patients, as was approved by the Institutional Review Board. The no-objection policy 
was approved as only one extra blood vial was collected during regular blood sam-
pling and patients were informed prior to blood sampling. All patients visiting the 
out-patient department are informed before they visit the clinic that data generated 
from their visit can be used for scientific studies as we are an academic hospital. 
Patients can actively opt out when visiting the out-patient clinic. This no-objection 
procedure has been approved for all outpatient visits. The protocol was approved 
separately. Blood sampling and the purpose of it are discussed with the patients 
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during their visit at the outpatient clinic as, according to Dutch law, patients have to 
be informed for which purpose blood samples are taken.
Between July 2007 and October 2012 a total of 264 patients enrolled in this 
study: 88 patients with HCA, 88 patients with FNH and 88 patients with HCC.
Patients aged 18 years and older, with a proven diagnosis of hepatocellular car-
cinoma, hepatocellular adenoma or focal nodular dysplasia, were included. The di-
agnosis was based on histopathology (95 patients, 36%), and if histopathology was 
not available, on two imaging modalities (magnetic resonance imaging, computed 
tomography or contrast enhanced ultrasound). All patients had been discussed by 
our multidisciplinary tumor board committee. Patients were excluded if there was 
doubt about the diagnosis or if multiple types of tumor were present in the liver.
Data characteristics and a 10-ml blood sample were collected from each patient in 
the out-patient clinic of the Erasmus University Medical Center. Each blood sample 
was centrifuged and the serum aliquotted and stored at -80°C until tested.
Blood samples were blinded for analysis. Quantitative ELISA (Antibodies-online 
GmH, Germany, ABIN365730, intra-assay CV% less than 8%, inter-assay CV% less 
than 10%.) was performed to measure GP73 levels according to the manufacturer’s 
instructions. A standard curve was run for each assay using six provided standards, 
measured in duplicate per ELISA.
The serum AFP level was also determined for each patient using the Elecsys AFP 
quantitative electrochemiluminescence immunoassay (Roche, Switzerland) and a 
value >10 µg/L was considered as an elevated level. The receiver operating charac-
teristic (ROC) curve, sensitivity and specificity, and positive predictive value of GP73 
were calculated and compared with those of AFP. To determine the optimal cut-off 
value for GP73, ROC was constructed using all possible cut-offs for each essay. The 
area under the curve (AUC) was constructed for both AFP and GP73, including 95% 
confidence intervals (CI). Approval was obtained from the medical ethics committee.
Our primary hypothesis was that GP73 was superior to the predictive value of AFP 
for the detection of HCC. A power analysis was conducted using a sensitivity of 85% 
for GP73 and 58% for AFP, with a specificity of 97% and 85%, respectively [9,10]. 
A minimum of 40 patients per group was needed for an alpha of 0.05 and a beta of 
0.20. The number of patients was increased to the maximum number of wells on the 
ELISA plates (N=88).
Data analysis
Variables were compared using the t-test or a one-way ANOVA, whenever appropri-
ate. Statistical significance was considered at a p-value < 0.05. All analyses were 
performed using the Statistical Package for the Social Sciences (SPSS) (IBM Corp. 
Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM 
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Corp). Patient characteristics and treatment were compared using the t-test, the chi-
square-test and the Fisher exact test whenever appropriate.
RESULTS
A total of 264 patients were enrolled in this study, including 88 patients with HCC, 
88 with HCA, and 88 with FNH. The demographic and etiologic data of these patients 
are shown in Table 1. The percentage of males, age, body mass index (BMI), alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl 
transferase (GGT) differed significantly between patients with HCC, HCA and FNH.
Table 2 shows the distribution of serum GP73 values (IU/l) in the different groups 
of patients. The mean serum concentration of GP73 was 47 IU/l in the HCC group, 21 
IU/L in the HCA group and 17 IU/l in the FNH group (P<0.001). Within the HCC group, 
GP73 did not differ between patients with hepatitis compared with patients without 
hepatitis, at 47 and 48 IU/l respectively (p=0.51). The median serum concentration 
of AFP was 9184 Ug/L in the HCC group, 3 Ug/L in the HCA group and 3 Ug/L in 
the FNH group (P=0.001). The data are shown in Table 2 and Figure 1. In Figure 1 
three outliers are depicted (1 HCA, 2 FNH). In the patient with the extreme (FNH) a 
biopsy was performed. In the two other patients the diagnosis was confirmed by two 
imaging modalities (magnetic resonance imaging, computed tomography or contrast 
enhanced ultrasound) in 2010. Follow-up did not reveal a HCC.
Table 1. Patient characteristics
 
HCC
N=88
HCA
N=88
FNH
N=88 P-value
Male gender (%) 62 (94%) 2 (3%) 2 (3%) <0.001
Age (years) 63 (34-82) 40 (20-58) 38 (19-70)  <0.001
BMI (kg/m2) 27 (17-39) 30 (19-62) 26 (16-37)  <0.001
AST (I/U) 82 (15-897) 30 (13-86) 26 (8-64)  <0.001
ALT (I/U) 61 (8-461) 33 (7-126) 26 (5-121)  <0.001
GGT (I/U) 304 (11-4570) 88 (8-802) 67 (11-372)  <0.001
Lesion size (mm) 65 (10-250) 61 (8-177) 54 (4-110)  0.178
HBV 16 (18%) - - -
HCV 15 (17%) - - -
Data are presented as median (range) unless other indicated
HCC: hepatocellular carcinoma, HCA: hepatocellular adenoma, FNH: focal nodular hyperplasia, BMI: 
body mass index, AST: aspartate aminotransferase, ALT: alanine aminotransferase, GGT HBV: hepatitis 
B virus, HCV: hepatitis C virus.
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ROC curves
ROC curves were plotted to determine the optimal cut-off value for GP73 and to 
identify the sensitivity and specificity of GP73 and AFP in differentiating patients 
with malignant and benign solid liver tumors (HCC vs. HCA and FNH). The AUC for 
GP73 was 0.701 with a 95% CI of 0.625 to 0.776, and a sensitivity of 60% and 
specificity of 77 %, using a cut-off value of 29.2 IU/L. The positive predictive value 
(PPV) for GP73 was 56% and the accuracy of the test was 71%.
The AUC for AFP was 0.91 (95% CI of 0.871 to 0.943); with a cut-off value of 10 
Ug/L, the sensitivity was 77% and the specificity was 96%. The PPV for AFP was 
89% with an accuracy of 85%. Comparing the two ROC curves showed AFP to be 
superior to GP73 (p<0.001) (Fig. 2).
Using a cut-off value of 2.92 IU/L, GP73 was positive in 17 out of 31 AFP-negative 
HCC patients. AFP and GP73 were combined and were reported as positive if one 
out of two markers, AFP or GP73, was positive. The sensitivity and specificity of the 
combined marker was 84% and 73%, respectively (Table 3).
Figure 1. Boxplot GP73
Boxplots showing the serum 
GP73 levels in patients with he-
patocellular carcinoma (HCC), he-
patocellular adenoma (HCA) and 
focal nodular hyperplasia (FNH). 
• indicates the outliers and *the 
extreme.
Table 2. Biomarkers to differentiate between benign and malignant liver tumors
  HCC HCA FNH P-value
GP73 (IU/ml) 39 (16-100) 13 (1.3-76) 14 (1.6-78) <0.001
AFP (Ug/L) 9184 (1-212600) 3 (1-16) 3 (1-50) 0.001
Data are presented as median (range)
HCC: hepatocellular carcinoma, HCA: hepatocellular adenoma, FNH: focal nodular hyperplasia, 
GP73: Golgi Protein 73, AFP: alpha-fetoprotein
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DISCUSSION
When a solid tumor of unknown origin is found in the liver an extensive diagnostic 
work-up is often necessary. In 10–40% of cases the final diagnosis remains unclear 
unless invasive techniques are used [4]. Therefore it is of utmost importance to find a 
serological marker, with a high sensitivity and specificity that is able to discriminate 
between benign and malignant solid liver tumors. Recent studies showed the poten-
tial of GP73 as a marker for HCC [7,10-12]. They suggested that GP73 might even be 
better than AFP [10]. This study showed the potential of GP73 to distinguish patients 
with HCC from patients with a solid benign liver tumor, HCA or FNH. However almost 
all serological data concerning GP73 and AFP in patients with HCC used patients 
with cirrhosis, hepatitis or no liver disease as controls [8,9,12-18].
It has been suggested that GP73 could be increased in liver disease due to viral 
causes (hepatitis B virus and hepatitis C virus) [19,20]. GP73 could even be associ-
ated with the progression of this liver disease [18]. However no significant differ-
ence was found between patients with HCC with hepatitis compared with patients 
without hepatitis. As there were no patients with hepatitis in the HCA or FNH group, 
this could not explain the elevated levels of GP73 in patients with HCA or FNH. 
Figure 2. ROC-Curve GP73 and AFP
ROC curves comparing AFP (straight line) 
and GP73 (dashed line). Pairwise com-
parison of ROC curves (Hanley & McNeil, 
1983) revealed a significant difference of 
P<0.0001
Table 3. Sensitivity and specificity of the biomarkers
  Sensitivity Specificity
GP73 60% 77 %
AFP 77% 96%
AFP combined with GP73 84% 73%
GP73: Golgi Protein 73, AFP: alpha-fetoprotein
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Riener et al. performed immunohistochemical staining of GP73 on tumor samples 
from HCC, as well as a small group of tumor samples of HCA and FNH, and found that 
GP73 is frequently expressed in samples of HCA and FNH [21]. In combination with 
our results, this suggests that GP73 is not a specific marker for HCC.
Two studies included serum from other focal liver lesions. Tian et al included 6 
patients with FNH, in 3 out of 6 patients (50%) serum GP73 was elevated (14). Mao 
et al. suggested that GP73 might be a useful tool for discriminating benign from 
malignant liver tumors (9.) Although they only studied a small group of patients 
with benign liver tumors (hepatic cysts, FNH and hepatic cystadenoma), they also 
found an elevated serum GP73 in the group of patients with benign liver tumors 
[9]. Our study, which was conducted in a larger and better-defined group of patients 
with solid liver tumors, confirmed the significantly higher levels of GP73 in patients 
with HCC. However, analysis of AFP in our study population indicated that AFP is 
superior to GP73 for discriminating patients with HCC from patients with a solid 
benign liver tumor. The low number of patients with a false positive test result for 
AFP was particularly noticeable.
In recent studies evaluating the value of GP73, three types of assay were used: 
immunoblot assay, Western blot assay and ELISA. It has been suggested that GP73-
specific antibodies might interfere with the ELISA analysis [7,22], as five studies that 
used ELISA found no significant elevation of GP73 when comparing the serum levels 
of HCC patients with their controls [14,15,17,23]. Immunoblot assay is too labor-
intensive for large patient numbers [12], therefore ELISA is preferred. As we found 
a significant difference in GP73 between malignant and benign solid liver tumors, 
we believe that the use of ELISA is no longer an obstacle for the performance of 
large-scale studies.
Although the ELISA GP73 test is suitable we do not believe that further testing 
and development for unknown solid tumors in the liver will lead to better results 
in patients with a solid liver tumor of unknown origin. We do not expect GP73 to 
complement the results of AFP, as we studied a large and unique group of patients 
with benign and malignant solid liver tumors. Therefore imaging will continue to 
have an important place, next to AFP, in distinguishing benign from malignant liver 
tumors. If GP73 is further developed and analyzed to determine whether it is able to 
distinguish patients with hepatitis and cirrhosis from patients with HCC, one should 
take into account that GP73 is also elevated in benign liver tumors.
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ABSTRACT
Because of the risk of hormone induced growth and spontaneous rupture of he-
patocellular adenoma (HCA) during pregnancy, special considerations are required. 
Due to the scarcity of cases there is no evidence-based algorithm for the evaluation 
and management of HCA during pregnancy. We think it should be questioned if it is 
justified to discourage pregnancy in all women with HCA. The biological behavior of 
this benign lesion might be less threatening than presumed and a negative advice 
concerning pregnancy has great impact on the lives of these young female patients. 
The balance between the pros and cons of hepatic adenomas and pregnancy should 
be reconsidered. In our centre pregnancy in women with a HCA up to 5 cm is no 
longer discouraged in close consultation with the patient, her partner and members 
of the liver expert team.
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A strong association between hepatocellular adenoma (HCA) and the use of oral 
contraceptives (OC) was first described in 1973(1). The hypothesis that there is a 
relation between steroids and HCA has been supported by many authors but is still 
not understood.(2-4) Due to the increased levels of endogeneous hormone produc-
tion, which may cause hormone induced growth and rupture, HCA requires special 
attention during pregnancy.(5, 6) Patients with a growing or ruptured HCA mostly 
present themselves with persistent or acute severe pain localized in the upper right 
quadrant and in the epigastric region. In the literature, the maternal and fetal mortal-
ity risks of ruptured HCA during pregnancy has been reported to be 44 and 38% 
respectively.(7) However, all these cases were published in the 1970s or 1980s, in 
which there might have been a delay in diagnosis as the entity of ruptured HCA was 
not well known and less advanced imaging methods were used.
In the recent years the widespread use of highly advanced image modalities has 
probably decreased the delay in the diagnosis of HCA and the associated maternal 
and fetal mortality significantly. Because of the unpredictable behavior of HCA dur-
ing the increased levels of endogeneous hormones we used to advise women with 
a large HCA or a growing and hormone sensitive HCA to avoid pregnancy, as most 
other experts in this field do.(6, 8) Even if HCA were incidental findings previous to a 
pregnancy without having caused any complications, women were still advised not 
to get pregnant as long as the HCA is present. Because of the overall agreed advice 
to avoid pregnancy in patients with HCA, the diagnosis of HCA has severe impact on 
the lives of these young fertile women.
As to date there are limited data about the behavior of HCA during pregnancy and 
labor.
From the international literature between 1966 and 2003, Cobey et al. retrieved 
26 cases of women presenting with HCA during pregnancy or early postpartum and 
proposed an algorithm for their diagnosis and management(7). Presentation was 
acute and often dramatic with rupture of the adenoma in 16 women, and frequently 
with a delay in establishing the correct diagnosis, with high maternal and fetal mor-
tality (44% and 38%, respectively). The hormone induced growth and risk of rupture 
seemed to by the highest during the third trimester of pregnancy, most probably 
because of the cumulating level of oestrogens and an increase in hyperdynamic 
circulation combined with an increase in vascularity of the liver.(7) An aggressive 
approach towards resection of HCA was advocated, especially for those greater than 
5 cm. Small adenomas were supposed to be managed by observation(7). It is im-
portant to realize that most of these reports were published in a time period during 
which this disease entity was relatively unknown and treatment in an emergency 
setting was less advanced.
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In our hospital, we monitored 12 women with one or more documented HCA’s 
during a total of 17 pregnancies. In four cases, HCA grew during pregnancy, requiring 
a Caesarean section in one patient (two pregnancies) and RFA in one patient during 
the first trimester of pregnancy because of significant growth of the adenoma. All 
pregnancies had an uneventful course with a successful maternal and fetal out-
come(9). We concluded not to discourage all women with HCA from pregnancy. In 
our tertiary referral centre, we closely observe pregnant women with a HCA smaller 
than 5 cm in a clinical trial(10). In this study, the size of the lesion is an exclusion 
criterion when exceeding 5 cm, but the number of HCA’s present in the liver is not. 
Three studies investigated the association between the risk of rupture and the num-
ber of HCA’s(11). This risk did not differ between single and multiple HCA’s(12-14). 
In our previous study, the number of HCA’s in the women observed during preg-
nancy varied between 1 and more than 10 HCA’s. We concluded that only in women 
with large tumours and a complicated pregnancy previously, pregnancy should be 
discouraged(9).
Furthermore, in our opinion, none of the subgroups from the molecular and 
pathological subtype classification of the Bordeaux group legitimizes objection 
against pregnancy. Although the number of cases described in literature is small no 
difference has been demonstrated in the risk of bleeding between the two major 
subgroups, the inflammatory and the hepatocyte nuclear factor 1α-inactivated 
HCA’s(15, 16).
If women have large tumours or have experienced complications of HCA in pre-
vious pregnancies, an intervention (surgery, RFA, embolisation) should be recom-
mended before pregnancy. Moreover, in 2006 we reported a series of 48 patients 
in which 44% of HCA were discovered after the patient had sustained at least one 
pregnancy(17).
Intervention during pregnancy may be associated with greater risk for both mother 
and child. The Society of American Gastrointestinal and Endoscopic Surgeons (SAG-
ES) provided guidelines for diagnosis, treatment, and use of laparoscopy for surgical 
problems during pregnancy.(18, 19) In one in 635 pregnancies a non-obstetric 
operation, in particular appendectomy, cholecystectomy and adnexal procedures, 
is required during pregnancy (20). These guidelines suggest that the laparoscopic 
approach should be preferred in stead of laparotomy in most abdominal operations.
The maternal and fetal outcomes following abdominal surgery in pregnancy 
improved over last decade but the exact risk of HCA-related interventions during 
pregnancy to both mother and fetus is unknown(21). Abdominal surgery may be 
more difficult during pregnancy in the late second and third trimester because of 
the limited wideness in the upper abdomen due to the enlarged uterus and risk 
of steatotic changes of the liver in these patients. General anaesthesia seems to 
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have the least risk in the 2nd trimester of pregnancy(5). The role of RFA during 
pregnancy is not yet been studied extensively. In our previous study we described 
a RFA procedure during the first trimester of pregnancy(9) and a pregnant patient 
with a HCA which was treated by RFA during her second trimester of pregnancy (18th 
week of gestation) was reported by Fujita et al.(22). After systematically reviewing 
the literature Wilson et al. suggested that angioembolisation and formal resection 
in case of haemorrhage of HCA during pregnancy is safe for both the mother and the 
fetus with good clinical outcomes(23). We believe that selective arterial embolisa-
tion should only be used as a live-saving treatment in those cases where RFA or 
surgery are inadequate or too risky to control the bleeding adenoma. ,The increased 
risk of radiation exposure to the fetus, especially before 26 weeks of gestation(24, 
25), should be avoided if possible.
Because HCA might have the tendency to rupture during delivery, some authors 
suggest a caesarean section (C-section). In our study three C-sections (two patients) 
were performed, without complications. In one case the C-section was performed 
in consultation with the patient because of marked growth and an unknown risk 
of rupture of the HCA’s. In the other C-section was due to decelerations on the car-
diotocography (9). All other patients had a normal delivery without complications. 
Therefore, in our opinion patients with HCA may deliver vaginally if there are no 
complicating factors, like perinatal problems.
In conclusion, it seems to be justified that a pregnancy should be discouraged in 
patients with a large HCA (> 5 cm) or those who experienced complications of the 
lesion in previous pregnancies (figure 1). In those case a surgical resection, RFA or 
embolisation should be recommended before pregnancy. In our centre we do not 
discourage pregnancy in women with a HCA <5cm (figure 2) if they accept the risk 
of interventions in case of growth of the adenoma. Close guidance of these women 
and monitoring of the hepatic adenoma by liver ultrasound every 6 weeks during 
pregnancy is strongly advocated .(10, 26)
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Women with a HCA and a wish 
for pregnancy.
HCA < 5 cm HCA ≥ 5 cm
Inclusion 
patients in our  
prospective 
study when 
pregnant 
No negative 
advice on 
pregnancy
Surgical 
resection not 
possible
Surgical 
resection 
possible
RFA or 
embolisation
Resection
HCA < 5 cm
No negative 
advice on 
pregnancy
No negative 
advice on 
pregnancy
Figure 1. Flowchart for wom-
en with a HCA and a wish for 
pregnancy
Figure 2. An example of a woman with a HCA of 4.2 cm in segment 2/3 in which pregnancy will not 
be discouraged.
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ABSTRACT
Background
Hepatocellular adenoma (HCA) in pregnant women requires special considerations 
because of the risk of hormone induced growth and spontaneous rupture, which 
may threaten the life of both mother and child. Due to scarcity of cases there is 
no evidence-based algorithm for the evaluation and management of HCA during 
pregnancy. Most experts advocate that women with HCA should not get pregnant or 
advise surgical resection before pregnancy. Whether it is justified to deny a young 
woman a pregnancy, as the biological behavior may be less threatening than pre-
sumed depends on the incidence of HCA growth and the subsequent clinical events 
during pregnancy.
We aim to investigate the management and outcome of HCA during pregnancy 
and labor based on a prospectively acquired online database in the Netherlands.
Methods/design
The Pregnancy And Liver adenoma Management (PALM) - study is a multicentre pro-
spective study in three cohorts of pregnant patients. In total 50 pregnant patients, 
≥ 18 years of age with a radiologically and/or histologically proven diagnosis of 
HCA will be included in the study. Radiological diagnosis of HCA will be based on 
contrast enhanced MRI. Lesions at inclusion must not exceed 5 cm. The study group 
will be compared to a healthy control group of 63 pregnant patients and a group of 
63 pregnant patients with diabetes mellitus without HCA. During their pregnancy 
HCA patients will be closely monitored by means of repetitive ultrasound (US) at 14, 
20, 26, 32 and 38 weeks of gestation and 6 and 12 weeks postpartum. Both control 
groups will undergo US of the liver at 14 weeks of gestation to exclude HCA lesions 
in the liver. All groups will be asked to fill out quality of life related questionnaires.
Discussion
The study will obtain information about the behaviour of HCA during pregnancy, the 
clinical consequences for mother and child and the impact of having a HCA during 
pregnancy on the health related quality of life of these young women. As a result 
of this study we will propose a decision-making model for the management of HCA 
during pregnancy.
Trial registration
Dutch trial register: NTR3034
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BACkGROUND
Hepatocellular adenoma (HCA) is rare benign tumor of the liver that occurs particu-
larly in women during their reproductive years. The incidence is not exactly known. 
Studies performed years ago show an estimate incidence of 1-1.3 per 1,000,000 
in women who have never used oral contraceptives (OC), compared to 30-40 per 
1,000,000 in long-term users. [1,2] The association of HCA with the use of OC was 
first described in 1973. [3] In subsequent years many authors have supported 
the hypothesis of an association between OC and HCA. [4–8] The mechanism by 
which estrogen or other steroids contributes to the development of HCA is still 
not understood and studies are rare. Symptomatic patients with HCA present with 
right upper quadrant abdominal pain or discomfort secondary to bleeding within 
the HCA, elevated liver enzymes and symptoms of life treating hemorrhage into the 
peritoneal cavity. However, most patients with HCA are asymptomatic and present 
as an incidental finding during ultrasonographic examination of the abdomen for 
unrelated reasons or are noted during laparoscopic cholecystectomy. Despite its 
benign nature, the diagnosis of HCA has a great impact of the lives of these, mostly, 
young women because HCA can be complicated by hormone induces growth and 
rupture. Besides that malignant transformation of HCA into hepatocellular carcinoma 
has been reported with an overall frequency of 4.2%. [9]
Regardless of the exact etiology and risk factors all female patients should be 
advised to stop OC’s and other hormone medication such as hormone replacement 
therapy, since regression of HCA may occur when steroids are withdrawn [10–13] 
and observation should be the first choice of treatment for most patients with HCA. 
Because of the risk for spontaneous rupture most authors believe that surgical re-
section is required if the diameter exceeds 5 cm after 6 months of follow-up without 
OC use, if the lesion does not show adequate regression after discontinuation of 
OC or if rebleeding occurs. [14–17] Surgical resection is also indicated if there is 
diagnostic doubt e.g. whether a tumor is malignant. [18,19]
HCA in pregnant women requires special considerations because of the risk of 
hormone induced growth and spontaneous rupture, due to increased levels of 
steroid hormones during pregnancy that may threaten the life of both mother and 
child. Most experts advocate that women with HCA should not get pregnant or 
advise surgical resection before pregnancy. [2,18] Cobey et al. reported a mater-
nal and fetal mortality risk of ruptured HCA during pregnancy of 44% and 38%, 
respectively. [20] However, all these cases were published in the 1970s and 1980s 
and nowadays the introduction and widespread use of highly advantage imaging 
modalities have probably decreased the doctors’ delay in the diagnosis of HCA. We 
recently proposed not to discourage all women with HCA from pregnancy, based on 
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a study in which we monitored twelve women with documented HCA during a total 
of 17 pregnancies. In 4 cases HCA’s grew during pregnancy, requiring a Caesarean 
section in 1 patient (2 pregnancies) and radiofrequency ablation (RFA) in 1 case dur-
ing the first trimester of pregnancy. All pregnancies had an uneventful course with 
a successful maternal and fetal outcome. [21] However, there is no evidence-based 
algorithm for the evaluation and management of HCA during pregnancy and labor, 
due to scarcity of cases. The conclusion not to discourage all women with HCA from 
pregnancy has, however, to be proven in a large multicentre study in which we will 
closely monitor pregnant patient with a HCA in a prospectively acquired database to 
give more insight in the behaviour of HCA during pregnancy.
METhODS/DESIGN
Study objective
In this study we will investigate the management and outcome of HCA during 
pregnancy and labor based on a prospectively acquired online database in the 
Netherlands.
Main objective of the PALM-study
– To investigate the incidence of HCA growth during pregnancy and labor.
Secondary objectives of the PALM-study
– To investigate in which trimester of pregnancy growth of HCA occurs;
– To investigate the degree of growth of HCA during pregnancy;
– To investigate whether there is regression of HCA postpartum;
– To investigate the HCA-related interventions during pregnancy and labor;
– To investigate the incidence of bleeding of HCA during pregnancy and labor;
– To investigate liver-related clinical signs during pregnancy;
– To investigate elevated liver enzymes during pregnancy;
– To evaluate the health related quality of life of pregnant patients with HCA;
– To investigate whether there is a difference between health related quality of life 
of pregnant patients with HCA and pregnant patients with other comorbidity that 
have an indication for pregnancy care at the obstetrician in secondary care and 
healthy pregnant patients.
STUDY DESIGN
The PALM-study is a multi-centre prospective study in three cohorts of pregnant 
women. The study started on November 1 2011 and inclusion of patients will be a 
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period of minimal 3 to maximal 5 years. In total 50 pregnant patients with HCA < 5 
cm will be included in the study. These patients will be compared to a healthy con-
trol group consisting of 63 pregnant patients without HCA and a group consisting 
of 63 pregnant patients with diabetes mellitus (DM). Approval of the Medical Ethics 
Committee of Erasmus Medical Centre was obtained, NL36058.078.11.
Patient selection
Study group
Properly Dutch speaking, pregnant patients, 18 years of age or older with a ra-
diologically and/or histologically proven diagnosis of HCA can be included in the 
study. Radiological diagnosis of HCA will be based on contrast enhanced magnetic 
resonance imaging (MRI) and if available in combination with (contrast enhanced) 
ultrasonography (US). Lesions must not exceed 5 cm. In the first weeks of pregnancy 
patients will be referred to the obstetrician for pregnancy care. Baseline starts at 14 
(+/−3) weeks of gestation. At this day and every 6 weeks patients will undergo US 
of the HCA lesion at the radiologist. Before US of the HCA lesions patients will be 
asked to fill out generic health related quality of life questionnaires (12-item Short 
Form SF 12 and EuroQol questionnaire EQ-5d), a generic anxiety questionnaire 
(State-Trait Anxiety Inventory STAI-6) and the Impact of Event Scale (IES) question-
naire for thoughts and feelings about HCA around the US. One week afterwards the 
study group will be asked to fill out the STAI-6 en IES again. At 14 and 32 weeks of 
pregnancy patients will undergo venapunction.
Control group 1 (healthy pregnant patients without HCA)
Properly Dutch speaking, healthy pregnant patients, 18 years of age or older without 
HCA.
In the Netherlands, pregnant women will start pregnancy care with an indepen-
dently practicing midwife early in pregnancy at the primary care level. [22] The 
midwife is responsible for the pregnant women as long as the pregnancy, labor or 
postpartum period is normal. [23] In case of complication, the midwife will refer the 
women to the obstetrician in secondary care. [22,23] Women with a high risk profile 
based on their medical or obstetric history will be cared for the obstetrician from the 
start of pregnancy. [22,23]
Patients presenting at the practicing midwife will be asked to participate in the 
study. Thereafter, the patients will be included in the study by the study investiga-
tor. Patients will undergo US of the liver at 14 (+/-3) weeks of gestation to exclude 
HCA lesions in the liver. At this day and every other 6 weeks patients will be asked 
to fill out the SF-12 and EQ-5d questionnaire. At 14 and 32 weeks of pregnancy 
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patients will undergo venapunction. In case of an uncomplicated pregnancy, the 
patient remains under the care of her practicing midwife during her pregnancy and 
postpartum.
Control group 2 (pregnant patients with Diabetes Mellitus)
Properly Dutch speaking, pregnant patients, 18 years of age or older with Diabetes 
Mellitus, can be included in the study. These patients have an indication for preg-
nancy care at the obstetrician in secondary care. Patients will undergo US of the liver 
at 14 (+/-3) weeks of gestation to exclude HCA lesions in the liver. At this day and 
every other 6 weeks patients will be asked to fill out the SF-12 and EQ-5d question-
naire. At 14 and 32 weeks of pregnancy patients will undergo venapunction.
For all groups informed consent is mandatory. A patient can always withdraw 
her consent at anytime during the study where after she is referred for the present 
standard of care.
hypothesis
Pregnancy may be allowed in case of one or more known HCA < 5 cm (without previ-
ous intervention), because a HCA < 5 cm will not disturb the course of pregnancy.
Disrupted course of pregnancy:
– interventions during pregnancy (radiological and/or surgical intervention).
– Decreased quality of life and/or anxiety in patients during pregnancy related to 
the presence of HCA in the liver and possible growth during pregnancy.
Retrospective cohort study
We have previously reported that more than half of the HCA are discovered after 
the patient has sustained at least one pregnancy and none of these patients have 
reported problems during their pregnancies. [19] As mentioned above, recently we 
described a small but unique series of 12 women with documented HCA who were 
closely monitored during a total of 17 pregnancies between 2000 and 2009. In 4 
cases HCA’s grew during pregnancy, requiring a Caesarean section in 1 patient (2 
pregnancies) and RFA in 1 case during the first trimester of pregnancy to treat a 
hormone sensitive HCA, thereby excluding potential growth later on in pregnancy. 
No intervention was performed in the other 14 cases. All pregnancies had an un-
eventful course with a successful maternal and fetal outcome and we concluded 
that a “wait and see” management may be advocated in pregnant women presenting 
with HCA. In women with large tumours or in whom HCA had complicated previous 
pregnancies, surgical resection may be recommend. [21] However, additional data 
from different centres for the risk of hormone induces growth and rupture of HCA 
during pregnancy is needed.
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Interventions
During their pregnancy HCA patients will be closely monitored by means of repeti-
tive US (and MRI in case of growth of the lesion) at 14 (+/−3) and 20 and 26 and 
32 and 38 weeks of gestation and 6 and 12 weeks postpartum. At the same days 
both control groups will be asked to fill out the SF-12 and EQ-5d questionnaire 
at 14 (+/−3) and 20 and 26 and 32 and 38 weeks of gestation and at 6 and 12 
weeks postpartum. (Fig. 1) The study group will be asked to fill out the SF-12, EQ-5d, 
STAI-6 and IES questionnaires before and one week after US of the HCA lesion(s). 
Both control groups will undergo US of the liver at 14 (+/−3) weeks of gestation to 
exclude HCA lesions in the liver. At 14 and 32 weeks of pregnancy all patient groups 
will undergo venapunction.
Online database
We established a website which allows hepatologists, surgeons and gyneacologists 
to submit clinical data in an online database. Each centre will have a code to log 
in and patients will be consecutively assessed a unique number. Registration of a 
new patient includes entry of the following data: date of birth, weight, height, date 
of hospital admission, symptoms at presentation, known risk factors for HCA such 
as glycogenosis and familial polyposis, [24] previous pregnancies, previous use of 
OC or other hormone medication including hormone replacement therapy, course 
of HCA after discontinuation of OC, size of HCA before pregnancy, size of HCA 
during pregnancy (14 (+/−3) and 20 and 26 and 32 and 38 weeks), course of HCA 
postpartum (6 and 12 weeks postpartum), complications and management during 
pregnancy, gestation time, way of delivery (vaginally, Caesarean section), maternal 
and fetal outcome, complications and management after delivery. Only authorized 
users can gain action to the online database of his or her patients. The database 
offers excess to the registered data on anytime and anywhere. The coordinating 
investigator will monitor whether all required fields are completed.
Follow-up
Follow-up of patients takes place at 6 and 12 weeks postpartum postpartum by 
means of US (and MRI in case of growth) to document the size of HCA postpartum 
(table 1). Both control groups will be asked to fill out the SF-12 and EQ-5d question-
naires at these days. The study group will be asked to fill out the SF-12, EQ-5d, 
STAI-6 and IES questionnaires before and one week after US of the HCA lesion(s).
Chapter 11
158
Outcome measures
Primary outcome: Biological behaviour and clinical consequences of HCA < 5 cm 
during pregnancy. Growth is measured by repetitive US (and MRI in case of growth) 
at 14 (+/−3) and 20 and 26 and 32 and 38 weeks of gestation.
Secondary outcome: General health and pain scales as a measure for quality of life 
and anxiety related questionnaires for thoughts and feelings of adenomas around 
US. Other secondary outcomes are complications due to growth of the HCA dur-
ing pregnancy possibly followed by interventions during pregnancy, incidence of 
hemorrhage and rupture of the HCA, incidence of liver-related clinical signs during 
pregnancy (itch, icterus), incidence of elevated liver enzymes during pregnancy.
Power calculation
In our previous study we measured growth of HCA in 4 out of 17 pregnancies (24%) 
or in 3 out of 12 women (25%). On a yearly basis approximately 50 new patients 
with HCA are seen at the outpatient clinic of the Erasmus University Medical Centre. 
The expectation is that 5% (5) of these women get pregnant. The expectation is that 
a total of 50 pregnant HCA patients from different tertiary referral centres in the 
Netherlands can be included in the study during a period of 3 to maximum 5 years.
A difference of 0.5 Cohen’s D in health-related quality of life is a relevant differ-
ence. [25] We calculated that for this purpose 63 patients in both control groups 
have to be enrolled. A two-sample t test was performed with a two-sided significant 
level of 0.05 and a power of 0.80.
Table 1. Follow-up PALM-study
Pregnancy
Weeks Ultrasonography Venapunction Questionnaires
14 S, C1, C2 S, C1, C2 S, C1, C2 *
20 S   S, C1, C2 *
26 S   S, C1, C2 *
32 S S, C1, C2 S, C1, C2 *
38 S   S, C1, C2 *
Post-partum
Weeks Ultrasonography Venapunction Questionnaires
6 S   S, C1, C2 *
12 S   S, C1, C2 *
S, study group; C1 control group 1 (healthy pregnant patients without HCA); C2, control group 2 
(pregnant patients with Diabetes Mellitus)
*The study group will be asked to fill out the SF-12, EQ-5d, STAI-6 and IES questionnaires before 
and one week after US of the HCA lesion(s). Both control groups will be asked to fill out the SF-12 
and EQ-5d questionnaire
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Access to personal data
Medical data with which the identity of a patient could be traced will be replaced 
by a code number. The coordinating investigator is the only one who has the key 
to the code numbers and knows which code number stands for which patient. The 
principal investigator has only access to the coding system of his or her patients 
and will never be able to open the database from other centres. Only members 
of the investigating team and members of the medical ethical committee of the 
participating centres will have access to the medical data. All data will be collected 
in a prospectively acquired database by the principal investigators and managed by 
the coordinating investigator.
DISCUSSION
Once the diagnosis of HCA has been established, patients will be advised to dis-
continue OC. Expert opinions are very variable regarding treatment and follow up in 
complex situations were multiple factors play a role in determining the management 
strategy, like pregnancy. [18]
As to date there are limited data about the behavior of HCA during pregnancy 
and labor and therefore we cannot identify precisely those at risk for complications. 
However, in 2006 we reported a series of 48 patients of which in 44 % HCA were 
discovered after the patient had sustained at least one pregnancy. [19] None of 
these patients have reported problems during their pregnancies. Likely, only a small 
subgroup of patients may experience complications and to date pregnancy might be 
discouraged in too many patients caused by unnecessary intervention before preg-
nancy. We hypothesize that pregnancy may be allowed in case of one or more known 
HCA < 5 cm (without previous intervention), because HCA < 5 cm will not disturb the 
course of pregnancy. Close monitoring during pregnancy by means of repetitive US 
(and MRI in case of growth) should be carried out to rule out rapid growth of the 
lesion. The risk of rupture seems the highest during the third trimester of pregnancy. 
[20] Most likely due to the cumulating level of estrogens and an increase in hyperdy-
namic circulation combined with an increase in vascularity of the liver with growth 
of the adenoma. [20] Symptoms and the level of liver enzymes will be registered to 
find out if there is a relation between symptoms, elevated liver enzymes and growth 
of the HCA during pregnancy. Patients will be followed-up postpartum to investigate 
if there is a risk of HCA complications after delivery.
The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) provid-
ed guidelines for diagnosis, treatment, and use of laparoscopy for surgical problems 
during pregnancy. [26] However, these guidelines are mostly based on case reports 
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and retrospective studies and therefore graded at a low level of evidence. The SAGES 
suggest that MRI without the use of intraveneous gadolinium, and US is considered 
safe and can be used at any stage of pregnancy (Level IIIB and Level IIA respectively). 
[26] Data regarding safety of CEUS during pregnancy is scare and yet uncertain. How-
ever, Hua et al. reported an animal study in which SonoVue may affect the placenta. 
[27] Therefore, we will not use CEUS for patient follow-up during pregnancy.
One should be aware of the potential risks as an intervention may still be indi-
cated during pregnancy. In approximately one in 635 pregnancies a non-obstetric 
operation during pregnancy is required, especially appendectomy, cholecystectomy 
and adnexal precedures. [28] However, it is conceivable that more non-obstetric 
operations might be required due to the risk of hormone induced growth and spon-
taneous rupture of HCA during pregnancy. Despite maternal and fetal outcomes 
following abdominal disease and surgery in pregnancy improved over the past 
years, the exact risk of HCA-related interventions during pregnancy to both mother 
and fetus is unknown. [29] We do know that changes in physiology and abdominal 
anatomy characteristics of pregnancy make abdominal surgery more difficult. [29] 
The least risk of general anaesthesia is in the 2nd trimester of pregnancy. [30]
Based on a systematic review of the literature, Wilson et al. suggested angioem-
bolisation and formal resection in case of haemorrhage of HCA during pregnancy 
and suggested this strategy to be safe for both the mother and the fetus with good 
clinical outcomes. [31] The role of RFA during pregnancy is not well studied. In our 
previous study we described a RFA procedure during the first trimester of pregnancy 
[21] and Fujita et al. reported a pregnant patient with a HCA that was treated by RFA 
during her second trimester of pregnancy (18th week of gestation). [32]
The influence on the course of pregnancy, since a woman is aware of having a HCA, 
is also unknown. Patients can get horrified when confronted with the new diagnosis of 
a hepatic mass [20] and it is conceivable that women can be anxiety during pregnancy 
due to the presence of HCA in the liver and the possible growth during pregnancy. 
Therefore, quality of life will be an important measurement for future management of 
HCA during pregnancy. It is conceivable that frequent monitoring by means of US may 
comfort the patients or can be frightening. All patient groups will be asked to fill out 
the SF-12 and EQ-5d questionnaires every 6 weeks. HCA patients will be asked to fill 
out the STAI-6 and IES questionnaires before the US of the liver lesions and one week 
after US to investigate anxiety related to HCA and US during pregnancy.
Our main point of interest is whether it is justified to deny a young woman with 
a HCA < 5 cm a pregnancy. With this study we hope to obtain information about the 
behaviour of HCA during pregnancy and the impact of HCA during pregnancy on 
the life of these young women. Furthermore we hope to propose a decision-making 
model for the management of HCA during pregnancy.
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SUMMARY
In this thesis, the diagnosis and treatment of benign solid liver lesions is being 
studied. Among these, focal nodular hyperplasia (FNH) and hepatocellular adenoma 
(HCA) may offer the most challenge in management in daily clinical practice. In this 
thesis the characteristics of these lesions are described in more detail.
In chapter 2, the biological behaviour of FNH is studied and the relevance of 
change in size is analysed. In 162 patients with FNH, multiple imaging was performed 
with at least a six-months interval. In case there was suspicion of growth as defined 
by a 20% increase in size of the lesion according to the RECIST criteria, imaging was 
reviewed by two independent radiologists. Out of 162 patients diagnosed with FNH, 
19 had an increase in size ranging from 21% to 200%. We found that FNH lesions 
may grow significantly without causing any symptoms and conclude that an increase 
in size does not have to have implications but it is it is of imminent importance to 
diagnose these lesions with certainty.
In chapter 3 patients with HCA registered in our database were analysed over 
time, and compared with the presentation of patients with single and multiple le-
sions. Three groups were defined, including patients with a single adenoma, multiple 
adenomas and liver adenomatosis (>10 lesions). Through this study, it was observed 
that multiple HCAs are more frequently diagnosed in our institute than would be 
expected from the literature. Out of 458 patients diagnosed with hepatocellular 
adenoma, 121(26%) presented with a single adenoma, 223(53%) with multiple ad-
enomas and 82 (20%) with liver adenomatosis. The comparison between the three 
groups revealed a significant correlation between multiple adenoma/liver adeno-
matosis and BMI. The highest median BMI was found in the Inflammatory-HCA group. 
This result may support the hypothesis that HCA may be associated with obesity.
In females, a conservative approach for HCA is justified and consists of cessation 
of oral contraceptive and weight reduction. If, after a period of six months, radiologi-
cal imaging shows the HCA to remain stable in size or to regress to a diameter <5cm, 
annual imaging is indicated. Significant growth (>20% according to RECIST criteria) 
or a HCA diameter >5cm after six months is stated as an indication for resection. 
However, in cases of multiple HCA or large lesions located in the central part of the 
liver, resection may be challenging and a more balanced approach is warranted as 
liver resections may have a perioperative complication rate of up to 20% [17, 18] 
increasing significantly with the presence of steatosis. [19] In chapter 4 the natural 
behaviour of large hepatocellular adenomas >5 cm which were under surveillance 
for more than 6 months was assessed. In our cohort, the median number of weeks for 
the event “regression to ≤5cm” to occur was 81 weeks, in which no clinical events 
such as bleeding occurred. We therefore suggest that it may be warranted in cases 
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of multiple HCA or large lesions located in the central part of the liver to offer close 
surveillance with transversal imaging and follow a watchful waiting strategy.
In chapter 5 we describe the characteristics of HCA and FNH as depicted by a 
new imaging technique, the contrast-enhanced ultrasound (CEUS). We determined 
the presence of specific features and defined a model for prediction using age and 
the presence of a central scar, central artery, and enhancement pattern. With the 
formula 1/(1+e(0.778+(0.36 *Age) + (central scar) (central artery) (enhancement 
mixed) the probability of a lesion being an HCA can be predicted correctly in 0.854 
cases using CEUS.
In chapter 6 we compared the diagnostic performance of CEUS with MRI using 
gadobenate dimeglumine (CEMRI) for the diagnosis of HCA and FNH. A hundred 
and nineteen patients had undergone a CEUS as well as CEMRI in the prospective 
work-up. The final diagnosis was considered definitive when the outcome of CEUS 
and CEMRI were concordant. Histopathological assessment followed in cases of 
discrepancy. The sensitivity and specificity of CEUS was 83% and 72% respectively. 
CEUS and CEMRI were comparable for diagnosis of FNH and HCA with characteristic 
findings. However, in case of disconcordance between both imaging techniques 
there CEMRI demonstrated and advantage. Therefore, we recommend the use of 
CEMRI in all patients in which a HCA or FNH is suspected.
The role of CEMRI in HCA is further reviewed in chapter 7 and chapter 8 where 
we focus on the possibility of distinguishing between the different subtypes of HCA. 
It is important to diagnose H-HCA (HNF1A-mutated HCA) correctly as this steatotic 
subtype has a particular benign course, allowing a conservative approach. H-HCA 
is characterised by a large percentage of aberrant fat. The inflammatory subtype, 
Inflammatory HCA (I-HCA), is hyperintense on T2-weighted images and has a 
persistent enhancement on delayed imaging in the venous phase. MRI-features 
of β-catenin-HCA are being described as heterogeneous I-HCA lesions with a high 
specificity on imaging but with a significant risk on false negative diagnosis.
To support the differentiation between benign liver tumours including HCA and 
FNH from the malignant liver tumour hepatocellular carcinoma (HCC) we focused on 
biomarkers, as described in chapter 9. Golgi protein 73 is a resident Golgi-specific 
membrane expressed by biliary epithelial cells and enhanced in HCC. We included 
264 patients with HCC, HCA and FNH and found that although GP73 is a valuable 
marker in HCC, the serum marker may also be raised in HCA and FNH. Therefore, it 
cannot be used to discriminate HCC from the benign liver tumours HCA and FNH.
In chapter 10 we describe the evaluation and management of HCA < 5 cm during 
pregnancy. As HCA may increase in size due to hormones there is a tendency in the 
literature to discourage pregnancy in women with liver adenoma. We stated that the 
biological behaviour of HCA might be less threatening than presumed. As described 
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in chapter 10 we speculate that there is no need to discourage pregnancy in women 
with a HCA < 5cm. However, due to the scarcity of cases, there is as yet, no evidence-
based algorithm for the management of HCA during pregnancy. We initiated a study 
to demonstrate the safety of pregnancy in women with a liver adenoma< 5cm. In 
chapter 11 this protocol on Pregnancy and Liver Adenoma Management (PALM) is 
described.
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hoofdstuk 2 beschrijft het biologische gedrag van de goedaardige levertumor 
focale nodulaire hyperplasie (FNH). FNH wordt tegenwoordig steeds vaker gedi-
agnostiseerd doordat de kwaliteit en toegankelijkheid van beeldvorming sterk is 
toegenomen. Als er een afwijking in de lever gevonden is, wordt beeldvorming vaak 
herhaald om het goedaardige karakter van de afwijking te bevestigen. Patiënten, 
maar soms ook artsen, kunnen twijfelen aan de diagnose FNH en het goedaardige 
karakter van de afwijking als er groei van de afwijking wordt gezien. In hoofdstuk 2 
hebben we onderzocht hoe vaak FNH’s groeien. Er waren gegevens van 162 patiënten 
beschikbaar met een radiologisch of pathologisch bewezen en meerdere momenten 
van beeldvorming met een minimaal interval van 6 maanden. Bij vermeende groei 
van het FNH werden de opnames opnieuw door twee onafhankelijke radiologen 
beoordeeld. We definieerden groei als een toename van de diameter van tenminste 
20%, zoals beschreven in de RECIST-criteria voor solide levertumoren. Bij deze162 
patiënten bleken er 19 FNH’s te groeien, met een toename van de diameter met 
21 tot 200%. Het klinsche beloop bij deze patiënten was zonder problemen. We 
concluderen dat FNH’s kunnen groeien maar dat groei van een FNH geen invloed 
heeft op het welzijn van de patiënt en het beleid expectatief kan zijn. Indien de di-
agnose met zekerheid is gesteld aan de hand van criteria bij radiologisch onderzoek, 
is follow-up of resectie, niet geïndiceerd.
In hoofdstuk 3 vergelijken we 3 verschillende patiëntengroepen met een hepa-
tocellulair adenoom (HCA): patiënten met een solitair HCA, patiënten met multipele 
HCA (tussen de 2 en 9 adenomen) en patiënten met meer dan 10 HCA (het vroegere 
leveradenomatosis). In de literatuur staat beschreven dat HCA meestal solitair zijn 
en dat de minderheid van de patiënten meerdere HCA heeft. Multipele HCA bleken 
echter veel vaker te worden gediagnostiseerd dan in de literatuur wordt aange-
geven. Van de 458 patiënten die werden gediagnosticeerd met een HCA, hadden 
121(26%) patiënten een solitair HCA, 235 patiënten (51%) multipele adenomen 
en 102 patiënten (22%) meer dan 10 HCA. In de vergelijking tussen de drie groe-
pen bleek er een correlatie tussen het voorkomen van multipele adenomen en de 
Body Mass Index (BMI). Daarnaast bleek in deze groepen een zeer hoog percentage 
inflammatoire adenomen (I-HCA) voor te komen, een adenoom met verhoogd risico 
op bloeding. Wij concluderen dat multipele en inflammatoire adenomen vaker voor-
komen bij patiënten met obesitas.
Bij vrouwen met een HCA wordt in eerste instantie een conservatief beleid gevoerd 
door gebruik van orale anticonceptiva te ontraden en te adviseren om gewicht te 
reduceren, mocht er sprake zijn van overgewicht. Als na 6 maanden het HCA kleiner 
is geworden dan 5 cm wordt vervolgonderzoek met jaarlijkse beeldvorming geadvi-
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seerd. Significante groei van het HCA (>20%), of een persisterende grootte boven 
5 cm, is reden om een resectie te adviseren. Bij multipele adenomen kan dit beleid 
ingewikkeld zijn door de risico’s van leverresectie, zeker bij patiënten met een sterk 
overgewicht. In hoofdstuk 4 beschrijven we het biologische gedrag van HCA groter 
dan 5 cm bij wie een conservatief beleid gevolgd is voor meer dan 6 maanden. We 
zien dat de HCA ook na een half jaar nog kleiner dan 5 cm kunnen worden en dat de 
mediane tijd tot regressie 81 weken is. Patiënten hebben in de vervolgperiode geen 
complicaties gehad. Wij concluderen dat er veilig gekozen kan worden om patiënten 
niet chirurgisch te behandelen maar poliklinisch te vervolgen indien er sprake is 
van multipele adenomen of grote afwijkingen centraal in de lever die gerelateerd 
kunnen zijn aan grote operatierisico’s.
In hoofdstuk 5 beschrijven we de karakteristieken van HCA en FNH bij gebruik 
van contrast-echografie (CEUS). CEUS is een nieuwe opkomende techniek om 
leverafwijkingen in beeld te brengen en te diagnosticeren. We bestudeerden hoe 
vaak de beschreven karakteristieken van HCA en FNH op de contrast-echo daad-
werkelijk zichtbaar zijn en wat de voorspellende waarde is hiervan. We creëerden 
een betrouwbaar model: 1/(1+e(0.778+(0.36 *Age) + (central scar) (central artery) 
(enhancement mixed) waarbij we gebruik hebben gemaakt van de leeftijd, het al 
dan niet aanwezig zijn van de ‘central scar’ en de manier van aankleuren door het 
contrast. Met het model dat wij presenteren kan aangegeven worden of er sprake is 
van een HCA of een FNH.
In hoofdstuk 6 wordt de diagnostische kwaliteit van CEUS vergeleken met de 
contrast-MRI (CEMRI) voor het stellen van de diagnose HCA en FNH. 182 patiënten 
hebben zowel een CEUS als een CEMRI ondergaan. De definitieve diagnose was ze-
ker indien de uitkomst van de CEUS en CEMRI unaniem waren. Indien er sprake was 
van discrepantie volgde bespreking in de leverwerkgroep met meerdere radiologen 
en werd de beeldvorming opnieuw beoordeeld. Bij twijfel werd er gekozen voor een 
biopt. De sensitiviteit en specificiteit van de CEUS waren respectievelijk 83 en 72%. 
Zowel de CEUS als de CEMRI waren goed in staat om de diagnose HCA of FNH te 
stellen echter in het geval van discrepantie bleek de CEMRI vaker in staat de juiste 
diagnose te stellen. Wij adviseren daarom om in de diagnostische work-up altijd ook 
een CEMRI te verrichten.
De rol van de CEMRI in relatie tot subtypering van adenomen werd bestudeerd 
hoofdstuk 7. Er wordt een overzicht gegeven van de mogelijkheden van de CEMRI 
bij HCA voor nadere subtypering. Dit is belangrijk omdat er bij het H-HCA (L-FABP 
negatief HCA subtype) mogelijk gekozen kan worden voor een conservatiever beleid 
in de toekomst en vervolgonderzoek niet meer geïndiceerd zal zijn. Deze H-HCA 
kunnen gekarakteriseerd worden door de verhoogde aanwezigheid van vet in de 
afwijking. Ook het subtype met een verhoogd risico, het zogenaamde inflammatoire 
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adenoom (I-HCA) kan worden gediagnosticeerd met deze techniek. De typering van 
mogelijk premaligne adenomen (B-HCA) met CEMRI kan op dit moment nog niet met 
voldoende accuratesse worden verricht.
Een andere mogelijkheid om de benigne solide levertumoren te onderscheiden 
van het maligne hepatocellulair carcinoom wordt onderzocht in hoofdstuk 8. Hier 
onderzoeken we het Golgi eiwit 73 (GP-73); eerdere studies hebben aangetoond 
dat serum niveaus significant hoger zijn in patiënten met hepatocellulair carcinoom 
(HCC) in vergelijking met gezonde individuen. In 264 patiënten met HCC, HCA of 
FNH vergelijken wij of GP73 onderscheid kan maken tussen deze solide levertumo-
ren. Hieruit blijkt dat hoewel GP73 een waardevolle marker kan zijn voor het HCC 
het ook verhoogd kan zijn bij de goedaardige solide levertumoren als HCA en FNH. 
Hierdoor is het niet geschikt om te gebruiken in de differentiatie tussen deze drie 
tumoren.
In hoofdstuk 10 en 11 beschrijven we de modificaties die zijn opgetreden in het 
advies over zwangerschap aan vrouwen met een HCA. In hoofdstuk 10 worden data 
gepresenteerd die onderbouwen dat het hebben van een HCA gedurende de zwan-
gerschap minder gevaarlijk is dan voorheen werd verondersteld. In het Erasmus 
MC wordt zwangerschap bij vrouwen met een HCA < 5cm niet langer ontraden en 
wordt tijdens zwangerschap zorgvuldig met echografisch onderzoek vervolgd hoe 
het beloop is. Een wetenschappelijk onderbouwd advies aan vrouwen met een HCA 
en zwangerschap is op dit moment echter nog niet mogelijk door het lage aantal 
observaties dat we hebben uitgevoerd. Om hier een beter advies over te kunnen 
geven wordt momenteel de PALM-studie (Pregnancy and Liver adenoma Manage-
ment) uitgevoerd. Een multicenter, prospectieve studie die nader wordt beschreven 
in hoofdstuk 11.


ChAPTER 13
General discussion, recommendations 
and future perspectives

177
General discussion, recommendations and future perspectives
13
Compared to men, women more commonly present with the benign liver tumours; 
HCA and FNH. The pathophysiology of this gender difference is not completely 
understood. Oestrogen levels are thought to be associated with benign liver 
tumours, although the potential mechanisms are unclear (1-3). Data on increased 
hormone receptors or increased exogenous oestrogen levels due to oral contracep-
tives (OC) are inconsistent. In women with HCA, the use of OCs is reported in up 
to 80% of cases (4). OC use among women without HCA (15-44) is clearly lower, 
with a reported percentage of 25.9%(5). With the increasing widespread use of 
OC and the availability of more sensitive imaging techniques a rising incidence of 
HCA is reported from 0.001-0.004% up to 0.04% (6-8). Concurrent with this rising 
incidence, an increase of multiple HCAs has been observed. Our findings as well 
as reports from other studies indicate that these patients may be characterised by 
being overweight. Moreover, it has been suggested that the increase in adipose tis-
sue may be responsible for the production of excessive oestrogens (9, 10). Obese 
patients have higher oestrogen levels compared to non-obese individuals (10, 11). 
In case of obesity, weight loss in addition to cessation of OC-use, might be strongly 
recommended in the future management of women with HCA (12).
FNH has a different response to the use of oral contraceptives and being over-
weight when compared with HCA and therefore it is important to distinguishing 
both lesions from one another. In the clear majority of hepatic tumours, high-quality 
contrast enhanced transversal imaging allows accurate diagnosis (13, 14). MRI with 
the use of a liver specific contrast-agent has a specificity of nearly 100%, although 
its sensitivity is lower, especially in lesions smaller than 3 cm in diameter. When 
the diagnosis on MRI is uncertain, addition of contrast-enhanced ultrasound (CEUS) 
may provide a higher diagnostic accuracy (15, 16). If there is still doubt about the 
diagnosis, a biopsy of the lesion may be performed. When imaging does indicate 
heterogeneity in the tumour nodule, the absence of malignancy must be confirmed, 
as it is critical that HCA is differentiated from HCC. A biopsy may be the next step. 
However, it should be noted that this procedure may be complicated by bleeding in 
up to 3/1000 patients and that there may be a sample error. Thus, the differential 
diagnosis of HCC must be kept in mind if there is a discrepancy between pathology 
results of needle biopsies and if the level of suspicion is raised by imaging findings. 
Furthermore, a positive Beta-catenin staining may be difficult to demonstrate in 
needle biopsies and the absence in the needle biopsy may differ from the findings 
in the resected specimen (17).
In the molecular and pathological subtype classification system of Bordeaux, 
β-catenin has been introduced as an important biomarker for I-HCA at risk. This clas-
sification directs clinical management. MRI with the use of a liver specific contrast 
has been demonstrated to be correlated with the pathological classification as well 
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and MRI imaging is nowadays the modality of choice to characterise HCA subtypes 
in the first instance (14). If the diagnosis is unclear, a percutaneous biopsy may be 
used as mentioned above (18-20). In addition, treatment decisions are based on 
gender, size and pattern of progression and heterogeneity, and immunohistological 
staining on β-catenin. Today, mutation analysis is not used routinely, but it must be 
explored as to its utility in identifying patients at risk of acquiring multiple inflam-
matory adenomas. (22)
If HCA has been diagnosed, the patient’s life style should be addressed. It is 
recommended the patient stops the use of OC and for imaging to be repeated after 
6 months. After cessation of OCs, 79% of patients show regression of HCAs, some-
times with complete disappearance of the lesion on imaging (14, 23). If HCA shows 
regression, but the diameter still exceeds the limit of 5 cm, longer observation 
instead of resection might be considered. We state that the risk of complications like 
bleeding may be negligible in adenomas showing regression and the risk of clinical 
relevant haemorrhage is overestimated. However, further follow up is recommended 
to monitor the progress of HCA. Future studies will help determine whether annual 
follow-up is indicated for all subtypes and all sizes.
Although research on benign liver lesions has shown great progress in recent years 
there are still a number of issues to be addressed in order to better understand and 
manage these lesions. Directions for further research could include the influence 
of life style changes, including cessation of OC with or without reduction of body 
weight, the impact of pregnancy, the clinical relevance of β-catenin staining, and the 
relevance of molecular subtyping on the scheme and length of surveillance. With 
a multicenter approach these questions may be answered in the following years 
leading to a more evidence-based management of young women with the incidental 
finding of a benign liver lesion.
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DANkwOORD
Het is gelukt!! Wat waren de laatste loodjes zwaar... Promoveren doe je zeker niet 
alleen en daarom wil ik graag iedereen bedanken. Een aantal mensen wil ik in het 
bijzonder bedanken voor hun hulp, advies, steun en gezelligheid.
Mijn promotor, prof. dr. J.N.M. IJzermans, beste Jan, ik kan me nog goed herinneren 
dat ik in 2008 voor het eerst op 8-zuid bij u binnenkwam voor het bespreken van 
mijn keuzeonderzoek. Nu zoveel jaar later mag ik bij u promoveren. Soms afgeleid 
van het werk in de kliniek heeft u me altijd weer opnieuw weten te motiveren. Ik 
kijk er naar uit met u samen te werken in het Erasmus MC en dat ik van u naast de 
wetenschap ook de andere mooie kanten van het vak mag leren. Hartelijk dank voor 
het vertrouwen en de begeleiding.
Mijn promoter, prof R.A. de Man, beste Rob, heel erg bedankt voor de kritische blik 
op de stukken maar vooral ook de bemoedigende woorden in de afrondende fase. 
Je zorgde er in de gezamenlijke besprekingen altijd voor overzicht te bewaren 
waarvoor dank!
Leden van de leescommissie, Prof.dr. H.W. Tilanus, prof.dr. T.M. van Gulik en prof. dr. 
J.H.W. de Wilt, dank u wel voor het lezen en het beoordelen van dit proefschrift.
Roy Dwarkasing, Maarten Thomeer en Francois Willemsen, dank voor de gezamen-
lijke interesse en enthousiasme voor de goedaardige levertumoren. Bedankt voor 
jullie inzet.
Sanne, Marcia, Coebergh en Julia, veel dank voor het gezamenlijk schrijven en sub-
mitten van de stukken. Maar ook voor de gezellige momenten in de Z!
Heel veel dank aan alle overige co-auteurs voor het meedenken, analyseren en 
kritische blik op alle manuscripten.
Heel veel dank aan de secretaresses van de afdeling Heelkunde van het Erasmus 
MC. Conny wat heerlijk om bij je langs te komen, altijd geïnteresseerd in hoe het er 
voor staat! Wat een gemis dat je naar de andere kant van de gang verhuist..
Carola heel veel dank, je hield altijd het overzicht van alle subsidieaanvragen en de 
benodigde terugkoppelingen. Je wist uit alle gezamenlijke agenda’s altijd weer een 
moment te creëren dat we toch bij elkaar konden komen. En ook in de afrondende 
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fase wist jij precies wat en wanneer te doen en waar ik dan daarvoor precies moest 
zijn.. Dank!
Lieve Z-836 bewoners, Carlijn, Piet, Zaar en Joost wat hebben we toch veel schit-
terende momenten meegemaakt in dat kamertje! Dank voor de mooie tijd!
Sanne, Karel, Michiel, Gijs, Koen, Eelke, Joel, Steef, Kirstin, Niels en Shiro, dank voor 
de super gezellige borrels, congressen, weekendjes weg, de onvergetelijke ski-
tripjes, alle onderzoekers-lunchen en de cup!
Chirurgen en arts-assistenten uit het Reinier, wat hebben we het toch naar ons zin in 
het Delftse. Ik had me geen betere plek kunnen wensen om opgeleid te worden! Ik 
kan niet wachten om weer bij jullie terug te mogen komen.
Lieve Mareille, Anna, Cigdem en Victorien. Wat zijn de tennisavonden een heerlijke 
uitlaadklep en niet te vergeten de borreltjes erna! Dat we dit nog maar heel lang 
samen mogen blijven doen!
Lieve oud-huisgenootjes, het is alweer 12 jaar geleden dat we net samenwoonden 
op de Aegidiusstraat en wat hebben we daar een toptijd gehad! Kirs en Lot, naar 
onze maandelijkse bijklets-etentjes kijk ik altijd weer heel erg uit en wat heerlijk om 
dan al onze vaste onderwerpen weer de revue te laten passeren.
Familie van Dijke en Familie Bröker, dank voor jullie eeuwige interesse in mijn pro-
motie en opleiding!
Lieve schoonfamilie, bij elk bezoek werd vol interesse gevraagd hoe het er voor 
stond met de promotie, heel erg bedankt! Ook voor de heerlijke momenten op 
Schier waar meerdere stukken van het boekje op papier zijn gezet. 
Lieve jaarclub, wat kan ik toch genieten van al onze etentjes, borrels, dansjes en 
weekendjes weg! Dank ook voor jullie begrip als ik weer eens ondergedoken was 
vanwege diensten en mijn promotie. Mijn promotie is klaar, dus.. Wanneer gaan we 
weer?? Lieve Lyd nog in het bijzonder dank dat je naast me wil staan als paranimf 
op deze bijzondere dag!
Lieve papa en mama, fantastisch hoe jullie er altijd de volle 100 procent voor me 
zijn! Jullie steun en vertrouwen zijn onbeschrijfelijk. Met jullie als voorbeeld is het 
me allemaal gelukt. Wat kan ik toch ook heerlijk bij jullie bijtanken in het Velpse en 
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uitwaaien in Oostkapelle. Dank voor alles! Natuurlijk ook voordat dat jij vandaag 
mijn paranimf wil zijn paps! Nu snel maar weer een moeder-dochter en vader-
dochter-dagje plannen!
Roelf, lieve schat, wat ben ik toch gek op je. Wat kan ik samen met jou genieten en 
wat hebben we het toch heerlijk samen. Dank voor alle rustmomentjes tussen de 
promotiestress, ellelange kletsmomenten, alle lieve knuffels en dat je er altijd vol-
ledig voor me bent! Ik ben er van overtuigd dat we nog heel veel mooie en speciale 
momenten samen zullen gaan beleven. Ik hou super veel van je!
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PhD PORTFOLIO
Name PhD Student: Mirelle Bröker PhD Period: 2011-2017
Erasmus MC Department: Surgery Promotor: Prof. Dr. J.N.M. lJzermans 
Research School: Molecular Medicine Supervisor: Prof Dr. R.A. de Man 
1. PhD Training
 
General Courses Year workload
(ECTS)
Basiscursus Regelgeving en Organisatie (BROK), Erasmus MC, Rotterdam 2011 1
Research Integrity, Erasmus MC, Rotterdam 2012 0.6 
Biostatistics for clinicians, Erasmus MC, Rotterdam 2012 1 
Basic introduction course SPSS, Erasmus MC, Rotterdam 2012 0.8 
Molmed English biomedical writing and communication 2012 2.0 
Methodologie van patiëntgebonden onderzoek en voorbereiding van 
subsidieaanvragen), Erasmus MC, Rotterdam 
2012 0.3 
In-depth Courses Year workload 
(ECTS)
AASLD Transplant Surgery Workshop: Management of Rare Liver Tumors 2013 1
Presentations at (inter)national conferences Year workload
(ECTS)
Oral presentations    
The use of contrast-enhanced ultrasonography and MRI for the distinction 
between focal nodular hyperplasia and hepatocellular adenoma - ESSR, Lille
2012 1
The value of Golgi Protein 73 as a marker to differentiate between solid 
benign and malignant liver tumours - Belgische gastroweek, Antwerpen 
2013 1 
The value of Golgi Protein 73 as a marker to differentiate between solid 
benign and malignant liver tumours – NVGE, Antwerpen 
2013 1 
The value of Golgi Protein 73 as a marker to differentiate between solid 
benign and malignant liver tumours – ESSR, Istanbul 
2013 1 
The additional use of contrast-enhanced ultrasonography for the distinction 
between hepatocellular adenoma and focal nodular hyperplasia – AASLD, 
Washington 
2013 1 
The clinical significance of collagen peptides in urine – SEOHS, Maastricht 2013 1 
HCA en zwangerschap - Landelijke leverwerkgroep, Utrecht 2013 1 
FNH en Adenoom – EASL Richtlijn Benigne levertumoren NVGE Veldhoven 2013 1 
 2016 1 
Poster presentations    
The value of Golgi Protein 73 as a marker to differentiate between solid 
benign and malignant liver tumours – ESMO, Barcelona
2013 0.5
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The value of Golgi Protein 73 as a marker to differentiate between solid 
benign and malignant liver tumours – AASLD, Washington 
2013 0.5 
Multiple adenoma and liver adenomatosis: incidence, patient characteristics 
and management– AASLD, Washington 
2013 0.5 
Attendance at (inter)national Conferences Year workload
(ECTS)
Chirurgendagen, Nederlandse Vereniging voor Heelkunde –Veldhoven (6x) 2011-2017 6
360 degrees in liver metastases, Rome 2012 0.5 
Symposium Experimenteel Onderzoek Heelkundige Specialismen 2012 0.5 
2. Teaching
 
Supervising Practicals and Excursions, Tutoring Year workload 
(ECTS)
Examination Basic Life Support (EHBO) first year medical students 2011-2013 1
Supervising students 2011-2013 2 
MDL-minor teaching 2013 0.5 
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CURRICULUM VITAE
Mirelle Elmira Elizabeth Bröker werd op 29 augustus 1985 geboren in Utrecht. Ze 
groeide op in Groenekan, Westervoort en Velp, alwaar ze een heerlijke jeugd heeft 
gehad. In 2004 slaagde zij voor haar Atheneum-eindexamen aan Arentheem Col-
lege in Arnhem. Na 1 jaar Farmacie te hebben gestudeerd aan de Universiteit van 
Utrecht werd zij decentraal toegelaten tot de studie geneeskunde aan de Erasmus 
Universiteit Rotterdam.
Tijdens haar geneeskunde studie werkte ze in het medisch studententeam in 
het Erasmus MC op de afdeling transplantatiechirurgie. In haar vierde jaar deed ze 
haar keuze-onderzoek op de afdeling Heelkunde in het Sint Franciscus Gasthuis en 
het Erasmus MC (Prof. dr. J.N.M. IJzermans, Dr. W.W. Vrijland). Haar oudste-co-schap 
chirurgie volgde zij in het Reinier de Graaf Groep te Delft (Dr. M. van der Elst) alwaar 
zij in 2009 de wetenschapsprijs van de Reinier de Graaf groep behaalde.
Na het cum-laude behalen van haar arts-examen heeft zij 4 maanden als ANIOS 
Chirurgie op de afdeling Chirurgie gewerkt in het Erasmus MC (Prof. dr. J.N.M. IJzer-
mans) alvorens te beginnen aan haar promotieonderzoek op de afdeling hepatobi-
liaire chirurgie (Prof. dr. J.N.M. IJzermans). Vanaf november 2013 heeft zij als ANIOS 
gewerkt op de afdeling chirurgie van het IJsselland (Opleider: Dr. I. Dawson).
Sinds 1 juli 2014 is zij in opleiding tot chirurg in de Reinier de Graaf Groep te Delft 
(Opleider: Dr. M. van der Elst/ Dr. M.R. de Vries). Vanaf 1 juli 2017 heeft zij haar op-
leiding voortgezet in het Erasmus MC te Rotterdam (Opleider: Dr. B.P.L. Wijnhoven). 
In 2018 zal zij starten aan haar differentiatie Chirurgische Oncologie.
